Document:

EXHIBIT 10.3

February 4, 2009

CONFIDENTIAL

EpiCept Corporation

777 Old Saw Mill River Road

Tarrytown, NY 10591

			
	Attn:	 	Robert W. Cook

Senior Vice President & Chief Financial Officer

Dear Mr. Cook:

     This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC
(“Rodman” or the “Placement Agent”) and EpiCept Corporation (the
“Company”), that Rodman shall serve as the exclusive placement agent for the Company, on a
reasonable “best efforts” basis, in connection with the proposed placement (the
“Placement”) of registered securities (the “Securities”) of the Company, including
warrants (the “Warrants”) to purchase shares of the Company’s common stock, par value
$0.0001 per share (the “Common Stock”), and debentures (the “Debentures”)
convertible into Common Stock to be issued pursuant to the indenture between the Company and The
Bank of New York Mellon, as trustee (the “Trust Indenture”). The terms of such Placement
and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a
“Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that
Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for
the Company to issue any Securities or complete the Placement. This Agreement, the Securities
Purchase Agreement, the Warrants and the Debentures and related Trust Indenture shall be
collectively referred to herein as the “Transaction Documents.” The date of the closing of
the Placement shall be referred to herein as the “Closing Date.” The Company expressly
acknowledges and agrees that Rodman’s obligations hereunder are on a reasonable best efforts basis
only and that the execution of this Agreement does not constitute a commitment by Rodman to
purchase the Securities and does not ensure the successful placement of the Securities or any
portion thereof or the success of Rodman with respect to securing any other financing on behalf of
the Company.

SECTION 1. COMPENSATION AND OTHER FEES.

     A. Fees and Expenses. In connection with the services described above, the Company
shall pay to Rodman the following compensation:

          1. Placement Agent’s Fee. The Company shall pay to Rodman a cash placement fee (the
“Placement Agent’s Fee”) equal to 5% of the aggregate purchase price paid by each purchaser of
Securities, or $1,250,000. The Placement Agent’s Fee shall be paid at the closing of the
Placement (the “Closing”) from the gross proceeds of the Securities sold.

          2. Warrants. As additional compensation for the services, the Company shall issue to
Rodman or its designees at the Closing such number of warrants (the “Rodman Warrants”) to purchase
shares of Common Stock equal to 5% of the aggregate number of shares of Common Stock into which the

1251 Avenue of the Americas, 20th Floor, New York, NY 10020 § Tel: 212 356 0500 Fax: 212 430 1711

www.rodm.com § Member: FINRA, SIPC

 

 

EpiCept Corporation

February 4, 2009

Page 2

Warrants sold to the public in the Placement are initially convertible, or 1,388,889 Rodman
Warrants. The Rodman Warrants shall have the same terms as the warrants issued to the Purchasers in
the Placement, except that the exercise price shall be 125% of the initial conversion price of the
Debentures. The Rodman Warrants shall not have antidilution protections or be transferable for six
months from the date of the Placement except as permitted by Financial Industry Regulatory
Authority (“FINRA”) Rule 5110, and further, the number of Shares underlying the Rodman
Warrants shall be reduced if necessary to comply with FINRA rules or regulations.

          3. Expenses. The Company also agrees to reimburse Rodman’s expenses (with supporting
invoices/receipts) up to a maximum of 1% of the aggregate gross proceeds raised in the Placement,
but in no event more than $50,000. Such reimbursement shall be payable immediately upon (but only
in the event of) the Closing.

SECTION 2. REGISTRATION STATEMENT.

The Company represents and warrants to, and agrees with, the Placement Agent that:

     (A) The Company has filed with the Securities and Exchange Commission (the
“Commission”) a registration statement on Form S-3 (Registration File No. 333-153895) under
the Securities Act of 1933, as amended (the “Securities Act”), which was became effective
on October 21, 2008, for the registration under the Securities Act of the Warrants, the Debentures,
and Common Stock underlying the Warrants and the Debentures. At the time of such filing, the
Company met the requirement of Form S-3 under the Securities Act. Such registration statement
meets the requirements set forth in Rule 415(a)(1)(x) under the Securities Act and complies with
said rule. The Company will file with the Commission pursuant to Rule 424(b) under the Securities
Act, and the rules and regulations (the “Rules and Regulations”) of the Commission
promulgated thereunder, a supplement to the form of prospectus included in such registration
statement relating to the placement of the Securities, their respective pricings and the plan of
distribution thereof and has advised the Placement Agent of all further information (financial and
other) with respect to the Company required to be set forth therein. Such registration statement,
at the time it became effective, including the exhibits thereto filed at such time, as amended at
such time, is hereinafter called the “Registration Statement”; such prospectus in the form
in which it appears in the Registration Statement is hereinafter called the “Base
Prospectus”; and the supplemented preliminary form of prospectus, in the form in which it will
be filed with the Commission pursuant to Rule 433 (including the Base Prospectus as so
supplemented) is hereinafter called the “Preliminary Prospectus Supplement”; and the
supplemented form of prospectus, in the form in which it will be filed with the Commission pursuant
to Rule 424(b) (including the Base Prospectus as so supplemented) is hereinafter called the
“Prospectus Supplement.” The Registration Statement at the time it originally became
effective is hereinafter called the “Original Registration Statement.” Any reference in
this Agreement to the Registration Statement, the Original Registration Statement, the Base
Prospectus or the Prospectus Supplement shall be deemed to refer to and include the documents
incorporated by reference therein (the “Incorporated Documents”), pursuant to Item 12 of
Form S-3, which were or are filed under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), at any given time, as the case may be; and any reference in this Agreement
to the terms “amend,” “amendment” or “supplement” with respect to the Registration Statement, the
Original Registration Statement, the Base Prospectus or the Prospectus Supplement shall be deemed
to refer to and include the filing of any document under the Exchange Act after the date of this
Agreement, or the issue date of the Base Prospectus or the Prospectus Supplement, as the case may
be, deemed to be incorporated therein by reference. All references in this Agreement to financial
statements and schedules and other information which is “contained,” “included,” “described,”
“referenced,” “set forth” or “stated” in the Registration Statement, the Base Prospectus or the
Prospectus Supplement (and all other references of like import) shall be deemed to mean and include
all such financial statements and schedules and other information which is or is deemed to be
incorporated by reference in the Registration Statement, the Base Prospectus or the

 

 

EpiCept Corporation

February 4, 2009

Page 3

Prospectus Supplement, as the case may be. The Company has not received any notice that the
Commission has issued or intends to issue a stop order suspending the effectiveness of the
Registration Statement or the use of the Base Prospectus or the Prospectus Supplement or intends to
commence a proceeding for any such purpose. For purposes of this Agreement, “free writing
prospectus” has the meaning set forth in Rule 405 under the Securities Act and the “Time of
Sale Prospectus” means the Base Prospectus, together with the Preliminary Prospectus
Supplement, if any, and the free writing prospectuses, if any, used in connection with the
Placement, including any documents incorporated by reference therein.

     (B) The Original Registration Statement (and any further document to be filed with the
Commission) contains all exhibits and schedules as required by the Securities Act. Each of the
Registration Statement and any post-effective amendment thereto, at the time it became effective,
complied in all material respects with the Securities Act and the applicable Rules and Regulations
and did not contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading. The Base
Prospectus, the Time of Sale Prospectus and the Prospectus Supplement, each as of its respective
date, comply in all material respects with the Securities Act and the applicable Rules and
Regulations. Each of the Base Prospectus, the Time of Sale Prospectus, if any, and the Final
Prospectus, as amended or supplemented, did not and will not contain as of the date thereof any
untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading. The
Incorporated Documents, when they were filed with the Commission, conformed in all material
respects to the requirements of the Exchange Act and the applicable rules and regulations
promulgated thereunder, and none of such documents, when they were filed with the Commission,
contained any untrue statement of a material fact or omitted to state a material fact necessary to
make the statements therein (with respect to Incorporated Documents incorporated by reference in
the Base Prospectus or Prospectus Supplement), in light of the circumstances under which they were
made, not misleading. No post-effective amendment to the Registration Statement reflecting any
facts or events arising after the date thereof which represent, individually or in the aggregate, a
fundamental change in the information set forth therein is required to be filed with the
Commission. There are no documents required to be filed with the Commission in connection with the
transaction contemplated hereby that (x) have not been filed as required pursuant to the Securities
Act or (y) will not be filed within the requisite time period. As of the date hereof, except for
this Agreement, the Securities Purchase Agreement, the Warrants, the Trust Indenture and the
Debentures, there are no contracts or other documents required to be described in the Base
Prospectus, the Time of Sale Prospectus or Prospectus Supplement, or to be filed as exhibits or
schedules to the Registration Statement, which have not been described or filed as required.

     (C) The Company is eligible to use free writing prospectuses in connection with the Placement
pursuant to Rules 164 and 433 under the Securities Act. Any free writing prospectus that the
Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be,
filed with the Commission in accordance with the requirements of the Securities Act and the
applicable rules and regulations of the Commission thereunder. Each free writing prospectus that
the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or
that was prepared by or behalf of or used by the Company complies or will comply in all material
respects with the requirements of the Securities Act and the applicable rules and regulations of
the Commission thereunder. The Company will not, without the prior consent of the Placement Agent,
prepare, use or refer to, any free writing prospectus. Neither the Company nor any of its
directors and officers has distributed and none of them will distribute, prior to the Closing Date,
any offering material in connection with the offering and sale of the Securities other than the
Base Prospectus, the Time of Sale Prospectus, if any, the Prospectus Supplement, the Registration
Statement, copies of the documents incorporated by reference therein and any other materials
permitted by the Securities Act.

 

 

EpiCept Corporation

February 4, 2009

Page 4

     (D) Without the prior written consent of the Company, the Placement Agent hereby confirms that
it has not given and will not give to any prospective purchaser of the Securities any free writing
prospectuses other than as set forth on Schedule A hereto.

     (E) The Company and the Placement Agent have agreed that the information set forth on
Schedule A hereto (such information shall be referred to in this Agreement as the
“Scripted Information”) shall be orally conveyed by the Placement Agent to each Purchaser
prior to the Placement Agent’s confirming sales of Securities.

SECTION 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. Except as disclosed in
the Registration Statement, the Time of Sale Prospectus or the SEC Reports (as defined below), the
Company hereby represents and warrants to the Placement Agent as follows:

     (A) Authorization. The Company has the requisite corporate power and authority to
enter into and to consummate the transactions contemplated by each of the Transaction Documents and
otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of
each of the Transaction Documents by the Company and the consummation by it of the transactions
contemplated thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, its board of directors or its stockholders in
connection therewith other than in connection with the “Required Approvals” (as defined in
subsection 3(D) below). Each Transaction Document to which the Company is a party has been (or
upon delivery will have been) duly authorized and executed by the Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the valid and binding obligation of
the Company enforceable against the Company in accordance with its terms except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies, and (iii) that rights to indemnification and contribution thereunder may be
limited by federal or state securities laws or public policy relating thereto.

     (B) No Conflicts. The execution, delivery and performance of the Transaction
Documents by the Company, the issuance and sale of the Securities and the consummation by the
Company of the other transactions contemplated hereby and thereby do not and will not (i) conflict
with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or
constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any Lien upon any of the properties or assets of the Company or
any Subsidiary, or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected (except as may have been consented to or
waived), or (iii) subject to the Required Approvals, conflict with or result in a violation of any
law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or
governmental authority to which the Company or a Subsidiary is subject (including federal and state
securities laws and regulations), or by which any property or asset of the Company or a Subsidiary
is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not
reasonably be expected to have a Material Adverse Effect.

     (C) Filings, Consents and Approvals. The Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state, local or other governmental authority or other
“Person” (defined as an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company,
government (or an agency or subdivision thereof) or other entity of any kind) in connection with
the execution, delivery and performance by the Company of the Transaction Documents, other than
such filings as are required to be made under applicable Federal and state securities laws, by the
“Trading Market” (which, for

 

 

EpiCept Corporation

February 4, 2009

Page 5

purposes of this Agreement means the following markets or exchanges on which the Common Stock
is listed or quoted for trading on the date hereof: The Nasdaq Capital Market and OMX Nordic
Exchange), under the Securities Purchase Agreement, under the Trust Indenture Act of 1939 (the
“Trust Indenture Act”) and those which may be required by Hercules and holders of our
subordinated convertible notes due April 10, 2009 (collectively, the “Required Approvals”).

     (D) Certain Fees. Except as otherwise provided in this Agreement, no brokerage or
finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor
or consultant, finder, placement agent, investment banker, bank or other Person with respect to the
transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for
fees of a type contemplated in this Section that may be due in connection with the offer and sale
of the Securities contemplated by the Transaction Documents.

     (E) Regulation M Compliance.  The Company has not, and to its knowledge none of its
officer’s or directors have, (i) taken, directly or indirectly, any action designed to cause or to
result in the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any
compensation for soliciting purchases of, any of the Securities (other than for the Placement
Agent’s placement of the Securities), or (iii) paid or agreed to pay to any person any compensation
for soliciting another to purchase any other securities of the Company, other than, in the case of
clauses (ii) and (iii), compensation paid pursuant to Section 1.A.

     (F) FINRA Affiliations. To the knowledge of the Company, there are no affiliations
with any FINRA member firm among the Company’s officers, directors or any five percent (5%) or
greater stockholder of the Company, except as set forth in the Base Prospectus.

     In addition to the representations made in this Section 3, as of the Closing Date, the Company
hereby makes to Rodman each of the representations and warranties made by the Company to the
Purchasers in the Securities Purchase Agreement, as though restated in their entirety herein.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE PLACEMENT AGENT. The Placement
Agent hereby represents and warrants to the Company as follows:

     (A) Neither the Placement Agent, nor any of its directors, officers, or agents have
distributed, and none of them will distribute, prior to the Closing Date, any offering material in
connection with the offering or sale of the Securities other than the Prospectus, the Preliminary
Prospectus Supplement, and the Prospectus Supplement.

     (B) Neither the Placement Agent, nor any of its directors, officers, or agents have, (i)
taken, directly or indirectly, any action designed to cause or to result in the stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of any of
the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for
soliciting another to purchase any other securities of the Company.

     (C) The Placement Agent, nor any of its directors, officers, or agents have distributed, and
none of them will distribute, prior to the Closing Date, any offering material in connection with
the offer of the Securities other than the information set forth in Schedule A hereto, and in no
event, any materials that could be deemed a free writing prospectus under the Securities Act.

SECTION 5. INDEMNIFICATION. The Company agrees to the indemnification and other
agreements set forth in the Indemnification Provisions (the “Indemnification”) attached
hereto as Addendum A, the

 

 

EpiCept Corporation

February 4, 2009

Page 6

provisions of which are incorporated herein by reference and shall survive the termination or
expiration of this Agreement.

SECTION 6. ENGAGEMENT TERM. The term of Rodman’s engagement hereunder will begin
on the date hereof and end on the earlier of the consummation of the Placement or 10 days after the
receipt by either party hereto of written notice of termination. Notwithstanding anything to the
contrary contained herein, the provisions concerning confidentiality, indemnification, contribution
and the Company’s obligations to pay fees and reimburse expenses contained herein and the Company’s
obligations contained in the Indemnification Provisions will survive any expiration or termination
of this Agreement. Rodman agrees not to use any confidential information concerning the Company
provided to it by the Company for any purposes other than those contemplated under this Agreement.

SECTION 7. RODMAN INFORMATION. The Company agrees that any information or advice
rendered by Rodman in connection with this engagement is for the confidential use of the Company
only in their evaluation of the Placement and, except as otherwise required by law, the Company
will not disclose or otherwise refer to the advice or information in any manner without Rodman’s
prior written consent. Notwithstanding the foregoing, the Company may file this Agreement and any
Transaction Document with the Commission in any filing made by the Company pursuant to the
Securities Act, the Exchange Act or the rules and regulations thereunder, and may refer to Rodman’s
engagement hereunder and the terms of this Agreement in any such filing (including any exhibit
thereto).

SECTION 8. NO FIDUCIARY RELATIONSHIP. This Agreement does not create, and shall
not be construed as creating rights enforceable by any person or entity not a party hereto, except
those entitled hereto by virtue of the Indemnification Provisions hereof. The Company acknowledges
and agrees that Rodman is not and shall not be construed as a fiduciary of the Company and shall
have no duties or liabilities to the equity holders or the creditors of the Company or any other
person by virtue of this Agreement or the retention of Rodman hereunder, all of which are hereby
expressly waived.

SECTION 9. CLOSING. The obligations of the Placement Agent and the Purchasers, and
the closing of the sale of the Securities hereunder are subject to the accuracy, on the date hereof
and on the Closing Date, of the representations and warranties on the part of the Company and its
Subsidiaries contained herein, to the accuracy of the statements of the Company and its
Subsidiaries made in any certificates pursuant to the provisions hereof, to the performance by the
Company and its Subsidiaries of their obligations hereunder, and to each of the following
additional terms and conditions:

     (A) No stop order suspending the effectiveness of the Registration Statement shall have been
issued and no proceedings for that purpose shall have been initiated or threatened by the
Commission, and any request for additional information on the part of the Commission (to be
included in the Registration Statement, the Base Prospectus or the Prospectus Supplement or
otherwise) shall have been complied with to the reasonable satisfaction of the Placement Agent.
Any Exchange Act filings required to be made by the Company in connection with the offer and sale
of the Securities shall have been timely filed with the Commission.

     (B) All corporate proceedings and other legal matters incident to the authorization, form,
execution, delivery and validity of each of this Agreement, the Securities, the Registration
Statement, the Base Prospectus and the Prospectus Supplement and all other legal matters relating
to this Agreement and the transactions contemplated hereby shall be reasonably satisfactory in all
material respects to counsel for the Placement Agent, and the Company shall have furnished to such
counsel all documents and information that they may reasonably request to enable them to pass upon
such matters.

 

 

EpiCept Corporation

February 4, 2009

Page 7

     (C) The Placement Agent shall have received from outside counsel to the Company such counsel’s
written opinion, addressed to the Placement Agent and the Purchasers dated as of the Closing Date,
in customary form and substance, reasonably satisfactory to the Placement Agent.

     (D) Neither the Company nor any of its Subsidiaries shall have sustained since the date of the
latest audited financial statements included or incorporated by reference in the Base Prospectus,
any loss or interference with its business from fire, explosion, flood, terrorist act or other
calamity, whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree, otherwise than as set forth in or contemplated by the Base Prospectus, the
Time of Sale Prospectus, if any, the Prospectus Supplement or the Incorporated Documents and (ii)
since such date there shall not have been any change in the capital stock or long-term debt of the
Company or any of its Subsidiaries or any change, or any development involving a prospective
change, in or affecting the business, financial condition, stockholders’ equity or results of
operations of the Company and its Subsidiaries, otherwise than as set forth in or contemplated by
the Base Prospectus, the Prospectus Supplement or the Incorporated Documents, the effect of which,
in any such case described in clause (i) or (ii), is, in the judgment of the Placement Agent, so
material and adverse as to make it impracticable or inadvisable to proceed with the sale or
delivery of the Securities on the terms and in the manner contemplated by the Base Prospectus, the
Time of Sale Prospectus, if any, the Prospectus Supplement or the Incorporated Documents.

     (E) Subsequent to the execution and delivery of this Agreement, there shall not have occurred
any of the following: (i) trading in securities generally on the New York Stock Exchange or The
Nasdaq Capital Market or trading in any securities of the Company on any exchange or in the
over-the-counter market, shall have been suspended or minimum or maximum prices or maximum ranges
for prices shall have been established on any such exchange or such market by the Commission, by
such exchange or by any other regulatory body or governmental authority having jurisdiction, (ii) a
banking moratorium shall have been declared by federal or state authorities or a material
disruption has occurred in commercial banking or securities settlement or clearance services in the
United States, (iii) the United States shall have become engaged in hostilities in which it is not
currently engaged, the subject of an act of terrorism, there shall have been an escalation in
hostilities involving the United States, or there shall have been a declaration of a national
emergency or war by the United States, or (iv) there shall have occurred any other calamity or
crisis or any change in general economic, political or financial conditions in the United States or
elsewhere, if the effect of any such event in clause (i), (iii) or (iv) makes it, in the sole
judgment of the Placement Agent, impracticable or inadvisable to proceed with the sale or delivery
of the Securities on the terms and in the manner contemplated by the Base Prospectus and the
Prospectus Supplement.

     (F) No action shall have been taken and no statute, rule, regulation or order shall have been
enacted, adopted or issued by any governmental agency or body which would, as of the Closing Date,
prevent the issuance or sale of the Securities or materially and adversely affect or potentially
and adversely affect the business or operations of the Company; and no injunction, restraining
order or order of any other nature by any federal or state court of competent jurisdiction shall
have been issued as of the Closing Date which would prevent the issuance or sale of the Securities
or materially and adversely affect or potentially and adversely affect the business or operations
of the Company.

     (G) The Company shall have prepared and filed with the Commission a Current Report on Form 8-K
with respect to the Placement, including this Agreement as an exhibit thereto.

     (H) The Company shall have entered into subscription agreements with each of the Purchasers
and such agreements shall be in full force and effect and shall contain representations and
warranties of the Company as agreed to between the Company and the Purchasers.

     (I) FINRA shall have raised no objection to the fairness and reasonableness of the terms and
arrangements of this Agreement. In addition, the Company shall, if requested by the Placement
Agent,

 

 

EpiCept Corporation

February 4, 2009

Page 8

make or authorize Placement Agent’s counsel to make on the Company’s behalf, an Issuer Filing
with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the
Registration Statement and pay all filing fees required in connection therewith.

     (J) Prior to the Closing Date, the Company shall have furnished to the Placement Agent such
further information, certificates and documents as the Placement Agent may reasonably request.

     All opinions, letters, evidence and certificates mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Placement Agent.

SECTION 10. GOVERNING LAW. This Agreement will be governed by, and construed in accordance
with, the laws of the State of New York applicable to agreements made and to be performed entirely
in such State. This Agreement may not be assigned by either party without the prior written
consent of the other party. This Agreement shall be binding upon and inure to the benefit of the
parties hereto, and their respective successors and permitted assigns. Any right to trial by jury
with respect to any dispute arising under this Agreement or any transaction or conduct in
connection herewith is waived. Any dispute arising under this Agreement may be brought into the
courts of the State of New York or into the Federal Court, in either case, located in New York, New
York and, by execution and delivery of this Agreement, the Company hereby accepts for itself and in
respect of its property, generally and unconditionally, the jurisdiction of aforesaid courts. Each
party hereto hereby irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by delivering a copy thereof via overnight delivery
(with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law. If either party shall commence an action or proceeding to
enforce any provisions of this Agreement, then the prevailing party in such action or proceeding
shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

SECTION 11. ENTIRE AGREEMENT/MISC. This Agreement (including the attached
Indemnification Provisions) embodies the entire agreement and understanding between the parties
hereto and supersedes all prior agreements and understandings relating to the subject matter
hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any
respect, such determination will not affect such provision in any other respect or any other
provision of this Agreement, which will remain in full force and effect. This Agreement may not be
amended or otherwise modified or waived except by an instrument in writing signed by both Rodman
and the Company. The representations, warranties, agreements and covenants contained herein shall
survive the closing of the Placement and delivery and/or exercise of the Securities, as applicable.
This Agreement may be executed in two or more counterparts, all of which when taken together shall
be considered one and the same agreement and shall become effective when counterparts have been
signed by each party and delivered to the other party, it being understood that both parties need
not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or a .pdf format file, such signature shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile signature page were an original thereof.

SECTION 12. NOTICES. Any and all notices or other communications or deliveries
required or permitted to be provided hereunder shall be in writing and shall be deemed given and
effective on the earliest of (a) the date of transmission, if such notice or communication is
delivered via facsimile or e-mail at the facsimile number or e-mail address specified on the
signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the
next business day after the date of transmission, if such notice or communication is delivered via
facsimile or e-mail at the facsimile number or e-mail address on the signature

 

 

EpiCept Corporation

February 4, 2009

Page 9

pages attached hereto on a day that is not a business day or later than 6:30 p.m. (New York City
time) on any business day, (c) the business day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom
such notice is required to be given. The address for such notices and communications shall be as
set forth on the signature pages hereto.

 

 

EpiCept Corporation

February 4, 2009

Page 10

Please confirm that the foregoing correctly sets forth our agreement by signing and returning to
Rodman the enclosed copy of this Agreement.

	 	 	 	 	 
	 	Very truly yours,

RODMAN & RENSHAW, LLC

 	 
	 	By:  	/s/ John J. Borer 	 
	 	 	Name:  	John J. Borer III 	 
	 	 	Title:  	President 
	 

Address for notice:

1251 Avenue of the Americas, 20th Floor

New York, NY, 10020

     Attention: General Counsel

Accepted and Agreed to as of

the date first written above:

	 	 	 	 	 
	 	EPICEPT CORPORATION

 	 
	 	By:  	/s/
Robert W. Cook 	 
	 	 	Name:  	Robert W. Cook	 
	 	 	Title:  	Senior Vice President &
Chief Financial Officer	 
	 

Address for notice:

777 Old Saw Mill River Road

Tarrytown, NY 10591

			
	Attn:	 	Robert W. Cook

Senior Vice President & Chief Financial Officer

 

 

ADDENDUM A

INDEMNIFICATION PROVISIONS

     In connection with the engagement of Rodman & Renshaw, LLC (“Rodman”) by EpiCept
Corporation (the “Company”) pursuant to a letter agreement dated February 4, 2009, between
the Company and Rodman, as it may be amended from time to time in writing (the
“Agreement”), the Company hereby agrees as follows:

	1.	 	To the extent permitted by law, the Company will indemnify Rodman and its affiliates,
stockholders, directors, officers, employees and controlling persons (within the meaning of
Section 15 of the Securities Act of 1933, as amended, or Section 20 of the Securities Exchange
Act of 1934) against all losses, claims, damages, expenses and liabilities, as the same are
incurred (including the reasonable fees and expenses of counsel), relating to or arising out
of its activities hereunder or pursuant to the Agreement, except to the extent that any
losses, claims, damages, expenses or liabilities (or actions in respect thereof) are found in
a final judgment (not subject to appeal) by a court of law to have resulted primarily and
directly from Rodman’s willful misconduct or gross negligence in performing the services
described herein.
	 
	2.	 	Promptly after receipt by an indemnified party of notice of any claim or the commencement of
any action or proceeding with respect to which an indemnified party is entitled to indemnity
hereunder, the indemnified party will notify the indemnifying party in writing of such claim
or of the commencement of such action or proceeding, and the indemnifying party will assume
the defense of such action or proceeding and will employ counsel reasonably satisfactory to
the indemnified party and will pay the fees and expenses of such counsel; provided that if an
indemnified party fails to provide prompt notice of such claim or proceeding the indemnifying
party shall be relieved of its obligations set forth in paragraph 1 and 3 if and to the extent
the indemnifying party is materially prejudiced by such failure to so notify. Notwithstanding
the preceding sentence, the indemnified party will be entitled to employ counsel separate from
counsel for the indemnifying party and from any other party in such action if counsel for the
indemnified party reasonably determines that it would be inappropriate under the applicable
rules of professional responsibility for the same counsel to represent both the indemnifying
party and the indemnified party. In such event, the reasonable fees and disbursements of no
more than one such separate counsel will be paid by the indemnifying party. The indemnifying
party will have the exclusive right to settle the claim or proceeding provided that the
indemnifying party will not settle any such claim, action or proceeding without the prior
written consent of the indemnified party, which will not be unreasonably withheld.
	 
	3.	 	The Company agrees to notify Rodman promptly of the assertion against it or any other person
of any claim or the commencement of any action or proceeding relating to the Placement.
	 
	4.	 	If for any reason the foregoing indemnity is unavailable to the indemnified party or
insufficient to hold the indemnified party harmless, then the Company and Rodman agree to
contribute to the amount paid or payable by the indemnified party as a result of such losses,
claims, damages or liabilities in such proportion as is appropriate to reflect not only the
relative benefits received by the Company on the one hand and Rodman on the other, but also
the relative fault of the Company on the one hand and Rodman on the other that resulted in
such losses, claims, damages or liabilities, as well as any relevant equitable considerations.
The amounts paid or payable by a party in respect of losses, claims, damages and liabilities
referred to above shall be deemed to include any legal or other

1270 Avenue of the Americas, 16th Floor, New York, NY 10020 §
Tel:: 212 356 0500 Fax:: 212 581 5690

www.rodmanandrenshaw.com § Member: FINRA, SIPC

 

 

	 	 	fees and expenses incurred in defending any litigation, proceeding or other action or claim.
Notwithstanding the provisions hereof, Rodman’s share of the liability hereunder shall not be in
excess of the amount of fees actually received, or to be received, by Rodman under the Agreement
(excluding any amounts received as reimbursement of expenses incurred by Rodman). No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.
	 
	5.	 	These Indemnification Provisions shall remain in full force and effect whether or not the
transaction contemplated by the Agreement is completed and shall survive the termination of
the Agreement, and shall be in addition to any liability that the Company might otherwise have
to any indemnified party under the Agreement or otherwise.

	 	 	 	 	 
	 	RODMAN & RENSHAW, LLC

 	 
	 	By:  	/s/  John J. Borer	 
	 	 	Name:  John J. Borer III	 
	 	 	Title:  President	 	 
	 

Accepted and Agreed to as of

the date first written above:

	 	 	 	 	 
	 	EPICEPT CORPORATION

 	 
	 	By:  	/s/  Robert
W. Cook	 
	 	 	Name:  Robert W. Cook	 
	 	 	Title:  Senior Vice President &
Chief Financial Officer
	 

12

 

SCHEDULE A

SCRIPTED INFORMATION

FOR DISCUSSION PURPOSES ONLY

EpiCept Corporation

Ticker: EPCT

Exchange: NASDAQ

Proposed Term Sheet

Subordinated Convertible Note Shelf Offering

The following are terms for a financing of up to $25,000,000. Final terms will be set forth in a
securities purchase agreement, indenture and related documentation. Nothing contained in this term
sheet is intended to create any obligation on the part of the Issuer or Investor to close the
proposed transaction.

	 	 	 
	Offering Amount:

	 	7.5556 convertible notes (the
“Notes”) shall be sold for
$25,000,000.
	 
	 	 
	Notes Maturity:

	 	The principal of the Notes will
be due and payable on the fifth
anniversary of the closing
date.
	 
	 	 
	Notes Interest Rate and Payment Dates:

	 	7.5556% per annum, payable June
30 and December 31 of each
year, commencing June 30, 2009.
	 
	 	 
	Ranking of Notes:

	 	The Notes are unsecured and
will be pari passu in right of
payment with all our existing
and future senior subordinated
unsecured debt.
	 
	 	 
	Convertibility:

	 	Immediate (into Common),
subject to 9.99% (or 4.99%)
beneficial ownership blocker.
	 
	 	 
	Voluntary Conversion of Notes:

	 	100% of the closing bid on the
day of the initial signing plus
$0.05.
	 
	 	 
	Automatic Conversion of Notes:

	 	After the one year anniversary
of the issuance of the Notes,
the Notes will be automatically
converted into shares of common
stock if the common stock
trades for 20 days within any
30 day trading period at a
price equal to or greater than
200% of the closing bid on the
day of the initial signing.
	 
	 	 
	Make-Whole Payment:

	 	In the event that the Notes are
converted or redeemed
voluntarily by the holder at
any time prior to the 3 year
anniversary of the issuance
date, the holder of the
converted Notes will be paid an
amount equal to $377.78 per
$1,000 principal amount of
Notes converted, less any
interest payments made with
respect to the converted Notes.
(i.e., 3-year make-whole.)
	 
	 	 
	Escrow:

	 	An amount of the proceeds of
the offering equal to the
aggregate Make-Whole Payment of
the initially-issued Notes will
be deposited with the escrow
agent as paying agent to be
held for a period of 24 months
from closing. Amounts in the
escrow account will be released
to pay Make-Whole Payments with
respect to Notes converted
during the escrow period. At
the end of 24 months, the
amount remaining in

 

 

	 	 	 
	 

	 	the escrow
account will be released to the
Company.
	 
	 	 
	Covenants:

	 	Company shall not issue any
equity (subject to standard
exceptions) or equity-linked
debt before 120 days following
the closing.
	 
	 	 
	Warrants:

	 	40% coverage on investment
amount at exercise price of
$1.035.
	 
	 	 
	Documentation:

	 	The definitive documentation
shall contain such additional
and supplementary provisions,
including, without limitation,
representations, warranties,
covenants, agreements and
remedies, as are appropriate to
preserve and protect economic
benefits intended to be
conveyed to the Company and the
Investors pursuant hereto.

2c56549_ex10-1.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

  	Confidential Materials omitted and filed separately
        with the 

        

      Securities and Exchange Commission. Asterisks denote omissions

  	Exhibit 10.1

     COMMERCIAL SUPPLY AGREEMENT 

between 

SAVIENT PHARMACEUTICALS INC. 

and 

BIO-TECHNOLOGY GENERAL (ISRAEL) Ltd.

COMMERCIAL SUPPLY AGREEMENT

          This Commercial Supply Agreement (the “Agreement”) is made and entered into as of the 20th day of March 2007, (hereinafter the
”Effective Date”), by and between Savient Pharmaceuticals, Inc., a public company organized under the laws of the State of Delaware having its principal place of business at One Tower Center, 14th Floor, East Brunswick, New Jersey 08816, USA (“Savient”), and Bio-Technology General (Israel) Ltd., a private company organized under the laws of the State of Israel having its principal
place of business at Beer Tuvia Industrial Zone, POB 571, Kiryat Malachi 83104, Israel (“BTG”) (hereinafter, each of Savient and BTG a “Party” and, collectively, the “Parties”). 

W I T N E S S E T H:

          WHEREAS, pursuant to the Share Purchase Agreement (the “SPA”) and the Asset Purchase Agreement (“APA”), each dated March 23, 2005 (the SPA and APA,
collectively, the “Divestiture Agreements”), Savient has, on 17 July 2005, sold to Ferring B.V. all of the issued and outstanding share capital of BTG, and to Ferring International Centre S.A. all of Savient’s right, title and
interest in certain drug products and drug candidates developed and/or manufactured by BTG, but not in any case in the drug candidate known as “PEG-uricase” (or also known as “Puricase”); and 

          WHEREAS, the Parties to this Agreement have entered into a development agreement dated March 20, 2007, (the "Development
Agreement") according to which BTG renders continued development, manufacturing and other services in relation to Puricase. 

          WHEREAS, Savient wishes BTG, and BTG is willing, to supply Bulk Product for Commercial Launch and further commercial sales. 

          NOW THEREFORE, in consideration of the foregoing premises, which are incorporated into and made a part of this Agreement, and of the mutual covenants which are recited
herein, the Parties agree as follows: 

ARTICLE 1 

DEFINITIONS

1.01  “AE” shall mean, with respect to the Product, any adverse event associated with the use of the
Product in a patient or clinical investigation, whether or not considered drug related, including the following: an adverse event occurring in the course of the use of the Product in professional practice; an adverse event occurring from drug
overdose whether accidental or intentional; an adverse event occurring from drug abuse; an adverse event occurring from drug withdrawal; and any significant and consistent failure of expected pharmacological action. AE shall include, without
limitation, any unfavorable and unintended sign (including, without limitation, an abnormal laboratory finding), an exacerbation of a pre-existing condition, intercurrent illness, drug interaction, significant worsening of a disease under
investigation or treatment, significant failure of expected pharmacological or biological action, symptom or disease temporally associated with the use of the Product, whether or not considered related to 

  the Product. Notwithstanding anything foregoing to the contrary, with respect to the Territory in which the Product is marketed, AEs shall include any experience required to be reported to a relevant authority in any such
country.

  1.02  “Affiliate” shall mean any business entity which directly or indirectly controls, is controlled by,
or is under common control with any Party to this Agreement. A business entity shall be deemed to “control” another business entity if (i) it owns, directly or indirectly, at least fifty percent (50%) of the issued and outstanding voting
securities, capital stock, or other comparable equity or ownership interest of such business entity, or (ii) it has the de facto ability to control or direct the management of such business entity. If the laws of the jurisdiction in which such
entity operates prohibit ownership by a Party of fifty percent (50%) or more, “control” shall
be deemed to exist at the maximum level of ownership allowed by such jurisdiction; provided, however,
that there is a de facto ability to direct or control its management.

  1.03  “BLA” means
  a regulatory application filed with a governmental agency in a country or a
  group of countries (e.g. FDA or EU EMEA) for the purpose of lawfully marketing,
  selling, distributing, importing, exporting, manufacturing, developing or using
  a therapeutic or prophylactic product for the treatment or prevention of a
  disease or physical condition; a BLA shall include, without limitation, a Product
  License Application or Marketing Authorization in the European Union, and a
Biologics License Application or a New Drug Application in the United States. 

  1.04  “BTG Assigned Improvements” shall
  mean all developments, discoveries, inventions, improvements, designs, methods,
  processes, techniques, devices, formulae and trade secrets related to the Product
  (including, without limitation, its pharmaceutical utility) and/or Processing
  of the Bulk Product or Product which are (i) made, created, developed or conceived,
  or reduced to practice, by BTG or an Affiliate of BTG and (ii) dominated by
  the Savient Patent Rights or necessary or useful in the Processing of the Bulk
  Product or Product. Notwithstanding the foregoing, BTG Assigned Improvements
  shall not include any innovations which are of general use in biopharmaceutical
manufacturing. 

  1.05  “BTG Licensed Improvements” shall
  mean all developments, discoveries, inventions, improvements, designs, methods,
  processes, techniques, devices, formulae and trade secrets related to the Product
  (including, without limitation, its pharmaceutical utility) and/or Processing
  of the Bulk Product or Product which are (i) made, created, developed or conceived,
  or reduced to practice, by BTG or an Affiliate of BTG, and (ii) necessary or
  useful in the Processing of the Bulk Product or (iii) of general use in biopharmaceutical
manufacturing. 

  1.06  “BTG Indemnitee” shall
  mean BTG and its Affiliates, and each of their respective directors, officers,
employees and agents. 

  1.07  “BTG Know-How” shall
  mean all Know-How developed by BTG or any of its Affiliates during the Term
  or by BTG prior to July 17, 2005 relating to (i) the Bulk Product or Product
  (including, without limitation, its pharmaceutical utility) or (ii) the Processing
  of the Bulk Product or Product , and shall include, without limitation, all
  data (in any form, raw or analyzed or reported and whether maintained in paper,
electronic or other media forms) relating to 

  formulation, analytical methods, pre-clinical and clinical trials, pharmacology, toxicology, regulatory information, and data relating to the manufacture and use of such Bulk Product or Product.

  1.08  “Bulk Product” shall
  mean the bulk solution of polyethylene glycol (PEG) conjugate of uricase ordered
by Savient from BTG pursuant to this Agreement. 

  1.09   “Business Day” shall
  mean any day other than (i) Friday, Saturday or Sunday or (ii) a day on which
  banking institutions located in New York, New York, United States of America
  or in Israel are permitted or required by law, executive order or governmental
decree to remain closed. 

  1.10  “cGMP” shall
    mean current good manufacturing practices as set forth in Title 21, Parts
210 and 211 of the C.F.R. and 21 C.F.R. Part 312 (IND) and Part 314 (NDA), and 21 C.F.R. Part
600 (Biological Products), as established and amended by the FDA.

1.11  “Claim” shall
  mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands, judgments, orders, decrees, stipulations, injunctions, damages (including all incidental and consequential damages claimed by Third Parties), deficiencies, defaults, assessments, dues, penalties,
  fines, costs, amounts paid in settlement, liabilities, obligations, taxes, liens, losses, lost profits claimed by Third Parties, expenses, costs and fees (including without limitation interest, court costs, reasonable fees of attorneys, accountants
  and other experts or other expenses of litigation or other proceedings or of any claim, default or assessment), and includes all damages awardable pursuant to statute and treble damages. 

  1.12  “Commercial Bulk Product Specifications” shall
  mean the manufacturing and quality specifications for the Bulk Product, including,
  without limitation, unit descriptions established initially in accordance with
  Section 3.01(ii) and amended from time to time in accordance with Section 3.01(iii)
.. 

  1.13  “Commercial Launch” shall
mean the first commercial sale of the Product in any country of the Territory. 

  1.14  “Competing Product” shall
  mean any prescription pharmaceutical product that (i) contains [**] as an active
  ingredient or (ii) is used for the therapeutic or prophylactic treatment of
  gout (in any form) or other diseases and conditions involving hyperuricemia
and/or monosodium urate crystals.

  1.15  “Current Provisional Bulk Product Specifications” shall
mean those provisional specifications set forth on Exhibit C hereto and any amended and restated Bulk Product specifications which are agreed to by the Parties in accordance with Section 3.01(i) .

  1.16  “Development Agreement” shall
  mean that certain Development Agreement by and between the Parties hereto,
dated as of the date hereof. 

  1.17  “Dollar” shall
mean the United States dollar. 

  1.18  “FDA” shall
  mean the United States Food and Drug Administration or its foreign equivalent
as may be appropriate in any given context. 

  1.19  “Facility” shall mean, the BTG facility located at Be'er Tuvia Industrial Zone, POB 571, Kiryat
Malachi 83104, Israel, within which, and for the purposes of the calculation of “Pro Rata Basis” as
defined in Section 1.37 there is the:

       (i)  “Purification Area” of
  the Facility used in the Processing of Bulk Product and comprising the small
purification line totaling [**];

       (ii)  “Fermentation Area” of
  the Facility used from time to time for the Processing of Bulk Product and
comprising the fermentation suite, totaling [**];

       (iii)  “Recovery Area” of
  the Facility used from time to time for the Processing of Bulk Product and
comprising the recovery suite, totaling [**], and;

       (iv)  “Total Manufacturing Area” of
  the Facility comprising the portion of the Facility dedicated to product manufacturing,
excluding common areas such as buffer preparation, totaling [**].

  1.20  “Field” shall
  mean human therapeutic or prophylactic or diagnostic applications for the prevention,
treatment and/or cure of diseases and physical conditions. 

  1.21  “Filled Product” shall
  mean sterile Product that is in Process and has been filled into its final
primary packaging for further labeling or packaging activities. 

  1.22  “Genetic Material” shall
  mean the master cell bank of the E.
coli strain expressing the [**] used in the Processing of the Bulk Product.

  1.23  “IND” shall
  mean an Investigational New Drug application, as defined in 21 C.F.R. 312.3,
and filed with the FDA or any equivalent foreign Regulatory Agency. 

  1.24  “Joint Inventions” shall
  mean (i) all patentable inventions jointly invented (as determined in accordance
  with United States patent law) by Savient (or its Affiliates) and BTG (or its
  Affiliates) pursuant to their activities relating to this Agreement during
  the Term, and (ii) all Know-How that Savient (or its Affiliates) and BTG (or
  its Affiliates) jointly make, create, develop, discover, conceive or reduce
  to practice pursuant to their activities relating to this Agreement during
the Term other than those inventions described in the preceding clause (i).

  1.25  “Know-How” shall
  mean all technical information, data (including, without limitation, regulatory
  data) patentable and unpatentable inventions, developments, discoveries, methods
  and processes that are, in each case, not disclosed in a published patent application
  or patent or otherwise publicly available, and includes, without limitation,
BTG Know-How. 

  1.26  “Legal Requirements” shall
  mean (i) any present and future national, state, local or similar laws (whether
  under statute, rule, regulation or otherwise), (ii) requirements under permits,
  orders, decrees, judgments or directives, and requirements of applicable Regulatory
  Agencies (including, without limitation, cGMP) and (iii) regulations pertaining
to commercially 

  available biologic pharmaceutical products or to maintaining a BLA (with respect to each of the foregoing, as amended or revised from time to time). 

  1.27  "Negligence” shall
  mean an act or omission implying either a failure to exercise the care which
  a reasonable or prudent person would do in the circumstances, or taking action
  which such a reasonable person would not; as used herein, a reasonable or prudent
  person shall be considered to have such expertise as would be required in order
  to allow such party to perform the obligations of the parties hereunder with
the level of skill and competence which prevail in the pharmaceutical industry. 

  1.28  “Non-Conforming Bulk Product” shall
  mean any Bulk Product which, at the time of delivery in accordance with ARTICLE
7, does not meet the Commercial Bulk Product Specifications.

  1.29  “OCS” shall
  mean Office of Chief Scientist, The Ministry of Industry and Trade, State of
Israel. 

  1.30  “OCS Requirements” shall
  mean the requirements of OCS which apply to the Product, including, without
  limitation, as specified pursuant to The Encouragement of Research and Development
  in Industry Law of 1984, as amended, and in the agreements by and among Savient,
BTG and the OCS. 

  1.31  “Person” shall
  mean any individual, partnership, corporation, limited liability company, unincorporated
organization or association, any trust or any other business entity. 

  1.32  “Process” or “Processing”
shall mean the act of purification, preparation, filling, testing and any other
pharmaceutical manufacturing procedures, or any part thereof (including, but
not limited to, product or process specifications, testing or test methods, raw
material specifications or suppliers, equipment, etc.), relating to, as applicable,
the Bulk Product and Product. 

  1.33  “Product” shall
  mean pharmaceutical products containing Bulk Product ordered by Savient pursuant
to this Agreement. 

  1.34  “Product Liability Claim” shall
  mean a Claim of a Third Party (other than a Claim arising out of use of the
  Product in a clinical trial) that (i) arises as a result of the use of the
  Product during the Term that results in personal injury or death or (ii) is
  in anticipation of or intended to prevent or forestall personal injury or death
as a result of the use of the Product during the Term. 

  1.35  “Product Technology” shall
  mean the (i) Savient Patent Rights, (ii) Savient Know-How, (iii) BTG Assigned
  Improvements, (iv) BTG Licensed Improvements, (v) BTG Know-How, (vi) any developments,
  discoveries, inventions, improvements, designs, methods, processes, techniques,
  devices, formulae, and trade secrets which are or may be (A) developed, acquired
  or conceived by Savient and/or BTG and are derived from the Development Plan
  performed under the terms of the Development Agreement, developed by BTG prior
  to July 17, 2005 and related to the Bulk Product or used in the Processing
  of Bulk Product, or are derived from the manufacture and supply of Bulk Product,
or (B) used in the Processing of Bulk Product.

1.36  “Product Specifications” shall
      mean the manufacturing and quality specifications for the Product as attached
hereto as Exhibit G as they may be modified from time to time. 

1.37  “Pro-Rata Basis” shall
      mean when Facility changes will be implemented pursuant to the provisions
of Section 6.03(ii)(B) and:

     (i) such Facility changes will impact the totality of the Total Manufacturing Area and/or the common and technical areas related to manufacturing, the cost of the changes multiplied by a percentage, where such percentage equals 

[**]

     (ii) when
    such Facility changes will impact only the Fermentation Area, [**]

     (iii) when such Facility changes will impact only the Recovery Area, [**]

1.38  “Quality Agreement” shall
      mean that certain Quality Agreement by and between the Parties hereto,
dated as of the date hereof and attached to this Agreement as Exhibit D. 

1.39  “Regulatory Agency” shall
      mean with respect to the United States, the FDA, or, in the case of a country
      in the Territory other than the United States, such other appropriate regulatory
agency with similar responsibilities.

1.40  “Residual Rights Agreement” shall
      mean that certain Amended and Restated Residual Rights Agreement by and
      between Savient and BTG, effective as of July 17, 2005, and attached hereto
as Exhibit F. 

1.41  “SAE” shall
      mean, with respect to the Product, any serious adverse event occurring
      during clinical trials of the drug at any dose that results in any of the
      following outcomes: death, a life-threatening adverse drug experience,
      inpatient hospitalization or prolongation of existing hospitalization,
      a persistent or significant disability/incapacity, or a congenital anomaly/birth
      defect. Important medical events that may not result in death, be life-threatening
      or require hospitalization may be considered a serious adverse drug experience
      when, based upon appropriate medical judgment, they may jeopardize the
      patient or subject and may require medical or surgical intervention to
      prevent one of the outcomes listed in this definition. Examples of such
      medical events include allergic bronchospasm requiring intensive treatment
      in an emergency room or at home, blood dyscrasias or convulsions that do
      not result in patient hospitalization, or the development of drug dependency
or drug abuse. 

1.42  “Savient Improvements” shall
      mean all inventions related to the Bulk Product or Product (including,
      without limitation, its pharmaceutical utility) and/or Processing of the
      Bulk Product or Product which are made, created, developed or conceived,
      or reduced to practice or come to be owned, by Savient or an Affiliate
of Savient and are dominated by the Savient Patent Rights.

1.43  “Savient Indemnitee” shall
      mean Savient and its Affiliates, and each of their respective directors,
officers, employees and agents. 

  1.44  “Savient Know-How” shall
  mean all Know-How developed by Savient or any of its Affiliates during the
  Term relating to (i) the Bulk Product or Product (including, without limitation,
  its pharmaceutical utility) or (ii) the Processing of the Bulk Product or Product,
  and shall include, without limitation, all data relating to formulation, analytical
  methods, pre-clinical and clinical trials, pharmacology, toxicology, regulatory
  information, and data relating to the manufacture and use of such Bulk Product
or Product.

  1.45  “Savient Patent Rights” shall
  mean all valid patent claims contained in (i) the patent(s) and patent applications
  listed on Exhibit A; (ii) all converted provisionals, divisions, continuations, continuations-in-part, reissues, reexaminations or extensions thereof; (iii) any
corresponding foreign counterparts and equivalents thereof; and (iv) any patents or patent applications filed after July 17, 2005. 

  1.46  “Sublicensee” shall
  mean any Third Party or Affiliate to whom a sublicense has been granted pursuant
to Section 2.05. 

  1.47  “Term” shall
    have the meaning set forth in Section 11.01.

  1.48  “Territory” shall
    mean, collectively, each country in the world.

  1.49  “Third Party” shall
    mean any Person who is not a Party or an Affiliate under this Agreement.

  1.50  “Time” shall
  mean for the purposes of the calculation of Pro Rata Basis, as defined in Section
1.37, the percentage based on [**]

  1.51  “United States” shall
  mean the fifty states of the United States of America, the District of Columbia
  and all territories and possessions of the United States of America and any
  other location where the FDA has jurisdiction over medicinal products intended
for human use. 

  ARTICLE 2

  INTELLECTUAL PROPERTY LICENSES

2.01  Grant of Licenses; Assignment.

     (i)  No restriction of license rights under the Residual Rights Agreement.
The parties are agreed that the following provisions shall
  not in any way remove or restrict the rights pertaining to the grant of licenses
  to either party (“RRA License Rights”) as they exist pursuant to
  the Residual Rights Agreement. In the event of a conflict between this Agreement
  and the Residual Rights Agreement with respect to the RRA License Rights, the
relevant provisions of the Residual Rights Agreement shall take precedence. 

       (ii)  Grant by Savient.
  Savient hereby grants to BTG, and, if applicable, shall cause its Affiliates
  to grant to BTG, a fully paid-up, royalty-free, non-exclusive license within
  the State of Israel (“BTG Territory”) to manufacture, have manufactured,
  produce, have produced, develop, have developed, use, have used, offer for
sale, have offered for sale, sell, have sold, 

  export, and have exported Bulk Product under the Savient Patent Rights, the Savient KnowHow, and the rights to the Savient Improvements for supply exclusively to Savient.

       (iii)  Grant by BTG. BTG hereby grants to Savient and, if applicable, shall cause
its Affiliates to grant to Savient, a fully paid-up, royalty-free, non-exclusive license in the Territory to manufacture, have manufactured, produce, have produced, develop, have developed, use, have used, offer for sale, have offered for sale,
sell, have sold, export, and have exported Bulk Product under the BTG Licensed Improvements and BTG Know-How.

       (iv)  Assignment by BTG. BTG shall promptly assign (and, if applicable, shall cause its Affiliates to assign)
to Savient all right title and interest in and to any invention or discovery which may be claimed as a BTG Assigned Improvement. BTG shall execute (and, if applicable, shall cause its Affiliates to execute) such documents as may be necessary to
obtain, perfect or maintain any patent rights arising out of the BTG Assigned Improvements, and shall cooperate with Savient so far as reasonably necessary with respect to furnishing all information and data in its possession which is reasonably
necessary or useful to obtain and maintain such patent rights.

  2.02  Notice
  of Improvements & Joint Inventions. BTG shall give Notice to Savient of all BTG Assigned Improvements, BTG Licensed
Improvements and Joint Inventions promptly within due course of the discovery or creation thereof, but in any event at least thirty (30) days prior to any proposed publication thereof by BTG, its Affiliates or Sublicensees. Savient shall give Notice
to BTG of all Savient Improvements and Joint Inventions promptly within due course of the discovery or creation thereof, but in any event at least thirty (30) days prior to any proposed publication thereof by Savient, its Affiliates or Sublicensees.
The Parties shall, in any event, notify each other no less than annually, of whether they have made any BTG Assigned Improvements, BTG Licensed Improvements, Savient Improvements or Joint Inventions, as the case may be. 

  2.03  Disclosure of Know-How. BTG shall disclose, and shall cause its Affiliates to disclose, as soon as reasonably practicable, to Savient
all BTG Know-How acquired, developed or which comes to be possessed by the BTG or any of its Affiliates after the date hereof (and upon reasonable request by Savient, shall make such disclosure in writing).

2.04  Use of Joint Inventions. 

       (i)  Subject to subsections (ii) and (iii) hereof, each Party shall have the right to practice under the Joint Invention rights without any duty of accounting to the other Party. 

       (ii)  BTG agrees that, except as otherwise agreed by the Parties in writing, it shall not (and shall, if applicable, ensure that its Affiliates
shall not) (A) grant any license under the Joint Invention Rights to any other Person to manufacture, have manufactured, produce, have produced, develop, have developed, use, have used, market, have marketed, import, have imported, export, have
exported, sell or have sold any Competing Product, or (B) practice any Claim under the Joint Inventions rights to manufacture, have manufactured, produce, have produced, develop, have developed, use, have used, market, have marketed, import, have
imported, export, have exported, sell or have sold any Competing Product.

       (iii)  Each Party agrees that it shall (and shall, if applicable, ensure that its Affiliates shall) notify the other Party before granting any
license to any other Person to manufacture, have manufactured, produce, have produced, develop, have developed, use, have used, import, have imported, export, have exported, offer for sale, have offered for sale, sell or have sold any product
outside the Field under the Joint Invention rights; provided, however, that neither Party shall grant or purport to grant any license under the Joint Invention rights that is exclusive as to
the other Party or its assignees or Sublicensees without the prior written consent of such other Party. 

  2.05  Sublicensing. Savient shall have the right to grant sublicenses of licenses granted to it in Section 2.01 of this Agreement to its
Affiliates and to any Third Party; provided, however, that Savient,
to the extent applicable, (i) ensures that each such Sublicensee and Third Party
shall consent to be bound by the terms of this Agreement as a Sublicensee or
Third Party and to the same extent as Savient with respect to such Sublicenses
or Third Party’s activities, (ii) informs BTG, in
confidence, of each sublicense granted, and any modification or termination thereof,
within sixty (60) days after the modification, or termination of a sublicense
and (iii) guarantees to BTG the performance of any of its obligations which it
fulfills through sublicensing and remains primarily liable for the performance
of such obligations. 

  2.06  OCS Requirements. BTG shall not without prior written approval of Savient (and, if applicable, shall ensure that its Affiliates shall not) take any action (including,
without limitation, Processing the Bulk Product outside the State of Israel) which would (i) cause either Party (or any of their Affiliates) to violate any of the OCS Requirements or (ii) result in any increase of royalties due to OCS. Additionally,
upon request by Savient, BTG shall cooperate and collaborate with Savient in applying to the OCS for Savient to carry out the manufacture of the Bulk Product through a Third Party outside the State of Israel. The Parties acknowledge the rights and
obligations of each Party under Section 5 of the Residual Rights Agreement and each Party shall honor such rights and obligations set forth therein.

  ARTICLE 3

  SPECIFICATIONS; ONGOING REGULATORY ASSISTANCE

  3.01  Specifications.

       (i)  Current Provisional Bulk Product Specifications. The Current Provisional Bulk Product Specifications are attached as Exhibit C. The Parties are agreed that the Current Provisional Bulk Product Specifications may still be subject to modification
based on the outcome of the Validation, as defined and performed pursuant to the Development Agreement, and subject to the mutual agreement of the parties, such agreement not to be unreasonably conditioned, delayed or withheld. 

       (ii)  Initial Commercial Bulk Product Specifications. The initial Commercial Bulk Product Specifications shall
be agreed upon in writing by the Parties, as soon as reasonably practicable after the conclusion of the Validation, as defined and performed pursuant to the Development Agreement, but in no event later than ninety (90) days from the conclusion
of

  the Validation, unless the Parties shall mutually
  agree to extend such time period (hereinafter the “Commercial Bulk Product Specifications”).
  The Commercial Bulk Product Specifications shall be incorporated into this
  Agreement by formal amendment as Exhibit C-1 and shall be the controlling standards
  for the manufacture of Bulk Product pursuant to this Agreement unless and until
  they are changed by written agreement between the parties. In determining the
  Commercial Bulk Product Specifications, the Parties shall take into consideration
  particularly (i) the results of the subsequent development activity of BTG
  under the Development Agreement and (ii) the results of the Validation as defined
and performed pursuant to the Development Agreement.

       (iii)  Amendment of Commercial Bulk Product Specifications. Subject to the provisions of Section 6.02 and 6.03
(including the cost reimbursements provisions thereof), Savient shall have the right to amend the Commercial Bulk Product Specifications from time to time; provided, however, that (i) Savient shall use commercially reasonable efforts to minimize the frequency of such changes and shall provide BTG with reasonable advanced Notice of any changes to the Commercial Bulk
Product Specifications (but, in any event, at least ninety (90) days advance notice) and (ii) the Parties have agreed in writing upon the implications and costs related to any contemplated changes pursuant to this Section 3.01, which agreement shall
not be unreasonably conditioned, withheld or delayed. Without in any way limiting the foregoing, any modifications to the Commercial Bulk Product Specifications required by any Regulatory Agency with jurisdiction to require such modifications shall
be made in accordance therewith. 

    3.02  Ongoing Assistance by BTG for Initial and Subsequent Filings or Applications.

       (i)  Upon the expiration or earlier termination of the Development Agreement, BTG
hereby agrees to provide, in respect to any jurisdiction within the Territory (A) all information and assistance which is reasonably necessary for or useful in the preparation of (i) comprehensive and complete INDs and BLAs,
including, without limitation, the Chemistry Manufacturing and Controls (CMC) section of the BLAs for the Product, (ii) any amendments and supplements to such filings and applications, (iii) subsequent filings and applications for secondary
indications or additional marketing, sale, importing, exporting authorizations, or (iv) similar filings and applications and (B) access to the Facility and pertinent information to FDA inspectors conducting the pre-approval inspection. All documents
to be supplied by BTG pursuant to this Section 3.02 or any other provision of this Agreement shall be translated by BTG into the English language as may be necessary. Any labor costs of BTG employees and/or Third Party expenses incurred by BTG
related to this assistance shall be reimbursed by Savient in the manner and at the rates set forth on Exhibit B hereto. 

       (ii)  Ownership. The Parties agree that all INDs and BLAs arising under this Agreement, including any and all
modifications and supplements thereto, will be owned by and held in the name of Savient and will list BTG in accordance with its role as contemplated under this Agreement and in compliance with the Legal Requirements. BTG shall have no rights in or
to the IND or BLA and any and all modifications and supplements thereto, other than any rights specifically granted pursuant to this Agreement.

  3.03  Record and Files.
  Upon the expiration or earlier termination of the Development Agreement, BTG
  shall maintain those documents required by the applicable Legal Requirements
  during the Term and for any period required by such Legal Requirements. BTG
  shall maintain those records specified in 21 C.F.R. § 600.12(e) for cases
  of divided manufacturing responsibility for biologics and shall provide the
  records as specified therein to any Third Party fillers or manufacturers designated
by Savient. 

  ARTICLE 4

  SUPPLY OF INGREDIENTS AND MATERIALS

4.01  Procurement of Ingredients and Materials.

       (i)     Ordinary and Safety Stocks. Ingredients and materials necessary for the Processing of Bulk Product shall be purchased and stored by BTG in accordance with the terms of the Quality Agreement and in commercially reasonable and prudent production and safety stock quantities necessary to meet the Bulk
Product Forecast (as defined in Section 5.03) giving due regard to the potential for production and batch failures, Bulk Product loss until delivery to Savient and the amendment of the Bulk Product Forecast in accordance with Section
5.06.

       (ii)  PEG Purchases from NOF.
  The foregoing notwithstanding, Savient, in its sole and absolute discretion,
  shall have the right, but not the obligation, to directly contract with NOF
  Corporation for m-PEG-NPC (mono-methoxy polyethylene glycol nitro-phenyl carbonate)
  (hereinafter the “PEG”) necessary for BTG to Process the Bulk Product, provided, however, in
  the event Savient elects to do so, then (i) Savient shall use best efforts
  to ensure that adequate stock, including safety stock quantities, of PEG, in
  amounts to be agreed upon between the Parties, are delivered to BTG in a timely
  manner in order to enable BTG to fulfill its obligations to Process Bulk Product
  to meet the requirements of all Purchase Orders placed by Savient pursuant
  to Section 5.05; (ii) BTG agrees that it will, in accordance with the terms
  of the Quality Agreement, store and test, as applicable, such stock of PEG
  delivered by NOF; (iii) BTG shall reimburse Savient for the cost of any PEG
  utilized in the Processing of Bulk Product that is determined to be (a) Non-Conforming
  Bulk Product, or (b) a failed batch; (iv) that such agreement between Savient
  and NOF shall not materially interfere with the terms of this Agreement or
  unduly interfere with BTG’s ability to carry out its work; and (v) the
  inability of BTG to perform under the terms of this Agreement, where such failure
  is due to the failure of Savient to ensure the timely delivery to BTG of adequate
  stock of PEG shall not be deemed to be a breach by BTG of its obligations under
this Agreement.

  4.02  Maintenance of Genetic Material. From the Effective Date, BTG shall (or shall procure one of its Affiliates to) maintain such quantity
of Genetic Material to meet Purchase Orders placed and the Bulk Product Forecast provided by Savient pursuant to ARTICLE 5. In the event of the expiration or termination of this Agreement, BTG shall, within thirty (30) days of the effective date of
such expiration or termination, transfer to Savient or its designee any and all remaining quantities of Genetic Material. Any labor costs of BTG employees and/or Third Party 

expenses incurred by BTG related to transfer of Genetic Material shall be reimbursed by Savient in the manner and at the rates set forth on Exhibit B hereto. 

  4.03 Reference Materials. BTG shall provide Savient with any physical, chemical or biological material that is otherwise unavailable, which
is to be used as a reference standard in the testing of Bulk Product, ingredients or raw materials. Such physical, chemical or biological material shall be provided to Savient at [**]. Payments due by Savient under this Section 4.03 shall be payable
by Savient no later than [**] days after the invoice date. 

  ARTICLE 5

  BTG FACILITY CAPACITY, FORECASTING, PURCHASE ORDERS 

AND ORDER CONFIRMATIONS 

  5.01  BTG Facility Bulk Product Processing Capacity and Capacity Reservation Fee. BTG shall provide Savient with any physical, chemical or biological material that is otherwise unavailable, which
is to be used as a reference standard in the testing of Bulk Product, ingredients or raw materials. Such physical, chemical or biological material shall be provided to Savient at [**]. Payments due by Savient under this Section 4.03 shall be payable
by Savient no later than [**] days after the invoice date. 

       (i)  Existing Facility Capacity. Savient and BTG acknowledge that based on the (A)
Purification Area used in the Processing of Bulk
  Product, (B) the Fermentation Area and the Recovery Area used from time to
  time for the Processing of Bulk Product, (C) methods, processes and procedures
  currently utilized in the Processing of Bulk Material as of the Effective Date,
  and (D) [**] in the Facility as of the Effective Date (hereinafter the “Capacity Parameters”),
  the BTG Facility has the projected capacity to Process up to [**] batches of
  Bulk Product per calendar year in the absence of other products manufactured
  in the areas specified above. Additionally, Savient and BTG acknowledge that
  this capacity could be increased, upon appropriate advance notice, if additional
shift operations were implemented and/or certain Facility changes were made.

       (ii)  Subject
  to the terms set forth in this Section 5.01(ii), in order to reserve capacity
  at BTG for the Processing of Bulk Product, for all Bulk Product forecasted
  by Savient to be Processed by BTG and purchased by Savient prior to the Commercial
  Launch of the Product and through [**] (hereinafter the “Reservation Fee Period”),
  Savient shall remit to BTG a Processing Capacity Reservation Fee in the amounts
and manner set forth below: 

       (A)  Within
  ten (10) Business Days of the provision of the Preliminary Bulk Product Forecast
  pursuant to Section 5.02, Savient shall remit to BTG a Processing Capacity
Reservation Fee of [**] Dollars ($[**]). 

       (B)  Within
  ten (10) Business Days of the provision of the Bulk Product Launch Forecast
  pursuant to Section 5.03, Savient shall remit to BTG a Processing Capacity
  Reservation Fee equal to the amount required to bring Savient’s Processing
  Capacity Reservation Fee, when added to the amount remitted under Section 5.01(ii)(A),
  to [**] percent ([**]%) of the applicable Price, as defined in Section 8.01,
  of the number of batches of Bulk Product reflected on such Bulk Product Launch
  Forecast, provided, however, if the amount calculated under this Section 5.01(ii)(B)
  is less than the Processing Capacity Reservation Fee remitted under Section
  5.01(ii)(A) the Processing Capacity Reservation Fee shall remain at such higher
  amount. In the event that the initial Bulk Product Launch Forecast pursuant
to section 5.03 is not provided by September 30,

  2007, then Savient shall remit monthly to BTG an
  additional Processing Capacity Reservation Fee of $[**] for each additional
month that passes until the provision of the initial Bulk Product Launch Forecast.

       (C)   Within
  ten (10) Business Days of the provision of any Bulk Product Forecast pursuant
  to Section 5.03 or any Amended Bulk Product Forecast provided by Savient pursuant
  to Section 5.06 provided by Savient on or before July 1, 2009, Savient shall
  remit to BTG a Processing Capacity Reservation Fee equal to the amount required
  to bring Savient’s Processing Capacity Reservation Fee,
when added to the amount remitted under Sections 5.01(ii)(A) and 5.01(ii)(B),
  to [**] percent ([**]%) of the applicable Price, as defined in Section 8.01,
  of the number of batches of Bulk Product reflected on such Bulk Product Forecast
  or Amended Bulk Product Forecast that are projected for purchase during the
  Reservation Fee Period, provided, however, if the amount calculated under this
  Section 5.01(ii)(C) is less than the aggregate of the Processing Capacity Reservation
  Fee remitted under Sections 5.01(ii)(A) and 5.01(B) the Processing Capacity
Reservation Fee shall remain at such higher amount. 

       (D)  All Processing Capacity Reservation Fee amounts remitted by Savient to BTG under this Section 5.01(ii) shall: 

  (1)  earn interest at the [**] with the interest earned thereon inuring to the sole benefit of Savient; 

  (2)  be credited, inclusive of interest, by BTG on a per batch basis by providing a [**]% discount on the value of each batch at the time of invoicing for Bulk Product purchased by Savient during the Reservation Fee Period until it
is fully utilized, provided however, except as otherwise provided in Sections 5.01(ii)(F), 5.01(ii)(G) and 5.01(ii)(H), any uncredited Processing Capacity Reservation Fee, inclusive of interest, remaining at the end of the Reservation Fee Period due
to a failure by Savient to take delivery of Bulk Product which conforms to the Commercial Bulk Product Specifications and which is ordered pursuant to a Bulk Product Forecast provided pursuant to Section 5.03 or an Amended Bulk Product Forecast
provided pursuant to Section 5.06 and which is otherwise properly amended pursuant to Section 5.05 shall be forfeited by Savient to BTG. For purposes of clarity, the credit of the Processing Capacity Reservation Fee shall accrue upon the delivery of
the Bulk Product by BTG to Savient and shall be reflected on the invoice which relates to the Bulk Product shipment in question; and

  (3)  BTG shall provide to Savient a quarterly statement within [**] Business Days of the end of each calendar quarter of the then current balance of the Processing Capacity Reservation Fee, inclusive of interest, available for
credit to the purchase of Bulk Product by Savient. 

       (E)  Subject to the last sentence of this Section 5.01(ii)(E), Savient and BTG acknowledge and agree that by the conclusion of the Reservation
Fee Period the demand

  for Savient’s Product will be sufficiently
  capable of reliable forecasting as to negate the need for a Processing Capacity
  Reservation Fee and that such will not be required for Bulk Product forecasted
  for purchase beyond the expiration of the Reservation Fee Period. On that basis,
  the final Processing Capacity Reservation Fee shall be due based on [**] percent
  ([**]%) of the applicable Price, as defined in Section 8.01, of the number
  of batches of Bulk Product reflected on the Bulk Product Forecast or Amended
  Bulk Product Forecast that is submitted for the period [**]. If there is a
  delay in the commercial launch of the Product beyond [**] or any other factor
  reasonably preventing a reliable Bulk Product forecasting by the conclusion
  of the Reservation Fee Period, then the Parties will meet in good faith and
  discuss whether a further capacity reservation fee is necessary or appropriate
and, if it is agreed necessary, for what duration and amount, if any.

       (F)  Anything to the contrary notwithstanding, in the event that any amount of the Processing Capacity Reservation Fee, inclusive of interest,
remains unused or unapplied at the end of the Reservation Fee Period due to a failure by BTG for any reason, including Force Majeure conditions affecting BTG or the import, export or
transportation of the Bulk Product which is beyond the reasonable control of BTG or Savient, to timely deliver any number of batches of Bulk Product properly ordered and accepted in accordance with the terms of this Agreement, then any amount of the
Processing Capacity Reservation Fee, inclusive of interest, which would have been used for or applied to the purchase of Bulk Product but for the non-delivery or untimely delivery thereof, shall be refunded to Savient by wire transfer within [**]
Business Days of the end of the Reservation Fee Period. For purposes of determining timely delivery pursuant to this section, the delivery dates identified in a Purchase Order submitted and accepted in accordance with Section 5.05 herein shall be
considered binding, except in the event of a Force Majeure condition affecting BTG or the import, export or transportation of the Bulk Product which is beyond the reasonable control of BTG
or Savient, in which case the Parties shall agree upon a reasonable extension of the delivery date in accordance with Section 14.14 hereof.

       (G)  In the event this Agreement is terminated by Savient pursuant to Sections 11.02 (ii) (for Force
Majeure conditions affecting BTG), 11.02 (iii) (Material Breach by BTG), or 11.02 (v) (for insolvency of BTG) hereof, any amount of the Processing Capacity Reservation Fee and accrued interest thereon which has not been
applied to payments for Bulk Product actually purchased by and delivered to Savient, shall be returned to Savient via wire transfer within [**] days of the effective date of termination of this Agreement. In the event this Agreement is terminated
with the mutual consent of both Parties, then, as part of such mutual consent, the Parties shall discuss in good faith and reach resolution with regard to the disposition of the then-existing Capacity Reservation Fee, including any interest thereon,
having due regard for the reasons and basis that lead the Parties to terminate this Agreement by mutual consent.

       (H)  Savient
  and BTG further acknowledge and agree that in the event the BLA for Savient’s
  Product is not filed with the FDA on or before December 31, 2008 then the Processing
  Capacity Reservation Fee previously paid by Savient to BTG and accrued interest
thereon relating to Bulk Product Forecasts provided by Savient before December 

  31, 2008 shall be refundable to Savient only in the event and to the extent that BTG is able, with the use of best efforts, to mitigate its losses by scheduling into the Processing Capacity reserved for Savient during such period
production of a product or products on behalf of BTG, an Affiliate, or a third party, or any combination thereof.

  5.02  Preliminary Bulk Product Forecast.
  As soon as reasonably practicable, but in no event later than thirty (30) days
  from the date of full execution of this Agreement, Savient shall provide BTG
  a preliminary, non-binding projection of its first eighteen month rolling forecast
  that sets forth Savient’s then best estimate of the date for the delivery of the first commercial quantity
of Bulk Product and the total quantity of Bulk Product for commercial supply that Savient expects to order from BTG within the eighteen (18) month period following delivery of such first commercial quantity (“Preliminary Bulk Product
Forecast”). In the Preliminary Bulk Product Forecast, Savient shall: 

       (i)  set forth the assumptions it is utilizing for the establishment of the date for the delivery of the first commercial quantity of Bulk
Product; 

       (ii)  include a breakdown of the total quantity of Bulk Product by month for the eighteen months following the delivery of the first commercial
order; and

       (iii)  identify the variables, Process and regulatory questions and issues and logistical considerations that could impact the date for the
delivery of the first commercial quantity of Bulk Product. 

  Within thirty (30) days of the issuance of the Preliminary Bulk Product Forecast, Savient and BTG shall meet to commence good faith discussions and agree on the methodology and timeline for bringing to resolution and conclusion
any and all Process and regulatory questions, issues and logistical considerations outlined in the Preliminary Bulk Product Forecast. Savient and BTG shall use their mutual best efforts to conclude these discussions and reach final resolution as
soon as reasonably practicable, but in no event later than July 30, 2007, unless the parties mutually agree that additional time is required.

  5.03  Bulk Product Launch Forecast and Bulk Product Forecast.
  Commencing at least twelve (12) months prior to the delivery date of the first
  Firm Order, Savient shall submit to BTG its final initial launch Bulk Product
  forecast which shall set forth month by month an eighteen (18) month rolling
  forecast that sets forth the total quantity of Bulk Product for commercial
  supply that Savient either has ordered, desires to order, or expects to order
  from BTG within the eighteen (18) month period following delivery of such first
  commercial quantity (“Bulk Product Launch Forecast”). Thereafter, Savient shall provide on a monthly
basis on or before the first Business Day of each calendar month an updated Bulk Product forecast for the next ensuing eighteen (18) month rolling period (“Bulk Product Forecast”).
In the Bulk Product Forecast, Savient shall:

       (i)  include a breakdown of the total quantity of Bulk Product by month for the following eighteen (18) month rolling period; and 

       (ii)  in respect of the monthly breakdown under (i) above, identify the relevant set of Bulk Product Specifications. 

  As used herein, the term “Forecast” shall
  mean, as applicable, the Bulk Product Launch Forecast or Bulk Product Forecast,
as may be amended from time to time pursuant to Section 5.06 hereof. 

  5.04  Firm Orders and Firm Forecasts. The Bulk Product Forecast submitted monthly by Savient shall breakdown by month of the next ensuing eighteen (18) months of the Bulk
Product Forecast and shall consist of: 

       i.  a
  rolling firm irrevocable order for the first two (2) quarters (i.e. quarters
  1 and 2) of the Bulk Product Forecast (“Firm
Order”), which shall each be the subject of a Purchase Order delivered and
confirmed in accordance with Section 5.05;

       ii.  a
  rolling two (2) quarter forecast for the second two (2) quarters (i.e. quarters
  3 and 4) of the Bulk Product Forecast (each a quarterly
“Firm Forecast”); and 

       iii.  a
  rolling two (2) quarter estimate for the third two (2) quarters (i.e. quarters
  5 and 6) of the Bulk Forecast (each a quarterly
“Estimated Forecast”). 

  5.05  Purchase Orders and Order Confirmations.
  Savient will accompany its monthly update of the Bulk Product Forecast with
  a written purchase order (“Purchase
Order”) for each new Firm Order that was only a Firm Forecast in the previous month’s
Bulk Product Forecast. Each Purchase Order shall specify the Bulk Product ordered
and the time, manner and address of delivery, all of which shall be subject to
this ARTICLE 5. BTG shall confirm each Purchase Order in a written order confirmation
within seven (7) Business Days after receipt of the Purchase Order.

  5.06  Amending Forecasts.
  Any Bulk Product Forecast that is not a Firm Order is to be considered a forecast
  or estimate to be used for planning purposes, and shall not be construed as
  a firm commitment by Savient to BTG and thus can be increased or reduced by
  Savient from time to time. Savient shall be entitled at any time up until and
  including the time that a Firm Forecast or Estimated Forecast becomes a Firm
  Order, to increase or decrease such monthly Firm Forecast or Estimated Forecast
  for Bulk Product, provided, however, such increases or decreases on a monthly
  basis shall not be greater than twenty-five percent (25%) of the originally
  forecasted quantity for such month and each month may not be increased and
  decreased more than one time. As a request by Savient to increase the quantity
  of Bulk Product in a Firm Forecast prior to its becoming a Firm Order may require
  longer lead times for delivery than requested by Savient, both Parties shall
  agree jointly on a new delivery date as close as possible to the requested
  date having due regard for BTG’s commercial commitments to Third Parties
  and its own production needs, such agreement to not be unreasonably withheld,
  conditioned or delayed. Once a Firm Forecast becomes a Firm Order, Savient
  may not reduce it, but may request that BTG increase the quantity of Bulk Product
  subject to a Firm Order and BTG shall use commercially reasonable efforts to
fill the increased order.

5.07  Fulfillment of Purchase Orders; Review of Forecasts.

       (i)  BTG shall satisfy, in accordance
    with their terms, Savient’s Purchase Orders, provided and confirmed in accordance with Section 5.05. BTG shall promptly notify Savient if it becomes aware or believes that it will not be able to satisfy such Purchase Orders on time, in full, or at all, which Notice shall
include an explanation in reasonable detail of the reason for 

  BTG’s failure to comply with a confirmed Purchase Order and its proposed course of action for remedying such failure. Savient shall be entitled to request BTG to produce evidence to support its Notice, BTG’s
response to such request shall not be unreasonably denied or delayed.

       (ii)  Within ten (10) Business Days of its receipt of the Bulk Product Launch Forecast or a Bulk Product Forecast or any amendment thereto, BTG shall review such Forecast and in the event that BTG
believes that it will not be able to satisfy the quantity, time or manner for delivery of any portion of the order for any amount of Bulk Product identified in any portion therein (i.e.: in the Firm Order, Firm Forecast or Estimated Forecast
portions), BTG shall notify Savient of the same, provide a reasonable explanation of the cause of its inability to do so and provide alternatives for the delivery of the quantity and/or scheduling or manner of delivery to satisfy the requirements of
Savient.

       (iii)  Unless BTG has indicated, in accordance with Section 5.07(ii), an inability to satisfy the identified quantities of Bulk Product in the Bulk Product Launch Forecast, any Bulk Product Forecast,
or any amendment thereto, BTG may not refuse to accept a Purchase Order which does not deviate from the previously provided Bulk Product Launch Forecast, Bulk Product Forecast or amended forecast, as the case may be when, on a rolling basis, months
contained in a Firm Forecast or Estimated Forecast period becomes a Firm Order. 

       (iv)  In the
  event that BTG notifies Savient of its inability to supply any subject quantity
  of Bulk Product identified in the Bulk Product Launch Forecast, any Bulk Product
  Forecast or amended forecast, the parties agree to work together in good faith
  to expeditiously resolve the discrepancy between the subject forecast and BTG’s
inability to supply Bulk Product in accordance therewith.

  5.08  Effect of Supply Failure.
  In the event of a Supply Failure (as defined herein), no forecast or estimate
  shall be considered a Firm Order until such time as BTG proves to Savient’s
  reasonable satisfaction that the cause of such Supply Failure has been corrected. “Supply Failure” shall
  mean BTG has experienced [**] failed batches of Bulk Product within a calendar
  quarter, or [**] failed batches of Bulk Product aggregated over the course
  of two consecutive quarters, or [**] failed batches of Bulk Product aggregated
  over the course of a calendar year. For purposes of this definition, any Bulk
  Product that is discovered and notified by Savient in accordance with Section
  6.04 (iv) to be Non-Conforming Bulk Product after delivery shall be considered
  a failed batch. In the event of a Supply Failure during the Reservation Fee
  Period, the period covered by the Reservation Fee Period shall be extended
by the quarterly or other period of such Supply Failure.

  5.09  Preferential Right of Supply.
  BTG shall schedule its own products or those of an Affiliate for processing
  at the Facility and shall not accept from a customer that is a Third Party
  any orders for product processed at the Facility to the extent the fulfillment
  of such scheduling or order could, at the time of BTG’s scheduling or acceptance of such Third Party order, reasonably be expected to impede BTG’s
ability to fulfill Savient’s Bulk Product Requirements as reflected on the
then current monthly Firm Orders, Firm Forecast and Estimated Forecast submitted
by Savient pursuant to Section 5.04 and acted upon by the Parties pursuant to
Sections 5.05, 5.06, and 5.07 supra. 

  5.10  Alternative Supplier. Savient shall have the right to establish an alternative supplier for Bulk Product for up to twenty percent (20%) of its annual world-wide Bulk
Product requirements; provided, however,

       (i)  in the
  event of a Supply Failure under Section 5.08 above, Savient shall have the
  right to purchase all of its Bulk Product requirements from an alternative
  supplier upon reasonable prior written notice to BTG until BTG demonstrates
  to Savient’s reasonable satisfaction that BTG has fully remedied such
Supply Failure, and 

       (ii)  if
  despite the good faith efforts of BTG to modify its Capacity Parameters to
  meet the needs of Savient, or, as applicable, the Parties good faith efforts
  to agree on cooperative methods to modify the BTG Capacity Parameters, Savient’s Forecasts for orders of Bulk Product up to the OCS Requirements are reasonably anticipated to exceed BTG’s available capacity for the
Processing of Bulk Product, then Savient shall have the right to purchase any and all of its requirements of Bulk Product that Savient reasonably determines in good faith may exceed BTG’s available capacity from Savient’s
alternate supplier.

  BTG acknowledges its obligation to assist Savient with Technology Transfer to an alternative contract manufacturing organization in accordance with the terms and conditions of Section 5.02 of the Development Agreement.

  5.11  Effect of Termination on Purchase Order. Unless otherwise agreed to in writing by the Parties, the termination of this Agreement shall automatically terminate all
then existing Purchase Orders, except when the termination of this Agreement is pursuant to Sections 11.02 (i) (Elective) and 11.02(iv) (Material Breach by Savient), provided such material breach by Savient is not based on the non-payment of
non-disputed amounts for Bulk Product deliveries, in which case BTG shall honor and fulfill any then existing Purchase Order and Savient shall pay BTG for any Purchase Order so honored and fulfilled by BTG pursuant to the terms of this Agreement.

  ARTICLE 6 

  

  PRODUCTION

  6.01  Obligation to Supply and Purchase.
  BTG shall manufacture and supply all Bulk Product quantities ordered by Savient
  and confirmed by BTG in accordance with the provisions of this Agreement. The
  Parties acknowledge and agree that, pursuant to the OCS Requirements and subject
  to the terms of this Agreement, Savient is obligated to order at least 80%
  of its annual world-wide Bulk Product requirements from BTG (“OCS Annual Requirements”)
  and BTG is obligated to provide such OCS Annual Requirements. BTG shall bear
  all risk of loss associated with production and batch failures or loss of Bulk
  Product until delivery to Savient, in accordance with the provisions of Section
7.01.

  6.02  Process Changes.

       (i)  Prior Approval of Savient Required. Except as set forth in this Section 6.02, BTG shall not make any change to the Process for the Bulk Product that would have an impact on

  the Bulk Product or Product, result in a change to the Commercial Bulk Product Specifications or the Product Specifications or require submissions to or approvals from any Regulatory Agency, except by prior written approval of
Savient for such change, which approval shall not be unreasonably conditioned, withheld or delayed. 

       (ii)  Changes Based on Applicable Legal Requirements. BTG shall make such changes to the Process for the Bulk
Product as may be required pursuant to applicable Legal Requirements; provided that BTG shall have notified Savient in advance of any required change and shall have obtained the prior written approval of Savient for such change, which approval shall
not be unreasonably conditioned, withheld or delayed. Costs incurred by BTG in connection with changes to the Process for the Bulk Product that are required pursuant to Legal Requirements applicable solely to the Process for the Bulk Product,
including but not limited to the purchase of equipment, shall be paid by Savient in advance, or on such other basis as the parties may agree at such time, of the incurrence of such charges at (x) [**] percent ([**]%) of cost [**]; (y) [**], if
applicable, as per Exhibit B; (z) [**] at [**] percent ([**]%) of cost; provided, however, that Savient shall have explicitly approved in writing any contemplated changes pursuant to this
Section 6.02(ii) prior to BTG implementing any such changes. To the extent that the cost of any purchase of equipment is fully allocated to Savient, title to such equipment shall vest in Savient and Savient shall have the right, but not the
obligation, to remove such equipment at its sole cost and expense upon the expiration or termination of this Agreement. 

       (iii)  Changes Made at the Request of Savient.
  From time to time, Savient may request that BTG make certain changes (other
  than those required by Legal Requirements) to the Processing of the Bulk Product;
  provided, however, that (A) Savient shall seek to minimize such changes, (B)
  Savient shall enter into good faith negotiations with BTG regarding the implementation
  of any such change to the Processing of the Bulk Product, with BTG’s consent
  to such change not being unreasonably withheld, conditioned, delayed or denied
  and (C) after the Parties have agreed upon the implications and costs related
  to a change to the Processing of the Bulk Product, BTG shall implement such
  change. Costs incurred by BTG in connection with such changes shall be reimbursed
  by Savient at (x) [**] percent ([**]%) of cost excluding [**]; (y) [**], if
  applicable, as per Exhibit B; (z) [**] at [**] percent ([**]%) of cost. To the extent that the contemplated changes requested by Savient necessitate the purchase of equipment and the cost of
such purchase of equipment is fully allocated to Savient, title to such equipment shall vest in Savient and Savient shall have the right, but not the obligation, to remove such equipment at its sole cost and expense upon the expiration or
termination of this Agreement. 

       (iv)  Improvements by BTG. If BTG identifies a potential improvement that would (A) require changes to the
Process, (B) have an impact on the Product or Bulk Product or (C) require submissions to or approvals from any Regulatory Agency, then BTG shall notify Savient of such improvement and the Parties shall, in good faith, discuss implementation of such
improvement. Such improvement shall not be made unless the Parties reach agreement including, without limitation, agreement on allocation of cost, which agreement shall be at the sole discretion of the Parties. To the extent that the contemplated
changes necessitate the purchase of equipment and the cost of such purchase of equipment is fully allocated to Savient, [**]. 

     (v)   Price Adjustment. In the event of any changes to the Process, pursuant to this Section 6.02, the Parties
will meet and discuss the impact such Process changes have on the cost of Processing Bulk Product, either negative or positive, and will negotiate the resulting adjustment to the Price, as defined in Section 8.01, such adjustment to appropriately
reflect the investment made by each Party in such Process changes relative to the manner in which such changes impact the cost of Processing the Bulk Product. To effectuate this Section 6.02(v), both parties shall exchange appropriately detailed
documentation and analysis required to adequately assess the negative or positive impact such Process changes have on the cost of Processing Bulk Product.

  
    6.03    Facility Changes.

     (i) Facility Changes by BTG.
      From time to time, BTG may desire to make certain changes or modifications
      to its Facility (other than those required by Legal Requirements) (“Facility Changes”)
      which Facility Changes impact, directly or indirectly, the Processing of
      the Bulk Product. BTG shall be entitled to make Facility Changes which
      impact, directly or indirectly, the Processing of the Bulk Product without
      the prior approval of Savient, provided, however: 

       (A) prior to
  the approval of the BLA for Savient’s Product, BTG shall (x) use its best efforts to minimize Facility Changes which impact, directly or indirectly, the Processing of the Bulk
Product, and (y) not implement any Facility Changes that will inhibit BTG’s ability to meet its obligations to supply Savient’s requirements under this Agreement or require the approval of a Supplement to the BLA for Savient’s
Product, unless such change is unavoidable;

       (B) after the
  approval of the BLA for Savient’s Product, BTG shall not implement any Facility Changes that will inhibit BTG’s ability to meet its obligations to supply Savient’s
requirement under this Agreement unless and until the Parties have agreed to a plan for inventory stockpiling to satisfy Savient’s
requirements, and; 

       (C) BTG shall
  promptly provide Savient notice of its Facility Changes which may impact, directly
  or indirectly, the Processing of the Bulk Product prior to the anticipated
  commencement of such Facility Changes and shall enter into good faith negotiations
  with Savient regarding the implementation of any such Facility Change and the
  satisfaction of Savient’s requirements for the stockpiling of safety stocks
  on Bulk Product in order that Savient can meet the clinical and market demands
  of its Product.

  Under no circumstances shall BTG implement a Facility
  Change which may endanger the quality of the Bulk Product. Costs incurred by
  BTG in connection with such Facility Changes shall be borne by BTG. As used
  in this Section 6.03(i), “promptly” shall mean, given the nature
  and substance of the Facility Change, that period of time commercially reasonably
  necessary to complete the discussions and negotiations envisaged herein.

       (ii) Facility Changes Based on Applicable Legal Requirements. BTG shall make such changes to the Facility as
may be required pursuant to applicable Legal Requirements; provided that BTG shall promptly notify Savient in advance of such planned Facility Change;

provided, however,
that such notice from BTG shall be provided not later than ten (10) Business
Days following BTG’s being notified of the necessity of changes to the Facility
pursuant to Legal Requirements. Costs incurred by BTG in connection with such
changes shall be reimbursed by Savient as follows: 

       (A) Changes
  Specific to Savient’s Bulk Product.
  To the extent that changes to the Facility, including but  not limited to the
  purchase of equipment, are required pursuant to Legal Requirements applicable
  solely to the Bulk Product, costs incurred for such changes shall be paid by
  Savient in advance of the incurrence of such charges, or on such other  basis
  as the parties may agree at such time, at (x) [**] percent ([**]%) of cost
  [**]; (y) [**], if applicable, as per Exhibit B,
and; (z) [**] at [**] percent ([**]%) of cost; provided, however, that the Parties
shall have agreed to a plan for the satisfaction of Savient’s requirements
for safety stock of the Bulk Product to meet the clinical and market demands
of its Product. To the extent that the cost of any purchase of equipment is fully
allocated to Savient, title to such equipment shall vest in Savient and Savient
shall have the right, but not the obligation, to remove such equipment at its
sole cost and expense upon the expiration or termination of this Agreement. 

       (B) Changes
  Not Specific to Savient’s Bulk Product. To the extent that changes to the Facility are
required pursuant to Legal Requirements applicable to biopharmaceutical manufacturing in general, costs incurred for such changes shall be reimbursed by Savient [**]. 

       (C) Changes in Connection With Another Product. If changes to the Facility are required pursuant to Legal
Requirements applicable solely to other activities or the manufacture of other products in the Facility (even if such changes would not be required in the absence of the Processing of the Bulk Product at the Facility or if the Processing of the Bulk
Product benefits from such changes) the costs incurred for such changes [**]. 

  Provided, however,
  that in the event of changes to the Facility required pursuant to applicable
  Legal Requirements, the Parties shall enter into good faith negotiations regarding
  the implementation of any such Facility Change in a manner intended to minimize
  the interruption of the supply of Bulk Product and, in any event, shall agree
  on a method for the satisfaction of Savient’s requirements for the stockpiling
  of safety stocks of Bulk Product in order that Savient can meet the clinical
  and market demands of its Product. 

       (iii) Changes Made at the Request of Savient. From time to time, Savient may request that BTG make certain
changes to the Purification Area (other than those required by Legal Requirements); provided, however, that

  
         (A)   Savient
    shall seek to minimize such changes,

  
         (B)   Savient shall enter into good faith negotiations with BTG regarding the implementation of any such change,
with BTG’s consent to such change not being unreasonably withheld, conditioned,
delayed or denied and

       (C) after the Parties have agreed upon the implications and costs related to the Savient requested changes, BTG shall implement such changes.

  Costs incurred by BTG in connection with such changes to the Facility shall be reimbursed by Savient at (x) [**] percent ([**] %) of cost [**]; (y) [**], if applicable, as per Exhibit B, and; (z) [**] at [**] percent ([**]%) of cost. To the extent that the contemplated changes requested by Savient necessitate the purchase of equipment and the cost of such purchase of equipment is fully allocated to Savient, title to
such equipment shall vest in Savient and Savient shall have the right, but not the obligation, to remove such equipment at its sole cost and expense upon the expiration or termination of this Agreement. 

       (iv) Price Adjustment. In the event of any changes to the Facility, pursuant to this Section 6.03, the Parties
will meet and discuss the impact such Facility changes have on the cost of Processing Bulk Product, either negative or positive, and will negotiate the resulting adjustment to the Price, as defined in Section 8.01, such adjustment to appropriately
reflect the investment made by each Party in such Facility changes relative to the manner in which such changes impact the cost of Processing the Bulk Product. To effectuate this Section 6.03(iv), both parties shall exchange appropriately detailed
documentation and analysis required to adequately assess the negative or positive impact such Facility changes have on the cost of Processing Bulk Product.

       (v) Alternate Use of Purification Area. BTG shall have the right, but not the obligation, to utilize the
Purification Area for the production, handling or storage of other products during periods when the Purification Area is not being utilized for the Processing of Bulk Product pursuant to the terms and conditions of Section 5.7 in the Quality
Agreement. 

  
    6.04  Quality Assurance.

     (i)  Testing by BTG. BTG shall perform quality testing using assays proposed
by BTG and acceptable to Savient (which acceptance shall not be unreasonably conditioned, withheld or delayed) in order to assure that the Bulk Product complies with the Commercial Bulk Product Specifications, and shall retain
samples of Bulk Product produced and records of the tests made on each such batch in accordance with applicable Legal Requirements. In addition, except as otherwise agreed by the Parties in writing, no Bulk Product shall be delivered until such Bulk
Product has been processed in accordance with the tests, inspections and controls required under the Commercial Bulk Product Specifications and such other tests as the Parties may mutually agree upon in writing; provided, however, that the foregoing shall not relieve BTG of its obligation under ARTICLE 5. BTG shall maintain records with respect to the
quality testing and shall deliver such records to Savient by facsimile or email and overnight courier prior to shipment of the Bulk Product. Savient shall pay for any and all costs and expenses related to the delivery of records to Savient by
overnight courier. Such records shall also be made available to Savient during normal Israeli business hours, upon prior written request. 

       (ii) Notice of Non-Conforming Bulk Product.  BTG shall promptly notify Savient of any Non-Conforming Bulk
Product of which it becomes aware, whether or not such NonConforming Bulk Product been delivered to Savient or its designee, specifying the Bulk Product release testing and batch number. 

     (iii)   Testing by Savient.
At Savient’s election, Bulk Product may be subjected to testing by Savient at
Savient’s facilities or facilities of a Third Party designated by Savient
in order to verify conformance with the Commercial Bulk Product Specifications,
using assays proposed by BTG and acceptable to Savient (which acceptance shall
not be unreasonably conditioned, withheld or delayed). Savient shall maintain
records with respect to the scope and nature of any such testing and shall disclose
such records to BTG in a timely fashion. 

       (iv)   Notice of Delivery of Non-Conforming Bulk Product. Savient shall notify BTG in writing of any
Non-Conforming Bulk Product within

       (A)   forty-five (45) days of delivery of such Non-Conforming Bulk Product in the event of a defect which was discovered or could have been discovered by Savient through the use of reasonable testing
methods and procedures mutually agreed to by the Parties in writing or

       (B)   ten (10)
  Business Days of Savient’s discovery of the Non-Conforming status of the Bulk Product in the event of a defect not recognizable for Savient through the use of such testing methods
and procedures (hereinafter “Hidden Defect”).

  Savient’s notices of any non-conforming Bulk Product shall specify the manner in which the Bulk Product fails to meet the Commercial Bulk Product Specifications,. BTG shall have the right to examine and test any Bulk Product
in Savient’s possession that Savient claims is NonConforming. The Parties shall cooperate to determine the point at which the Bulk Product became Non-Conforming. In the event that the Parties cannot agree as to whether any Bulk Product was
Non-Conforming at the time of delivery, the Parties shall promptly appoint an independent specialist (appointed by mutual agreement between the Parties, which agreement shall not be unreasonably withheld, conditioned or delayed) who shall determine
whether such Bulk Product was Non-Conforming at the time of delivery. In the absence of manifest error, the independent specialist’s
decision shall be conclusive and binding on the Parties.

  Except as otherwise provided herein relating to Hidden Defects in the Bulk Product, if Savient fails to notify BTG in writing of any non-conforming Bulk Product within forty-five (45) days of delivery, then the Bulk Product
delivered by BTG to Savient shall be deemed to be in all respects in accordance with this Agreement and Savient shall be bound to accept and pay for the same accordingly. For the avoidance
of doubt, this shall apply irrespective of whether or not Savient has carried out quality testing in accordance with Section 6.04 (iii). 

       (v)   Observation by Savient.
  During the Term, Savient (including Savient’s agents and consultants) shall
have the right, at Savient’s sole cost and expense, during normal business
hours and upon reasonable notice, to visit the Facility as per the Quality Agreement.

       (vi)   Recalls and Voluntary Withdrawals. If either Party becomes aware of information about distributed Product
containing Bulk Product indicating that it may be NonConforming with respect to the Bulk Product or that there is potential adulteration, misbranding and/or any potential issues regarding safety or effectiveness with respect to the Bulk Product, it
shall promptly serve Notice to that effect on the other Party. Savient will initiate an investigation and assessment of such circumstances and shall promptly notify BTG 

  of its findings and any proposed course of action. The Parties shall meet to discuss such circumstances and to consider appropriate courses of action. Savient shall bear all costs associated with a recall of the Product unless
such recall is caused by a Hidden Defect with respect to the Bulk Product, in which case BTG shall pay all costs associated with the recall, up to the maximum value of the Product Price paid by Savient to BTG for the Bulk Product containing such
Hidden Defect. 

       (vii)   Filled Product Release Testing.
  The Parties acknowledge that BTG is performing the Filled Product release testing
  for Savient under the terms of this Agreement and the Development Agreement
  until such time as the Filled Product release testing and methods can be transferred
  to Savient’s new third party fill/finisher of Product (hereinafter “Third Party Fill/Finisher”)
or alternate Bulk Product or Product supplier. Savient will use its best efforts to effectuate the Technology Transfer of Product Technology to enable such Filled Product release testing to be performed by Savient’s Third Party Fill/Finisher or
its alternate Product supplier as expeditiously as commercially practicable, and upon the approval of such amendments to this Agreement, and, if still in effect at such time, the Development Agreement shall be entered into relieving BTG of its
obligation to perform release testing on Filled Product. It is the express intention of the Parties to mutually use best efforts to accomplish this Technology Transfer in adequate time to file the Product BLA with both BTG and Savient’s
Third Party Fill/Finisher as alternate parties designated to perform the release
testing of Filled Product, provided, however, the
failure to succeed in this regard shall not be deemed a breach by Savient, nor
shall it relieve BTG of its obligations to perform such release testing until
such time as Savient’s Third Party Fill/Finisher is approved to perform
such release testing.

  6.05   Labeling and Packaging. BTG shall label and package the Bulk Product in accordance with Legal Requirements applicable to pharmaceutical
products shipped in bulk for further processing, labeling, or repackaging. 

  6.06   Stability. Stability related activities for which BTG is responsible shall be completed in accordance with Quality Agreement. All costs
incurred by BTG related to such activities shall be reimbursed by Savient in the manner and at the rates set forth on Exhibit B hereto. 

  ARTICLE 7

  DELIVERY; INVOICES; WARRANTY

  7.01   Shipment and Delivery.
  BTG shall use its best efforts to deliver Bulk Product in accordance with the
  delivery dates specified in its order confirmations or the Purchase Orders,
  as may be appropriate. All shipments shall be made by BTG pursuant to Savient’s
  instructions FCA Ben Gurion Airport, Tel Aviv, Israel, (Incoterms 2000) with
  BTG being responsible for delivering the Bulk Product cleared for export to
the freight forwarder nominated by Savient.

  7.02   Certificate of Analysis. An appropriate Certificate of Analysis and all relevant batch records shall precede the shipment of each Bulk
Product batch delivered to Savient. BTG shall, for customs purposes, upon delivery of the Bulk Product, provide Savient with a valid 

  declaration of origin, in a form reasonably acceptable to Savient, in respect of all Bulk Product supplied to Savient under this Agreement, together with such other supporting documents relating to the origin of such Bulk Product
as Savient may reasonably require. If any of the foregoing documents are only available in a language other than English, the Parties shall agree upon an English language template for such document(s), and BTG shall provide to Savient an English
language translation of any deviations from the template(s); provided, however, that any documentation required by any Regulatory Authority to be supplied for the purpose of importing, exporting, selling, storing, transferring, or otherwise
disposing of Bulk Product, shall be provided in the English language.

  7.03   Method of Invoicing. All orders under this Agreement shall be invoiced at the price which is in effect at the time of shipment.

  7.04   Warranty. BTG hereby represents and warrants to Savient that (i) the quality (purity, physical and chemical properties) of the Bulk
Product supplied by it to Savient shall be in accordance with its Specifications, shall not be adulterated or misbranded within the meaning of the applicable US food and/or drug law or regulation, and shall comply with all Legal Requirements
(including cGMP) and those applicable laws, rules and regulations governing the formulation, manufacture, testing prior to delivery, packaging, labeling according to the Specifications for the Bulk Product and storage and delivery of the Bulk
Product and (ii) the Processing of the Bulk Product at the Facility shall be in compliance with the CMC section of the BLA, as reviewed and attested to as accurate by BTG. This warranty is exclusive and is in lieu of all other warranties, whether
written or oral, express, implied or statutory.

  ARTICLE 8

  

  PRICE 

  8.01   Price. The Parties agree that the Bulk Product shall be charged to Savient at the price set out in Exhibit
E attached hereto (the "Price"). 

  8.02   Remittance of Payments. Payments due by Savient under Section 8.01 shall be payable by Savient no later than [**] days after the
invoice date; provided, however, that Bulk Product associated with such payment was actually delivered in accordance with Section
7.01. Savient shall make payment by wire transfer of Dollars from a single source in the United States to a bank account designated by BTG or by such other payment method as the Parties may agree upon from time to time. Except where any amounts
payable are in dispute under this Agreement and to the extent such dispute is resolved in favor of Savient, in the event of late payment, interest on any past due payments shall accrue at the rate of [**] percent per month, or if such rate shall
exceed the maximum rate allowed by law, then at such maximum rate, and shall be payable on demand.

ARTICLE 9

  REPORTING OF EVENTS

9.01   Exchange of Drug Safety Information. The Parties shall have the rights and responsibilities pertaining to AEs, SAEs and biologic product deviations in accordance with
the provisions of the Quality Agreement attached hereto as Exhibit D.

9.02   Events Affecting Integrity or Reputation. During the Term, the Parties shall notify each other immediately of any circumstances of which they are or become aware of
whereby the integrity and reputation of the Product or of the Parties are threatened by the unlawful activity of any Third Party in relation to the Product. In any such circumstances, the Parties shall cooperate to limit any damage to the Parties
and/or to the Product. 

9.03   Governmental Inspection. Each Party shall advise the other of any governmental communication, inspection or report which addresses or affects the Bulk Product
promptly after becoming aware of it. Savient shall have the right to observe any such governmental inspection; provided, however that such governmental inspection is specifically related to
the Bulk Product. 

ARTICLE 10

NON-COMPETITION AND NON-SOLICITATION

  10.01   Non-Competition.
  During the Term of this Agreement, and for a period of thirty (30) months after
  the termination thereof, BTG agrees not to, and shall cause its Affiliates
  not to, use the Product Technology to manufacture, promote, market or sell
  any Competing Product in the Territory, nor will BTG acquire directly or indirectly
  any rights or interest in or to a Competing Product which is being manufactured,
  promoted, marketed or sold in the Territory. The Parties agree that an acquisition
  by BTG’s Affiliates of any rights or interest in or to a Competing Product
  which is being manufactured, promoted, marketed or sold in the Territory shall
  not be deemed to be an indirect acquisition by BTG, provided BTG has not participated
in the acquisition process of its Affiliate.  

  10.02   Non-Solicitation.
  During the Term and for a period of thirty (30) months after the termination
  of this Agreement, the Parties agree that neither Party shall solicit any employee
  of the other Party or any of its Affiliates, with whom it has come in contact
  or interacted for the purposes of the performance of this Agreement, to leave
  the employment of the other Party or its Affiliate and accept employment or
  work as a consultant with the first Party, except in the event the other Party
  has approved such solicitation in writing. Notwithstanding the foregoing, nothing
  herein shall restrict or preclude either Party’s
right to make generalized searches for employees by the issue of advertisement
  in the media (including trade media) or by engaging search firms to engage
  in searches that are not targeted or focused on an employee or employees of
the other Party. 

ARTICLE 11

TERM & TERMINATION

  11.01   Term.
  This Agreement shall be in effect from the Effective Date and shall continue
  in effect until terminated pursuant to a Notice served by either Party in accordance
with Section (the “Term”).

  
    11.02  Termination. This Agreement may be terminated in accordance with the following sections:

       (i)   Elective.
  Either Party may terminate this Agreement by giving at least three (3) years’ advance
Notice (“Elective Termination Notice”) to the other Party, which Elective
Termination Notice may not be given prior to the seventh (7th) anniversary of
the first delivery of Bulk Product by BTG under this Agreement but may be given
at any time thereafter. Upon the third (3rd) anniversary of the Elective Termination
Notice, this Agreement shall terminate, unless extended by mutual agreement of
the Parties. 

       (ii)   Force Majeure.
  In the event a Party (“Affected Party”) continues to experience a
  Force Majeure condition for a period of at least six (6) months after Notice
  of the Force Majeure was given pursuant to Section 14.04, the other Party shall
  be entitled to terminate this Agreement by giving a Notice of termination to
  Affected Party at any time while such Force Majeure persists thereafter with
the termination becoming effective on the date specified in the Notice of termination. 

       (iii)   Material Breach by BTG.
  Savient shall be entitled to terminate this Agreement, in the event that BTG
  commits a material breach of this Agreement (including, without limitation,
  in the event of a Supply Failure pursuant to Section 5.08 that is not due to
  an event of Force Majeure or a failure on the part of Savient to supply critical
  raw materials which it is obligated to supply pursuant to the terms of this
  Agreement) and BTG fails to cure such breach within sixty (60) days of receiving
  a Notice of default from Savient (or such longer period as Savient may reasonably
  agree if said breach is incapable of cure within such sixty (60) days) (“BTG’s Cure Period”), by giving a Notice of Termination to BTG (after expiration of BTG’s
  Cure Period, if applicable), with the termination to take effect on the date
  specified therein, provided, however, that if BTG experiences a second
  Supply Failure within any twelve (12) month period then BTG’s Cure Period
  shall be zero (0) days unless otherwise specified in the Notice of Termination
provided by Savient in its sole discretion. 

       (iv)   Material Breach by Savient.
  BTG shall be entitled to terminate this Agreement, in the event that Savient
  commits a material breach of this Agreement and Savient fails to cure such
  breach within sixty (60) days of receiving a Notice of default from BTG (or
  such longer period as BTG may reasonably agree if said breach is incapable
  of cure within such sixty (60) days) (“Savient’s Cure Period”),
  by giving a Notice of termination to Savient (after expiration of the Savient
  Cure Period, if applicable), with the termination to take effect on the date
  specified therein. For purposes of this Section only, any amount of the Processing
  Capacity Reservation Fee and accrued interest thereon which has not been applied
to 

  payments for Bulk Product actually purchased by and delivered to Savient shall be forfeited by Savient to BTG as of the effective date of termination of this Agreement.

       (v)   Insolvency.
  Either Party shall be entitled to terminate this Agreement, by giving Notice
  to the other Party (“Insolvent Party”), in the event of an Insolvency Event occurring in relation to the Insolvent Party, such termination to take effect upon delivery of the Notice of termination to the Insolvent Party. “Insolvency Event”
for the purpose of this Clause shall mean any commencement – whether voluntarily or involuntarily – of any action seeking any relief by liquidation, reorganization (other than for corporate reorganization), dissolution or similar act under
any bankruptcy, insolvency or similar law or otherwise any action seeking any arrangement between or with its creditors or any commencement of a proceeding or receipt of an order, judgment or decree seeking the liquidation, reorganization or
dissolution of a Party or any other relief under any bankruptcy, insolvency or similar law or an arrangement is made with respect to such Party’s
debts or business by its creditors with or without the consent of that Party.  

  11.03   Savient’s
  Rights Upon Termination. In the event Savient terminates this Agreement pursuant to Sections 11.02 (i) (Elective),
11.02 (ii) (for Force Majeure conditions affecting BTG), 11.02 (iii) (Material Breach by BTG), or 11.02 (v) (for insolvency of BTG) or in the event BTG terminates this Agreement pursuant to Section 11.02 (i), BTG shall promptly, upon request by
Savient, convey to Savient all Know-How, BTG Licensed Improvements and other information related to the Processing of the Product and/or Bulk Product sufficient to enable Savient or any other Persons engaged by Savient to manufacture, produce or
provide the Product and/or Bulk Product and BTG shall provide all other assistance that Savient may reasonably request, at no cost to Savient. Such Know-How, BTG Licensed Improvements and other information shall include, without limitation, all
records and reports related to (i) the development of the Bulk Product, Product and/or Process, (ii) the Processing of the Bulk Product and Product, (iii) testing for compliance with the Specifications, and (iv) batch records. Unless this Agreement
is terminated pursuant to Section 11.02 (iii), Savient shall be responsible for the reasonable labor costs and expenses incurred by BTG in conveying such Know-How, BTG Licensed Improvements and other information and providing such assistance. Such
labor costs of BTG employees and/or Third Party expenses shall be reimbursed by Savient in the manner and at the rates set forth on Exhibit B hereto.

  11.04   BTG’s
  Rights Upon Termination. In the event that BTG
  terminates this Agreement pursuant to Sections 11.02(i) (Elective), 11.02(ii)
  (for Force Majeure conditions affecting Savient), 11.02(iv) (Material Breach
  by Savient) or 11.02(v) (for insolvency of Savient), any and all outstanding
  non-disputed payments due from Savient pursuant to this Agreement shall become
  immediately due and payable. Anything to the contrary notwithstanding, upon
  termination by BTG, BTG shall promptly, upon request by Savient and at Savient’s cost, convey to Savient, all Know-How, BTG Licensed Improvements and other information
related to the Processing of the Bulk Product and/or Product sufficient to enable Savient or any other Persons engaged by Savient to manufacture, product or provide the Bulk Product and/or Product and BTG shall provide all other assistance that
Savient may reasonably request, at Savient’s sole cost. 

  11.05   Effect of Termination.
  Termination of this Agreement for any reason is without prejudice to the Parties’ accrued
  rights and shall not be construed to release either Party of any obligation
matured prior to the effective date of such termination.

  11.06   Survival.
  The following provisions shall survive the expiration or termination of this
  Agreement: 2.01(iii), 2.01(iv), 2.04, 3.02, 3.03, 4.01 (ii), 5.11, 6.04 (i),
  6.04(ii), 6.04 (iv), 6.04 (vi), 6.04 (vii), 6.06, ARTICLE 7, ARTICLE 8, ARTICLE
  9, Section 10.01 (except in the event of a termination by BTG pursuant to Section
  11.02 (iv) (Material Breach by Savient)), 10.02, 11.03, 11.04, 11.05, 11.06,
  ARTICLE 12, ARTICLE 13, ARTICLE 14. The survival of Sections 3.02, 3.03, 6.04
  (vii) and 6.06 shall be subject to BTG being compensated for any actions on
  their part under these provisions post expiration or termination on the basis
  of the principles set forth in this Agreement. The Parties expressly understand
  and agree that Section 2.01 (ii) shall not survive the expiration or termination
  of this Agreement. For the avoidance of doubt, even after the termination of
  this Commercial Agreement pursuant to either Section 11.02 (iii) or Section
  11.02 (iv), each Party’s rights under the Residual Rights Agreement shall
  subsist in full and irrespective of the grounds for such termination, except
  Savient may not compel BTG to perform any additional manufacturing services
as may be required by the Residual Rights Agreement.

  ARTICLE 12

  

  REMEDIES 

  12.01   Remedies for Non-Conforming Bulk Product. In the event BTG delivers to Savient Bulk Product that does not meet the Commercial Bulk
Product Specifications, Savient shall, at its option, be entitled to (A) the replacement of such Non-Conforming Bulk Product with corresponding Bulk Product meeting the Bulk Product Specifications and with the cost of the PEG material supplied by
Savient and the cost of shipment for such replacement Bulk Product being borne by BTG; or (B) a refund of (x) any price paid by Savient for such Non-Conforming Bulk Product, (y) the cost of the PEG material supplied by Savient for such
Non-Conforming Bulk Product, and (z) the shipment costs associated with such Non-Conforming Bulk Product, provided, however, that
Savient has notified BTG in writing of the non-conforming Bulk Product in accordance
with Section 6.04 (iv). In addition, Savient shall, at BTG’s option and
cost, either destroy or return to BTG at its Facility any Non-Conforming Bulk
Product. 

  
    12.02  Indemnity by BTG.

       (i)   BTG
  shall defend, indemnify and hold harmless each Savient Indemnitee from and
  against (i) all Claims of Third Parties that arise as a result of a material
  breach of any covenant, agreement, warranty or representation made by BTG under
  this Agreement, and (ii) all Product Liability Claims, or such portion of Product
  Liability Claims, as are allocated to BTG pursuant to Section 12.04.

       (ii)   BTG shall not be obligated under this Section 12.02 to the extent it is shown that the Claim was the direct result of a material breach of
any covenant, warranty or representation made by Savient under this Agreement. 

 (iii)     BTG
shall have no obligation under this Section 12.02 unless  

(A)     Savient
    gives BTG prompt written notice of any Claim for which it seeks to be indemnified
under this Agreement,

(B)     BTG
  is granted full authority and control over the defense against such Claim,
and 

(C)     Savient
  cooperates fully with BTG in defense of the Claim (all reasonable out-of-pocket
  expenses of such cooperation to be borne by BTG).

Savient shall have the right to participate in the defense of any such Claim utilizing attorneys of its choice, at its own expense; provided, however, that BTG shall have full authority and control to handle any such Claim, including without limitation any settlement or other disposition thereof, for which Savient seeks indemnification under this
  Section 12.02; provided, however, further that any settlement that includes
  an admission of fault, culpability or liability on the part of Savient shall
  not be concluded without Savient’s consent, which consent shall not be unreasonably
  conditioned, withheld, delayed or denied. 

       (iv) BTG shall
  indemnify and hold Savient harmless for any income tax or other taxes which
  Savient may be required by current or future Legal Requirements to pay on behalf
  of BTG with respect to any monies payable to BTG under this Agreement, including
  without limitation, any associated penalties, fines and interest (hereinafter,
  a “Tax Claim”); provided, however, that if
Savient becomes aware of any Legal Requirements according to which Savient is required to pay any taxes on behalf of BTG or to withhold any amounts with respect to any such Tax Claim, then Savient shall act in strict compliance with such Legal
Requirements and shall promptly serve written notice to that effect on BTG. Furthermore, upon learning of the existence of a Tax Claim, Savient shall provide prompt written notice to BTG where such notice shall include copies of all materials
received by Savient which pertain to the Tax Claim. Additionally, upon request by BTG, Savient shall provide reasonable assistance to BTG to enable BTG to defend any such Tax Claim and/or support a claim for a refund or a foreign tax credit with
respect to any such Tax Claim; provided that BTG shall reimburse Savient
for any out-of-pocket expenses which Savient incurs in rendering any assistance
to BTG pursuant to this provision within thirty (30) days of receipt of a reasonably
specific demand for reimbursement with accompanying documentation demonstrating
such amounts claimed. Savient shall obtain the approval of BTG for any individual
out-of-pocket expense in excess of [**] Dollars ($[**]), such approval not
to be unreasonably withheld, delayed or conditioned. BTG shall have the sole
right to handle any such Tax Claim utilizing attorneys of its choice, at its
own expense; provided, however, that any settlement that includes
an admission of fault, culpability, penalty fine or any other liability on the
part of Savient shall not be concluded without Savient’s consent, which
consent shall not be unreasonably conditioned, withheld, delayed or denied. 

 

 12.03 Indemnity
by Savient. 

     (i) Savient shall defend, indemnify and hold harmless each BTG Indemnitee from and against all Claims of Third Parties that arise as a result
  of (A) a material breach of any covenant, agreement, warranty or representation made by Savient under this Agreement, and (B) patent infringement involving the manufacture, use, importation, sale or marketing of the Bulk Product or Product, and (C)
  all Product Liability Claims, or such portion of Product Liability Claims, as are allocated to Savient pursuant to Section 12.04.

       (ii) Savient shall not be obligated under this Section 12.03 to the extent it is shown that the Claim was the direct result of a material
breach of any covenant, warranty or representation made by BTG under this Agreement.

     (iii) Savient
    shall not be obligated under this Section 12.03 unless

 (A)     BTG
    provides Savient with prompt written Notice of any Claim for which it
seeks to be indemnified under this Agreement,

(B)     Savient
is granted full authority and control over the defense against such Claim,
and

(C)     BTG
  cooperates fully with Savient in defense of the Claim (all reasonable out-of-pocket
  expenses of such cooperation to be borne by Savient).

BTG shall have the right to participate in the defense of any such Claim utilizing attorneys of its choice, at its own expense; provided, however, that Savient shall have full authority and control to handle any such Claim, including without limitation any settlement or other disposition thereof, for which BTG seeks indemnification under this
Section12.03; provided, however, further that any settlement that includes
an admission of fault, culpability or liability on the part of BTG shall not
be concluded without BTG’s
consent, which consent shall not be unreasonably conditioned, withheld, delayed
or denied. 

  12.04 Product Liability Claims. Notwithstanding the foregoing Sections 12.02 and 12.03, the Parties' responsibilities with respect to
Product Liability Claims shall be governed by this Section12.04. 

       (i) BTG
  shall be solely responsible for all Product Liability Claims that arise out
  of Non-Conforming Bulk Product, provided, however, that the following conditions
  are cumulatively satisfied: (A) such nonconformance existed at the time the
  Bulk Product was delivered by BTG and (B) such nonconformance was the result
  of BTG’s failure to manufacture the Bulk Product in strict adherence
with the Process and (C) such Non-Conformance was the result of a Hidden Defect.
  Savient shall be solely responsible for all Product Liability Claims that arise
  out of Non-Conforming Bulk Product in each of the following cases: (A) such
  nonconformance occurred after the Bulk Product was delivered to Savient or
  (B) the NonConforming Bulk Product was manufactured by BTG in strict adherence
with the Process or (C) such Non-Conformance was not the result of a Hidden Defect.

       (ii) Each Party shall give the other prompt written notice of any Product Liability Claim, but the omission of such notice shall not relieve either Party from its obligations under this Section 12.04, except to the extent the other Party can establish actual prejudice and direct

  damages as a result thereof. With respect to each Product Liability Claim, Savient shall have the first right to defend and settle such Product Liability Claim. In the event that Savient does not assume the defense of such Product
Liability Claim within ninety (90) days following Savient's receipt of notice of the commencement or assertion of such Product Liability Claim, BTG may notify Savient of BTG's desire to take the lead role in the defense of such Product Liability
Claim. If, within ten (10) days after BTG notifies Savient of such desire, Savient does not assume the defense of such Product Liability Claim, then BTG may take the lead role in the defense of such Product Liability Claim. 

  The Party assuming the defense of any Product Liability
  Claim as permitted under this Section 12.04 (the "Controlling Party") shall consult with the other Party on all material aspects of the defense, including without limitation
settlement, of such Product Liability Claim, and the Parties shall cooperate fully with each other in connection therewith. The non-defending Party shall also have the right to participate in the defense of any Product Liability Claim utilizing
attorneys of its choice, at its own expense. In furtherance of the Parties' cooperation, the Controlling Party will consult with the other Party regarding strategic decisions, including without limitation the retention of counsel and defense of each
Product Liability Claim. The Controlling Party will otherwise keep the other Party fully informed of the status and progress of the defense and any settlement discussions concerning the Product Liability Claim. Any settlement of a Product Liability
Claim that would admit liability on the part of any Party or its Affiliates or Agents, or that would involve any relief other than the payment of money damages, shall be subject to the prior written approval of both Parties, such approval not to be
unreasonably withheld or delayed. All damages and expenses (including attorney’s
fees) incurred in connection with the defense of a Product Liability Claim shall
be allocated between the Parties in accordance with Section 12.04 (i). 

  12.05 Limitation of Damages. Notwithstanding anything to the contrary set forth in this Agreement, in no event shall either Party be liable
to the other Party for, and each Party shall procure that none of its Affiliates or Sublicensees shall make any claim against the other Party (or its Affiliates and Sublicensees) for, any lost profits, loss of business, loss of contracts, diminished
goodwill, diminished reputation, or consequential, indirect, incidental or special damages arising under or in connection with this Agreement or the Bulk Product. 

  ARTICLE 13

  DISPUTE RESOLUTION AND ARBITRATION

  13.01 Governing Law. This Agreement and any and all matters arising directly or indirectly herefrom shall be governed by and construed in
accordance with the laws of the State of New York, United States of America, without giving effect to (A) its conflict of law principles and (B) the United Nations Convention on Contracts from the International Sale of Goods. 

  13.02 Arbitration. Any dispute, controversy or claim arising out of or in relation to this contract, including the validity, invalidity,
breach or termination thereof, shall be resolved by arbitration in accordance with the Swiss Rules of International Arbitration of the Swiss Chambers of Commerce in force on the date when the Notice of Arbitration is submitted in 

  accordance with these Rules. The number of arbitrators shall be three; the seat of the arbitration shall be Zurich, Switzerland; the arbitral proceedings shall be conducted in English and shall take place in London, England.

  ARTICLE 14 

  

  MISCELLANEOUS

  14.01 Confidentiality.
  During the Term of this Agreement or the Commercial Agreement, whichever expires
  later, and for a period of three (3) years thereafter, each Party (the “Receiving Party”) shall keep strictly confidential any Confidential Information disclosed by any other Party (the “Disclosing Party”),
  using at least the same degree of care that it uses to protect its own confidential
  or proprietary information, but in no event less than reasonable care. The
  provisions of this ARTICLE 14 shall apply to all Confidential Information,
  and to all proprietary information of the Disclosing Party relating to the
  Product and/or the Process that is disclosed (or known) to a Receiving Party
  prior to the date hereof (which shall be deemed to be Confidential Information,
  subject to the exceptions in clauses (i) through (iv) below, for purposes of
  this Agreement). The nature and terms of this Agreement shall be deemed to
  be Confidential Information of each Party, subject to the exceptions set forth
  in clauses (i) through (iv) below, for purposes of this Agreement. The Receiving
  Party shall use Confidential Information solely for the purposes of this Agreement
  and the activities contemplated hereby and shall not disclose or disseminate
  any Confidential Information to any Person at any time, except for disclosure
  to those of its Affiliates, directors, officers, employees, consultants, accountants,
  attorneys, advisers and agents that have a need to know such information to
  permit the Receiving Party to exercise its rights or fulfill its obligations
  pursuant to this Agreement, provided that such Persons are bound to maintain
  the confidentiality of such Confidential Information to the same extent as
  if they were parties hereto. The obligations set forth in this Section 14.01
are subject to the following exceptions: 

       (i) The
  Receiving Party may disclose the Disclosing Party’s Confidential Information
  that is required to be publicly disclosed by law or by regulation; provided, however, that: (A) the Receiving Party shall, where possible, seek confidential treatment for any
Confidential Information of the Disclosing Party, and shall provide the Disclosing Party with prompt advance notice of such disclosure and reasonable opportunity to review any such disclosure so that the Disclosing Party may, if it desires, seek a
protective order or other appropriate remedy; and (B) the Parties or their Affiliates may disclose the terms of this Agreement in any filings with the U.S. Securities and Exchange Commission (provided that the Parties or their Affiliates, as
applicable, use commercially reasonable efforts to seek confidential treatment for any trade secrets, commercial terms or information, or financial terms or information). 

       (ii) Pursuant to an agreement to maintain confidentiality, any Party may discuss, or provide a copy of, this Agreement to its accountants, its
attorneys, and its current, future or potential investors or shareholders. 

       (iii) Pursuant
  to an agreement containing confidentiality obligations and subject to the other
  Parties’ written consent, either Party may
provide a copy of this Agreement or relevant portions thereof to any Third Party
  sublicensee, if required pursuant to the relevant license agreement with such
Third Party. 

       (iv) Any other disclosure of the nature or terms of this Agreement (including, without limitation, any public announcements, press releases or
similar publicity with respect to this Agreement) by any Party, must be approved in advance in writing by Savient, in its sole discretion, as to form and content of such disclosure; provided, however, that the contents of any public announcement, press release or similar publicity which has been reviewed and approved can be re-released by any Party in any form
without a requirement for re-approval. 

  14.02 BTG Insurance.
  BTG and/or its Affiliates shall obtain and maintain during the Term and for
  five (5) years thereafter comprehensive general liability insurance on a claims-made
  basis, with endorsements for product liability with annual coverage limits
  of not less than [**] Dollars ($[**]) per claim and [**] Dollars ($[**]) annual aggregate. All of BTG’s insurance
policies shall be issued by “A-rated” insurers as designated by Standard and Poor’s Corporation and/or by acceptable other means. The minimum level of insurance set forth herein shall not be construed to create a limit on BTG’s
liability hereunder. On the Effective Date and upon the request of Savient (provided that such request shall be made no more than once per calendar year), BTG shall furnish to Savient a certificate of insurance evidencing such coverage as of such
date. Each such certificate of insurance, as well as any certificates evidencing new or modified coverages of BTG, shall include a provision whereby thirty (30) days written notice must be received by Savient prior to coverage modification or
cancellation by either BTG or the insurer. In addition, BTG shall promptly notify Savient of any cancellation or modification of such insurance coverage and of any new or modified coverage. In the case of a modification or cancellation of such
coverage, BTG shall promptly provide Savient with a new certificate of insurance evidencing that BTG’s
coverage meets the requirements in the first sentence of this Section 14.02. 

  14.03 Savient Insurance.
  Savient shall obtain and maintain during the Term and for five (5) years thereafter
  comprehensive general liability insurance on a claims-made basis, with endorsements
  for product liability with annual coverage limits of not less than [**] Dollars
  ($[**]) per claim and [**] Dollars ($[**]) annual aggregate. All of Savient’s insurance policies shall
be issued by “A-rated” insurers as designated by Standard and Poor’s Corporation and/or by acceptable other means. The minimum level of insurance set forth herein shall not be construed to create a limit on Savient’s liability
hereunder. On the Effective Date and upon the request of BTG (provided that such request shall be made no more than once per calendar year), Savient shall furnish to BTG a certificate of insurance evidencing such coverage as of such date. Each such
certificate of insurance, as well as any certificates evidencing new or modified coverages of Savient, shall include a provision whereby thirty (30) days written notice must be received by BTG prior to coverage modification or cancellation by either
Savient or the insurer. In addition, Savient shall promptly notify BTG of any cancellation or modification of such insurance coverage and of any new or modified coverage. In the case of a modification or cancellation of such coverage, Savient shall
promptly provide BTG with a new certificate of insurance evidencing that Savient’s
coverage meets the requirements in the first sentence of this Section 14.03. 

  14.04 Notices.
  All notices, requests, demands, claims and other communications hereunder (each,
  a “Notice”) shall be in writing.
Any notice, request, demand, claim or other communication hereunder shall be
  deemed duly delivered four (4) Business Days after it is sent by registered
  or certified mail, return receipt requested, postage prepaid, or one (1) Business
  Day after it is sent by overnight delivery via a reputable national courier
service, in each case to the intended recipient as set forth below: 

  If to Savient, to:

  Savient Pharmaceuticals Inc. 

  One Tower Center, 14th Floor 

  East Brunswick, New Jersey 08816, USA 

  Telecopy: +1-732-418-9065 

  Attention: Philip K. Yachmetz, EVP & CBO

  with copies, which shall not constitute notice hereunder, sent to:

   

	Savient Pharmaceuticals, Inc.

        One Tower Center, 14th Floor 

        East Brunswick, NJ 08816 U.S.A. 

        Attention: John Petrolino 	 and	Wilmer Cutler Pickering Hale and Dorr LLP

        60 State Street 

        Boston, MA 02109 

        Telecopy: +1-617-526-5000 

        Attention: David E. Redlick, Esq. 

If to BTG, to:

  Bio-Technology General (Israel) Ltd.

  Beer Tuvia Industrial Zone

  POB 571 

  Kiryat Malachi 83104, Israel 

  Telecopy: +972-8-8612288 

  Attention: General Manager 

  with copies, which shall not constitute notice hereunder, sent to:

	Ferring International
    Center SA 	 and	Ferring International
    Center SA 
	 	 	 
	Chemin de la Vergognausaz 50

     CH-1162 Saint-Prex 

Switzerland 

Attention: General Counsel	 	Chemin de la Vergognausaz 50 

CH-1162 Saint-Prex 

Switzerland 

Attention: EVP, Technical Operations

 

  Any Party may give any notice, request, demand, claim, or other communication hereunder using any other means (including personal delivery, expedited courier, messenger service, telecopy, telex, ordinary mail, or electronic mail),
but no such notice, request, demand, claim or other communication shall be deemed to have been duly given unless and until it actually is received by the Party for whom it is intended. Any Party may change the address to which notices, requests,
demands, claims and other communications hereunder are not be delivered by giving the other Party notice in the manner herein set forth. 

  14.05 Entire Agreement. This Agreement and all attachments, including the exhibits hereto, constitutes the entire agreement between Savient
and BTG with respect to the subject matter hereof, and supersedes any prior agreements or understandings, both written and oral, between Savient and BTG with respect to such matters, other than the Divestiture Agreements and the Residual Rights
Agreement, which shall be read together with this Agreement. 

  14.06 Order of Precedence. In the event of a conflict or inconsistency that relates to the subject matter hereof between any of the terms of
the following documents, the following order of precedence shall control:

 (i)      this Commercial Supply Agreement
between the Parties, and Exhibits hereto

(ii)      the Development Agreement between
the Parties, and Exhibits thereto

(iii)      the Residual Rights Agreement, and
  Exhibits thereto

  Without limiting the generality of the foregoing,
  and for the avoidance of any doubt, the following sections of the Residual
  Rights Agreement are hereby superseded by this Agreement as far as the subject
  matter hereof is concerned: (A) Section 3 - Research & Development; Regulatory Services; Manufacturing Services; (B) Section 4 - Technology Transfer; (C) Section 9 - Indemnification; (D) Section 13 – Governing
  Law and Dispute Resolution; (E) Annex C (Development and Regulatory Work-Puricase);
  (F) Annex D (Term Sheet Manufacturing Services); and (G) Annex E (Term Sheet
  for Technology Transfer). In resolving any such conflicts, these documents
  shall be read as a whole and in a manner most likely to accomplish their purposes.
  Any amendments to these documents on which the Parties may agree to in accordance
  with the terms of each document shall take precedence over any conflicting
  terms in the prior release of each document. Each Party shall promptly report
  to the other in writing any inconsistencies in these documents, even if the
inconsistency is resolvable using the above order of precedence.

  14.07 Covenant of Further Assurances. The Parties covenant and agree that, subsequent to the execution and delivery of this Agreement and
without any additional consideration, each of the Parties shall execute and deliver any further legal instruments and perform such acts which are or may become reasonably necessary to effectuate the purposes of this Agreement. 

  14.08 Waivers; Amendments. The failure of either Party to insist, in any one or more instances, upon the performance of any of the terms,
covenants or conditions of this Agreement or to exercise any right hereunder, shall not be construed as a waiver or relinquishment of the future 

  performance of any such term, covenant or conditions or the future exercise of such right, and the obligation of the other Party with respect to such future performance shall continue in full force and effect. Savient and BTG may
(A) mutually amend or waive any provision of this Agreement at any time and (B), from time to time after the date hereof, modify and/or replace any of the exhibits hereto, which modified or replaced exhibits shall automatically constitute part of
this Agreement; provided, however, that no amendment or waiver of any provision of this Agreement and no modification and/or replacement of any exhibits hereto shall be valid unless the same
shall be in writing and duly signed by both of the Parties. 

  14.09 Relationship. BTG is an independent contractor engaged by Savient for the provision of the Bulk Product and certain services as set
forth in this Agreement. Nothing in this Agreement shall constitute BTG as an employee, agent or general representative of Savient. This Agreement shall not constitute either Party as the legal representative or agent of the other, nor shall either
Party have the right or authority to assume, create or incur any liability or any obligation of any kind, express or implied, against, or in the name of or on behalf of, the other Party. This Agreement shall not constitute, create or in any way be
interpreted as a joint venture, partnership or formal business organization of any kind. 

  14.10 Publicity.
  Except as otherwise required by Legal Requirements, neither Party shall use
  the other’s name or refer to it directly
or indirectly in an advertisement, news release or release to any professional
  or trade publication or issue any news release relating to this Agreement,
  without the prior written approval from such Party for such use or release.
  The Parties agree that a news release with respect to the consummation of this
  transaction and the details thereof will be made, the content and form of which
  shall be reasonably agreed between the Parties. In addition, the Parties agree
  that Savient shall be permitted to disclose this Agreement and the transactions
  contemplated hereby in filings made with the U.S. Securities and Exchange Commission
or other regulatory authorities in accordance with Section 14.01.

  14.11 Severability. If any term of other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law
or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic and legal substance of the underlying transaction in any country in the Territory is not affected in
any manner materially adverse to either Party. Upon such determination that (i) any term of other provision is invalid, illegal or incapable of being enforced and (ii) the economic or legal substance of the underlying transaction in any country in
the Territory is affected in a manner materially adverse to either Party, the Parties shall modify this Agreement, with respect to such country in the Territory, so as to effect the original intent of the Parties as closely as possible in a mutually
acceptable manner to the fullest extent permitted by Legal Requirements in such country in the Territory in order that the underlying transaction be completed as originally contemplated to the fullest extent possible. 

  14.12 No Assignment.
  Neither this Agreement nor any of the rights, interests, or obligations hereunder
  may be assigned by either Party without the prior written consent of the other
  Party hereto, except that Savient may assign its rights, interests, or obligations
  hereunder to any Third Party acquiring rights to the Product and either Party
  may assign its rights hereunder to any Affiliates or any entity that acquires
  all or substantially all of such Party’s business or assets (provided
  that no such assignment shall relieve the assigning Party of its obligations
hereunder, 

  and the assigning Party shall remain primarily liable for such obligations). Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted
assigns. 

  14.13 Headings. The headings used in this Agreement are included for convenience only and are not to be used in construing or interpreting
this Agreement. 

  14.14 Force Majeure. If either of the Parties is impeded in fulfilling its undertakings in accordance with this Agreement by circumstances
beyond its reasonable control, such as, but not limited to, labor conflict, lightening striking, acts of God, fire, war, mobilization or unforeseen military call-up of a large magnitude, requisition, confiscation, commandeering, public decrees,
riots, insurrections, general shortage of transport, goods or energy and faults or delays in deliveries from subcontractor or suppliers caused by any circumstances referred to in this Section 14.14, the impediment shall be considered a Force Majeure
condition and the Party shall be exempted from liability for delays due to such reasons; provided, however, that it notifies the
other Party thereof without undue delay after such a circumstance has occurred. Upon such notification, the Parties shall agree upon a reasonable extension of the time for performance, not to exceed an extension equal to the period the Force Majeure
condition continues to exist. 

  14.15 Counterparts. This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which
together will constitute one and same instrument. 

       IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective officers hereunto duly authorized as of the Effective Date. 

	
    SAVIENT PHARMACEUTICALS, INC. 	   	
    BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. 
	   
	   
	
    By: 	
    /s/ Philip K. Yachmetz	   	
    By: 	
    /s/ Dov Kanner 
	   	
    Name: Philip K. Yachmetz 	   	   	
    Name: Dov Kanner 
	   	
    Title: EVP & CBO 	   	   	
    Title Managing Director 

  Exhibit A 

  Savient Patent Rights

 

	 	 	 	 	 	 
	   	
    TITLE 	
       COUNTRY 	
    SERIAL NO 	
    PATENT NO 	
    STATUS 
	[**] 	   	
    [**] 	[**] 	   	[**] 

  Confidential Materials omitted and
  filed separately with the Securities and Exchange Commission pursuant to
  a request for confidential treatment. A
total of five pages were omitted. 

   

 

A-1

 

Exhibit B

Compensation for Services and Reimbursement of Expenses

    BTG shall submit invoices to Savient on a quarterly basis in arrears, which invoices shall provide an account of (i) detailed descriptions of the services performed, (ii) the number of hours such services were performed,
(iii) the levels of the individuals performing such services and (iv) detailed descriptions of any Third Party expenses incurred (documentation of such expenses shall be provided to Savient upon request).

     Payment to BTG shall be due within forty-five (45) days of the date of the invoice (provided that the invoice is received by Savient within three (3) Business Days of the date thereof) or
within forty-five (45) days of Savient’s receipt of the invoice (if received by Savient four (4) or more Business Days after the date thereof). 

  	
      Compensation Rates:  	   
	   
	   	
      Daily Rate  
	
                                               Level  	
      (eight (8) hour day)  
	
       Vice President or Senior Director  	
      $[**]  
	
       Department Head or Director  	
      $[**]  
	
       Unit Head  	
      $[**]  
	
       Exempt Non-Management Employee, Group Leader &  	
      $[**]  
	
       others  	   

  

Beginning on January 1, 2008, and on each successive January 1st thereafter, the above rates shall increase by an amount equal to the average
increase in the United States Consumer Pricing Index (CPI) over the immediately preceding twelve (12) month period.  

Third Party Expenses:

Savient
  shall reimburse BTG for documented expenses paid to a Third Party; provided that,
  other than BTG’s travel expenses for travel at the request of Savient, expenses for raw materials, expenses for
  subcontractors/consultants, BTG shall be required to obtain Savient’s pre-approval in writing for any expenses to be incurred in excess of [**] Dollars ($[**]). 

Exhibit C

Current Provisional Bulk Product Specifications

	
    SPECIFICATION PEG-URICASE API  
	         Parameter 	
                              Test  	
                          Specification  
	
      [**]  	
        [**]  	
      [**]  
	
             [**]  	
        [**]  	
      [**]  
	
        [**]  	
      [**]  
	
      [**]  	
        [**]  	
      [**]  
	
      [**]  	
        [**]  	
      [**]  
	
      [**]  	
        [**]  	
      [**]  
	   	
        [**]  	
      [**]  
	   	
        [**]  	
      [**]  
	         [**] 	
        [**]  	
      [**]  
	   	
        [**]  	
      [**]  
	   	
        [**]  	
      [**]  
	   	
        [**]  	
      [**]  

  Exhibit D 

  Quality Agreement

  

  QUALITY ASSURANCE RESPONSIBILITY AGREEMENT

  BETWEEN

  SAVIENT PHARMACEUTICALS, INC.

  AND

  BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.

  (COMMERCIAL PHASE)

	  	  	  	  	
CONFIDENTIAL  
	
Table of Contents  
	
1  	
.  	  	
Purpose & Scope:  	
1  
	
2  	
.  	  	
Definitions:   	1
	
3  	
.  	  	
Notification of Process Deviations and Documentation Changes  	
3  
	
4  	
.  	  	
Materials:  	
4  
	
5  	
.  	  	
Manufacturing:  	
6  
	
6  	
.  	  	
Release and Shipment of Products(s):  	
8  
	
7  	
.  	  	
Deviations in Process or Product:  	
8  
	
8  	
.  	  	
Storage of Products(s):  	
9  
	
9  	
.  	  	
Traceability of Products(s)  	
9  
	
10  	
.  	  	
Conflict of Terms:  	
9  
	
11  	
.  	  	
Compliance with Laws:  	
9  
	
12  	
.  	  	
Inspections:   	9
	
13  	
.  	  	
Observations by SAVIENT:  	
10  
	
14  	
.  	  	
Adverse Events:  	
10  
	
15  	
.  	  	
Stability:  	
11  
	
16  	
.  	  	
Regulatory Action:  	
11  
	
17  	
.  	  	
Annual Report to FDA”  	
11  
	
18  	
.  	  	
APPENDIX I:  	
13  
	
19  	
.  	  	
APPENDIX II:  	
14  
	
20  	
.  	  	
APPENDIX III  	
17  

  ARTICLE 1

  PURPOSE AND SCOPE:

  1.01 Savient Pharmaceuticals, Inc. (“SAVIENT”)
  and Bio-Technology General (Israel) Ltd. (“BTG”) have entered
into a Supply Agreement of (event date) herewith (the “Supply Agreement”). 

  This document (the “Quality Agreement”)
  defines the quality assurance responsibilities between SAVIENT and BTG. This
  Quality Agreement applies only to the manufacture and supply by BTG to SAVIENT
of the Product (as defined in the Supply Agreement). 

  ARTICLE 2 

  

  DEFINITIONS:

  2.01 Capitalized terms used but not otherwise defined in this Quality Agreement will have the meanings ascribed thereto in the Supply Agreement. For ease of reference, the following definitions from the Supply Agreement which are
used in this Quality Agreement are copied in full below, amended where appropriate for the purposes of this Quality Agreement: 

	 	
    (i)        	
“BLA” means a Biologics
    License Application filed with the FDA and/or any other application required
    for the purpose of marketing or selling or using a therapeutic or prophylactic
    product to be filed with a governmental agency in a non-U.S. country or group
    of countries, including, without limitation, a Product License Application
    or Marketing Authorization in the European Union.
  
	 	 	 
	 	
    (ii)        	
“Bulk Product” shall mean
    the bulk solution of polyethylene glycol (PEG) conjugate of uricase ordered
    by Savient from BTG pursuant to the Supply Agreement.
  
	 	 	 
	 	
    (iii)        	
"Bulk Product Specifications" shall
    mean the manufacturing and quality specifications for the Bulk Product, including,
    without limitation, unit descriptions established from time to time in accordance
    with section 3.01 of the Supply Agreement.
  
	 	 	 
	 	
    (iv)        	
"Business Day" shall mean any day
    other than (i) Friday, Saturday or Sunday or (ii) a day on which banking
    institutions located in New York, New York, United States of America or in
    Israel are permitted or required by law, executive order or governmental
    decree to remain closed.
  
	 	 	 
	 	
    (v)        	
"cGMP" shall mean current good manufacturing
    practices as set forth in Title 21, Parts 210 and 211 of the C.F.R. and 21
    C.F.R. Part 312 (IND) and Part 314 (NDA), and 21 C.F.R. Part 600 (Biological
    Products), as established and amended by the FDA.
  

	 	 	
  (vi)        	
“FDA” shall mean the United
    States Food and Drug Administration or, where applicable, its regulatory
    equivalent in a foreign jurisdiction.
  
	 	 	 	 
	 	 	
  (vii)        	
“Facility” shall mean, as applicable, the Be’er
    Tuvia manufacturing facility located at Beer Tuvia Industrial Zone, POB 571,
    Kiryat Malachi 83104, Israel
  
	 	 	 	 
	 	 	
  (viii)        	
"IND" shall mean an Investigational
    New Drug application, as defined in 21 C.F.R. 312.3, and filed with the FDA
    or any equivalent foreign Regulatory Agency.
  
	 	 	 	 
	 	 	
  (ix)        	
"Legal Requirements" shall mean (i)
    any present and future national, state, local or similar laws (whether under
    statute, rule, regulation or otherwise), (ii) requirements under permits,
    orders, decrees, judgements or directives, and requirements of applicable
    Regulatory Agencies (including, without limitation, cGMP) and (iii) regulations
    pertaining to BLAs (with respect to each of the foregoing, as amended or
    revised from time to time).
  
	 	 	 	 
	 	 	
  (x)        	
“Process” or “Processing” shall
    mean the act of purification, preparation, filling, testing and any other
    pharmaceutical manufacturing procedures, or any part thereof (including,
    but not limited to, product or process specifications, testing or test methods,
    raw material specifications or suppliers, equipment, etc.), relating to,
    as applicable, Bulk Product and Product.
  
	 	 	 	 
	 	 	
  (xi)        	
“Product” shall mean pharmaceutical
    products containing Bulk Product ordered by Savient pursuant to the Supply
    Agreement.
  
	 	 	 	 
	 	 	
  (xii)        	
“Regulatory Agency” shall
    mean with respect to the United States, the FDA, or, in the case of a country
    in the Territory other than the United States, such other appropriate regulatory
    agency with similar responsibilities.
  

	2.03      	In addition,
    the following definitions apply to this Quality Agreement:

	 	 	 
	 	(i)      	“Bulk Product” shall
    mean bulk solution of polyethylene glycol (PEG) conjugate of uricase
          in its final formulation which is in Process, and has been produced
    for sterilization, filling or other finishing activities.

	 	

	 	(ii)      	“Filled Product” shall
    mean sterile Product that is in Process and has been filled into
    its final primary packaging for further labelling or packaging activities.

	 	

	 	(iii)      	“Final Product” shall
    mean finished Product in its final packaged and labeled form
          which is ready for distribution to the marketplace or third party distributors
    for sale or clinical use.

	 	

	 	(iv)      	“Release” shall
    mean control, approval and authorization of shipment.

 

  ARTICLE 3

  NOTIFICATION OF PROCESS DEVIATIONS AND DOCUMENTATION OF CHANGES: 

  3.01 BTG shall provide to SAVIENT, within two Business
  Days of BTG’s discovery of its occurrence, written notification of (i)
  any deviation from the Process as set forth in the Bulk Product Specifications
  and the BLA and any deviation from cGMP requirements, regulations and standards,
  and any event that represents an unexpected or unforeseeable event that may
  affect safety, purity or potency of Bulk Product; and (ii) any deviation in
  the quality (purity, physical and chemical properties) of the Bulk Product
  from the Bulk Product Specifications. Appendix I sets forth a list of examples
  of deviations from the Process, for purposes of illustration only, and is not
intended to be comprehensive or definitive.

  (i) BTG shall not conduct any retesting or reprocessing as the result of deviations described above without prior written authorization from SAVIENT Quality Assurance unless a delay of retesting or reprocessing would result in
increased risk to the safety, purity or potency of the Bulk Product or Product. 

  3.02 Any changes to be made to this Quality Agreement in accordance with the provisions set out in this section 3 must be documented as an addendum to this Quality
Agreement, and must be signed by authorized representatives from each of the BTG QA department and the SAVIENT QA department, in addition to authorized representatives from any other departments as may be specified in relation to the matters set
forth in section 3.3 below. This Quality Agreement will be reviewed by BTG and SAVIENT on a periodic basis (approximately once per year) and revised as appropriate. 

3.03 Change
Control

(i) Specifications that control the Process for
    the manufacture, including packaging, holding, and test of Bulk Product and
    Product, must be signed by authorized representatives from BTG and SAVIENT
    Quality Assurance, SAVIENT Regulatory Affairs, and SAVIENT Manufacturing.
    Such documents include, but are not limited to Bulk Product Specifications
    (including specifications for intermediate), Product Specifications (including
    specifications for product, component and packaging). Changes to such documents
    must be signed by authorized representatives from SAVIENT Quality Assurance,
  SAVIENT Manufacturing and SAVIENT Regulatory Affairs.  

(ii) Changes
  to additional documents that control the Process for the manufacture of Bulk
  Product and Product (including test methods, manufacturing procedures and
  batch records) must be assessed according to the BTG change control process
  described in section 3.4. Any change that would have an impact on the Process,
  Bulk Product or Product, or require submissions to or approvals from any
  Regulatory Agency must receive prior written approval by authorized representatives
  from SAVIENT Quality Assurance, SAVIENT Manufacturing and SAVIENT Regulatory
  Affairs. If there is no such impact, BTG may proceed with the change, but
  must notify SAVIENT Quality

 

  Assurance no later than 5 days from the initiation
  of the BTG change control process. If SAVIENT does not agree with BTG’s
  assessment of impact, SAVIENT must respond to BTG no later than within 5 days
of receipt of notification.

(iii) The stability protocol as well as any changes to the stability protocol must be approved by SAVIENT QA and SAVIENT Regulatory Affairs.

(iv) Critical Raw Materials. The current specifications for Critical Raw Materials are attached as Appendix III. The Parties acknowledge and agree that these specifications
  may be amended from time to time by the supplier of the material. With respect to such amendments: 

  BTG shall notify SAVIENT as soon as reasonable practicable, but no later than within 5 days of receipt of notification by BTG. 

The Parties will meet and agree as to suitability of the material produced according to the amended specification for manufacture of the Bulk Product. 

  3.04 BTG will utilize a documented system of written procedures for the control of changes to documents relating to raw materials, packaging materials, labeling, suppliers,
equipment, manufacturing methods, batch size, product, intermediates and raw materials specifications, sampling, analytical test methods and Release requirements and any other Processing by BTG, relating to the Bulk Product. 

  3.05 Any changes to any matter relating to the manufacture and supply of Bulk Product by BTG shall be governed by the procedures set out in the Supply Agreement at Article 3
in relation to changes to the Bulk Product Specifications, and Article 6 in relation to changes to the Process.

  3.06 SAVIENT Regulatory Affairs will have responsibility for determining the regulatory impact of any proposed change. SAVIENT Regulatory Affairs will determine the
classification and requirements for notification to, or approval by FDA.  SAVIENT is responsible for communication of any changes to FDA. SAVIENT Regulatory Affairs will have responsibility to advise BTG of any changes to the BLA prior to
submission. 

  BTG will ensure that changes are evaluated and qualified in accordance with all applicable ICH (International Conference on Harmonization) requirements in addition to all Legal Requirements, including but not limited to:

  ICH Guideline Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. 

  ARTICLE 4 

  

  MATERIALS:

	
    4.01        	
Procurement of Components
  
	 	
BTG will procure all the components described in the Bulk Product Specifications in such quantities as may be necessary to meet Purchase Orders placed by SAVIENT pursuant to the Supply Agreement, and store the
components in appropriate storage conditions under quarantine until tested.

  
	 	 
	
    4.02        	
Inspection and Testing of Materials
  
	 	 
	 	
Upon receipt, BTG shall sample in accordance with acceptable statistical methods, inspect and test containers of all materials to be used in the Process or in connection with the supply and manufacture of Bulk
Product on a batch-by-batch basis, in accordance with the Bulk Product Specifications.

  
	 	 
	
    4.03        	
Bulk Product
  
	 	 
	 	
BTG will be responsible for ensuring that Bulk Product is manufactured, tested and stored in compliance with all applicable ICH guidance documents (including, without limitation, the guidance contained therein for
master and working cell banks) in addition to all Legal Requirements. ICH Guidance includes, but is not limited to:

  
	 	 
	 	
Q5D Quality of Biotechnological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products.

  
	 	 
	 	
Q7A, Good Manufacturing Practices Guidance for Active Pharmaceutical Ingredients

  
	 	 
	
    4.04        	
Retention, Storage and Handling of Materials and Product Samples
  
	 	 
	 	
BTG shall sample and retain such
    amounts of Bulk Product and of all materials to be used in the Process or
    in connection with the supply and manufacture of Bulk Product (“Retains”)
    except water, compressed gasses and any highly volatile compounds as set
    forth in Appendix II or as otherwise required in accordance with applicable
    Legal Requirements. BTG will store for five years, or such longer period
    as may be required in accordance with Appendix II or by Legal Requirement,
    sample Product and Retains for each batch or lot of intermediates and raw
    materials. Reasonably prior to the expiry of such retention period, or upon
    termination of this Quality Agreement, BTG shall offer all such materials
    to SAVIENT. Any labor costs of BTG employees and/or Third Party expenses
    incurred by BTG related to the transfer of such materials shall be reimbursed
    by SAVIENT in the manner and at the rates set forth on Exhibit B to the Supply Agreement.

  
	 	 
	 	
A schedule of specific Retains, storage
    conditions and retention periods for Puricase® is listed in Appendix
    II.

  
	 	 

	4.05      	Transmissible Spongiform
          Encephalopathy (TSE)

	 	 
	 	
BTG will provide a written TSE declaration that all materials (including non-dedicated equipment) used in the manufacturing process are free from animal derived material. In addition, BTG must have available, on
site, written TSE declarations from the supplier, where appropriate, of raw material used in the manufacturing process verifying exclusion of animal derived material. If BTG is unable to provide the above declarations, BTG will comply with
applicable TSE laws and regulations and will obtain all associated TSE documentation as requested by SAVIENT. This documentation may include a TSE Certificate of Suitability in accordance with European directive 75/318/EEC as amended by directive
1999/82/EEC, the note for guidance EMEA/410/01 rev2 as amended and AP-CSP(99)4, Appendix 2, as amended.

  
	 	 
	
    4.06        	
Supplier Audits
  
	 	 
	 	
BTG and SAVIENT will provide each other with copies of supplier audit reports for materials used in the Process or manufacture of the Product.

  

  ARTICLE 5

  MANUFACTURING, PACKAGING, INSPECTION AND TEST:

  5.01 The Processing, packaging, and labeling of Bulk Product will be performed and documented by BTG. BTG will not subcontract any of the Processing, packaging, and labeling functions except as may be permitted in accordance with
the Bulk Product Specifications, and if so permitted, in accordance with the provision set forth in Section 2.05 of the Supply Agreement.

  5.02 BTG shall not Process or store Bulk Product
  in the same building in which BTG manufactures, stores or processes potentially
  hazardous substances (including, without limitation, certain antibiotics such
  as beta-lactam and cephalosporins, cytotoxic compounds, toxins or poisons such
  as pesticides or herbicides, (collectively, “Potential Contaminants”)
  unless the Potential Contaminants are stored or manufactured in contained environments
  and in compliance with all Legal Requirements and the Bulk Product is Processed
  and stored in compliance with building, cleaning, validation and changeover
  requirements of all cGMPs and all Legal Requirements. BTG shall promptly notify
  SAVIENT if any of the Potential Contaminants are manufactured, processed or
  stored in any portion of the Facility which may result in the introduction
  of Potential Contaminants into the areas of such facilities where the Bulk
  Product is Processed. Savient is aware that other products are processed in
  the Facility, the nature of those other products existing today and that certain
  equipment (multi-use equipment) is used in the processing of both the Bulk
  Product and these other existing products. Savient has also had the opportunity
  to assess the risk to the Processing of Bulk Product of the use of such certain
  multi-use equipment with respect to the other existing products. However, in
  the instance where BTG intends to introduce a new product or substance to its
  Facility which is out of the matrix of existing products and use such multi-use
  equipment in the processing or handling of such new product or substance, Savient
  will need to reassess the risks to the Processing of Bulk Product with this
  new product or substance utilizing the multi-use equipment. Therefore, whenever
  BTG plans to introduce a new product or molecular entity which is out of the
matrix of

  existing products to equipment shared with Puricase production, BTG will provide no less than 30 days prior notice of its intent, and will contemporaneously make supporting cleaning validation data/rationale available to Savient.
Savient will make its assessment of the risk potential for adulteration of its own product through examination of cleaning validation documentation prior to any further Puricase production and will respond to BTG within 5 days of its receipt of
cleaning validation data/rationale as to its conclusion(s) about the introduction. 

  5.03 BTG will provide to SAVIENT: a copy of all master batch record documents and production and control records, a Certificate of Analysis (PEG-uricase API and uricase),
executed batch records and associated batch documentation, which shall include, without limitation: formulation records, label records, manufacturing records, environmental monitoring data, microbiological data, in-process and final analytical data,
including lab control results, sterility data, deviations/out-of-specification reports and cleaning records for any critical product contact equipment (for example, fermentors or any other non-dedicated product contact equipment).

	 	
    (i)        	
Translation: BTG will provide an English translation of all such documents, including, without limitation, all reports, notes or comments on records that are not part of the master batch record but if any of the
foregoing documents are only available in a language other than English, the Parties shall agree upon an English language template for such document(s), and BTG shall provide to Savient an English language translation of any deviations from the
template(s). When required by SAVIENT, translations shall be performed by an independent, translation firm. Translations by a third party firm must be verified by BTG to ensure translation of company or process specific language. Any labor costs of
BTG employees and/or Third Party expenses incurred by BTG in relation thereto shall be reimbursed by SAVIENT in the manner and at the rates set forth on Exhibit B to the Supply
Agreement.
  

  5.04 Upon request by SAVIENT, BTG will provide access to additional records that are not normally part of the batch record but which bear a reasonable relation to the Bulk
Product for SAVIENT to review, which may include, without limitation, maintenance and use records, water testing data, training records, raw material release records, log books, receiving and shipping records, inventory records and vendor
qualification records Any labor costs of BTG employees and/or Third Party expenses incurred by BTG in relation thereto shall be reimbursed by SAVIENT in the manner and at the rates set forth on Exhibit B to the Supply Agreement. 

  5.05 BTG will retain copies of all completed batch records for a minimum of five years, or such longer period as may be required by Legal Requirement. Reasonably prior to
the expiry of such retention period, or upon termination of this Quality Agreement, BTG shall offer such completed batch records to SAVIENT. Any labor costs of BTG employees and/or
Third Party expenses incurred by BTG related to the transfer of such materials shall be reimbursed by SAVIENT in the manner and at the rates set forth on Exhibit B to the Supply Agreement.

5.06 Use
of BTG Manufacturing Space for Bulk Product 

	 	BTG has allotted an amount of manufacturing
      floor space at the Facility for the Processing of Bulk Product (Purification
      Area in the Agreement). This space may be used for the production of other
    products subject to the following limitations: 
	 	 
	
    (i)                 	
BTG may use the Purification Area for alternate product manufacturing only during periods when the Purification Area is not used for the Processing of Bulk Product.
  
	
    (ii)        	
BTG adheres to all relevant cGMPs including, without limitation, procedures for prevention of mix-ups, prevention of contamination, labeling requirements, cleaning requirements and changeover requirements
  
	
    (iii)        	
BTG, shall not, under any circumstances utilize any equipment dedicated to the Processing of Bulk Product for such alternate product manufacturing
  
	
    (iv)        	
BTG adheres to limits and procedures described in section 5.2 for Potential Contaminants.
  

  ARTICLE 6

  RELEASE AND SHIPMENT OF PRODUCT(S):

  6.01 Bulk Product shall be Released in accordance with the procedures set forth in the Supply Agreement, together with the additional obligations described in this section 0
of the Quality Agreement. BTG QA will review the records described in section 5.3 above. Following review and acceptance by BTG QA, BTG will send copies of these documents to SAVIENT QA. SAVIENT QA and Manufacturing will then review the
documentation and notify BTG whether or not documentation is acceptable.  If such documentation is not reasonably acceptable to SAVIENT, BTG will cooperate in taking such steps as SAVIENT may reasonably require to ensure that the documentation, and
any Processing described therein complies with the Bulk Product Specifications and all Legal Requirements. 

  6.02 BTG QA will be responsible for the QC testing of Filled Product until such time as a third party laboratory has been qualified to perform such testing. BTG will provide a Certificate of Analysis and/or stability results for
each batch that BTG tests. Savient QA will be responsible for the review of the manufacturing batch record for Filled Product, review of the Certificate of Analysis and Release of the Filled Product. 

 6.03 SAVIENT
QA will be responsible for the Release of the Final Product.

 6.04 Product
    shall be delivered in accordance with the provisions of Article 7 of the
Supply Agreement.

6.05 BTG will not ship any SAVIENT products to any destination, as identified by SAVIENT, unless prior approval has been received from SAVIENT. 

  ARTICLE 7

  DEVIATIONS IN PROCESS OR BULK PRODUCT:

  In the event of a notification of a deviation by
  BTG in accordance with the section above, BTG shall investigate and fully document
  in English such deviation within 30 days of its discovery. If BTG cannot resolve
  the deviation within the 30-day period, BTG will provide weekly updates of
  the investigation progress. At SAVIENT’s request, BTG shall conduct such
  additional or more detailed investigation of the deviation as SAVIENT may reasonably
  instruct. Investigation documentation will be retained by BTG as part of the
  batch documentation for the batch affected. When a deviation has occurred,
  SAVIENT will have the final review and decision making responsibility as to
  the impact of the deviation on the Bulk Product or Product, which will include
the disposition of affected lots.

  ARTICLE 8

  STORAGE OF PRODUCT(S):

  Bulk Product will be stored under appropriate storage conditions and in a secure area to ensure that they comply with the Bulk Product Specifications, including all the label requirements, quality specifications and attributes as
well as Legal Requirements. 

  ARTICLE 9

  TRACEABILITY OF PRODUCT(S):

  SAVIENT will be responsible for traceability of products to first consignee within the US. BTG will be responsible for traceability from the finished product lot number to raw material and component lots used in
manufacture.

  ARTICLE 10

  CONFLICT OF TERMS:

  To the extent that there exists any conflict between the terms of this Quality Agreement and the Supply Agreement, the latter shall prevail. To the extent that there exists any conflict between the terms of this Quality Agreement
and any Legal Requirements, the latter shall prevail. 

  ARTICLE 11

  COMPLIANCE WITH LAWS:

  BTG will ensure that all of its activities pursuant
  to this Agreement are performed in accordance with all Legal Requirements (including
  cGMPs), the respective Bulk Product Specifications, conditions of the BLA,
  and BTG’s
Standard Operating Procedures (SOPs). BTG will ensure that the Bulk Product supplied
  by it to SAVIENT shall not itself cause the Final Product to be adulterated
  or misbranded within the meaning of the Federal Food, Drug, and Cosmetic Act
and regulations.

  ARTICLE 12 

  

INSPECTIONS:

  Each party shall advise the other of any governmental communication, inspection or report, including, without limitation, that of any appropriate regulatory agency in any jurisdiction with responsibilities similar to those of the
FDA in respect of the United States, any environmental agency, health agency or other governmental or administrative agency having jurisdiction over the Product or the Processing. The notifying party shall promptly notify the other party by fax and
telephone, to the person and on the contact numbers set out below:

	
    TO SAVIENT: 	   
	
    •  	Contact Name:	
    Robert Lamm, Ph.D., Sr. VP of Quality and Regulatory 
	   	   	
    Affairs 
	• 	
    Telephone: 	
    732-418-9300 
	• 	
    Fax: 	
    732-418-0766 
	
    TO BTG: 	   	   
	• 	
    Contact Name: 	
    Rivka Zaibel, VP, Quality Assurance 
	• 	
    Telephone: 	
    972-8-861-2007 
	• 	
    Fax: 	
    972-8-861-2166 

ARTICLE 13

  OBSERVATION BY SAVIENT:
	 	Observation by SAVIENT or its
        authorized representative shall be governed the following. Observation
        will be limited to not more than one quality audit every 12 months. One
        additional quality audit may be conducted within the 12 month period
        if BTG receives a communication from any regulatory authority threatening
        license approval or supply of the Product due to compliance deficiencies
        at BTG facilities or if BTG was found to be in material non-compliance
        of this Agreement during or since the last quality audit. Person-in-Plant
        visits may be conducted at the discretion of SAVIENT during the manufacture
        of Bulk Product at BTG facilities. The frequency and duration of any
    additional visits must be agreed to by SAVIENT and BTG.

 

ARTICLE 14 

ADVERSE EVENTS:

14.1   BTG will provide to SAVIENT within 48 hours of becoming aware, any information from any source that suggests an adverse event or serious adverse event has occurred.  This information will include any adverse drug experience
or reaction reports or any other information indicating that the product has any toxicity, sensitivity reactions or is otherwise alleged to cause illness or injury due to a possible product quality problem, adulteration or misbranding. 

14.2   Quality Assurance Investigations. Upon notification to BTG that SAVIENT has received an SAE, AE, product complaint or inquiry regarding a Product supplied or
incorporating a Bulk Product supplied, BTG shall conduct a quality assurance investigation to determine if any process or testing deviations or events may have contributed to the SAE, AE, product complaint or inquiry. BTG shall provide a written
report on the results of the investigation to SAVIENT in not more than 30 days from Savient’s notification.  In cases where a more comprehensive investigation might be required, the Parties will jointly develop an investigation plan. BTG shall
reasonably cooperate with SAVIENT and regulatory agencies regarding an investigation or inquiry that may be initiated by a regulatory agency or otherwise required in response to a consumer or healthcare professional. BTG shall further provide
SAVIENT with all data or other information that SAVIENT may reasonably require in connection with any reports or correspondence that SAVIENT provides to the regulatory agency, consumer or healthcare professional relative to any such AE, SAE or
product complaint.  BTG shall make records accessible to SAVIENT for purposes of FDA or other regulatory agency inspection.

14.3   Exchange of Drug Safety Requests.  The Parties shall immediately provide each other with copies of all drug safety requests from all governmental and other regulatory
health authorities.  Proposed answers affecting the Product will be exchanged between the Parties before submission and the Parties shall cooperate with respect to such answers. SAVIENT shall have the ultimate decision-making authority with respect
to the answers relating to the Product. The Parties shall exchange decisions from applicable health authorities immediately. 

ARTICLE 15

STABILITY:

  BTG will perform the stability testing, data interpretation, reporting and updating of stability information to regulatory documents for the Product and Bulk Product and for Product until such time as a third party laboratory has
been qualified to perform such testing. Stability related activities for which BTG is responsible shall be completed in accordance with the timing specified in stability protocols and BTG procedures. 

ARTICLE 16

  REGULATORY AFFAIRS:

  Each Party shall advise the other Party of any regulatory action of which it is aware which would affect the Product in any country of the Territory. 

  ARTICLE 17

  ANNUAL REPORT TO FDA:

BTG will prepare a summary of all changes to the product, production process, quality controls, equipment or facilities that have a potential to affect the identity, strength, quality, purity or potency of the Product. Such data
will be prepared and sent to SAVIENT within thirty days of the end of the review period.  BTG will also ensure that the results of all stability testing performed within the review period are sent to Savient within thirty days of the end of the
review period. 

Approvals

	   	
      Print Name 	
      Signature 	
      Date 
	
      SAVIENT QA 	
      Robert B. Lamm 	
      /s/ Robert B. Lamm 	
      20-Mar-07 
	   	   	   	 
	  BTG QA 	
      Rivka Zaibel 	
      /s/ Rivka Zaibel 	
      20 March 2007 

APPENDIX I 

  Listing of Example Deviations 

  The following is a non-exclusive list of deviations requiring notification in accordance with section 0: 

	
Deviation impacting any filed regulatory document.

	
Use of manufacturing or testing site (finished products, intermediates, API or excipients) other than that specified in Bulk Product and Product Specifications and/or BLA.

	
Change of manufacturing scale from that specified in Bulk Product Specifications and/or BLA.

	
Deviation from packaging or packaging specifications from that specified in Bulk Product Specifications and/or BLA.

	
Deviation from suppliers, sources or specifications of starting and Critical Raw Materials or supplier of any filters for Products or intermediates set forth in Bulk Product Specifications and/or BLA.

	
Change in the layout, functioning or structure of the Facility, equipment or utilities (HVAC, nitrogen, water or compressed gasses) that may affect the quality of the Bulk Product.

	
Use of solvents or reagents (including volatile reagents), other than those specified in Bulk Product Specifications and/or BLA, or change of specifications for such solvents, reagents, or intermediates, or change in analytical methods of solvents, reagents, or intermediates.

	
Deviation in amounts of solvents or reagents used from that specified in the Process, Bulk Product Specifications and/or BLA.

	
Change in [**] status of any raw material or product(s).

	
Any reprocessing or rework of any step of the Process.

	
A physical contamination, cross-contamination or other chemical contamination.

	
Any manufacturing, packaging, labeling, sampling or testing deviation that affects the quality, safety or purity of the Product.

	
Departures from the SOPs, IPC tests, stability SOPs, the Stability Protocol or Batch Records outside the filed limits, excursions or any deviation with potential registration impact.

	
Any unexpected results from stability testing.

	
Environmental monitoring results that are out-of-specification.

APPENDIX II

Schedule of Retains, Storage Conditions and Retention Periods for Puricase®

  The following is a list of the reserve/retention samples that are taken during the manufacturing processes of bulk uricase and PEG-uricase as well as from the final bulk uricase and the final bulk PEG-uricase (Bulk
Product).

  The document was prepared based on the following BTG QC SOPs:

	 	
    1.	
SOP 04-68-1288 (v2): QC Sampling Plan for Bulk Uricase
  
	 	
    2.	
SOP 04-68-1830 (v1): QC Sampling Plan for PEG-Uricase API
  
	 	
    3.	
SOP 04-68-1861 (v1): IPC Testing of Bulk Uricase Batches
  
	 	
    4.	
SOP 04-68-1862 (v1): IPC Testing of PEG-Uricase
  
	 	 	 
	 	Table 1 details
      the reserve/retention samples that are taken during the manufacturing process
    of bulk uricase and from the final bulk uricase.
	 	 
	 	Table 2 details
      the reserve/retention samples that are taken during the manufacturing process
    of PEG-uricase and from the final bulk PEG-uricase (Bulk Product).
	 	 
	 	All IPC samples
      (including reserve/retention samples) are to be discarded after the Final
    Product is released by Savient. 
	 	 
	 	Uricase retention
      and reserve samples will be kept for one year after manufacturing. PEG-Uricase
    retention and reserve samples will be kept for six years after manufacturing
	 	 

Table
1. Reserve/Retention Samples for Bulk Uricase (IPC and Final)

	
  Process Step  	 	
Sample name  	 	
Number of  	 	
Storage  
	   	 	   	 	
Samples  	 	
Temperature  
	
  [**]  	 	
[**]  	 	
[**]  	 	
[**]  
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	   	 	   	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	   	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	   	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	
[**]  
	   	 	
[**]  	 	
[**]  	 	   
	
  [**]  	 	
[**]  	 	
[**]  	 	   
	   	 	
[**]  	 	
[**]  	 	   
	   	 	
[**]  	 	
[**]  	 	   
	
[**]  	 	
[**]  	 	
[**]  	 	   
	   	 	
[**]  	 	
[**]  	 	   
	
[**]  	 	
[**]  	 	
[**]  	 	   
	   	 	   	 	
[**]  	 	   
	   	 	 	 	 	 	 
	
[**]  	 	   	 	
[**]  	 	   
	   	 	 	 	 	 	 
	
[**]  	 	   	 	
[**]  	 	   

           [**]

Table 2. Reserve/Retention Samples for PEG-Uricase API
  (IPC and Final)

  

	
  Process Step  	   	Sample name  	   	
Number of  	   	
Storage  
	   	   	   	   	
Samples  	   	
Temperature  
	
  [**]  	                     	[**]  	                     	
[**]  	                     	
[**]  
	
  [**]  	 	[**]  	 	
[**]  	 	   
	
  [**]  	 	[**]  	 	
[**]  	 	   
	   	 	[**]  	 	
[**]  	 	   
	
  [**]  	 	[**]  	 	
[**]  	 	   
	   	 	[**]  	 	
[**]  	 	   
	   	 	[**]  	 	
[**]  	 	   
	
  [**]  	 	[**]  	 	
[**]  	 	   
	   	 	[**]  	 	
[**]  	 	   
	 	 	 	 	[**]	 	 
	  [**]	 	[**]	 	 
	  [**] 	 	   	 	[**]	 	   

	
                        [**]  	   	   

APPENDIX III 

Critical Raw Materials Used in the Production of Recombinant Uricase and PEG-Uricase

	
   Material  	   	
Manufacturer  	   	
Cat. No.  	   	
Testing  	   	
Source  	   	
Origin  
	   [**] 	                     	
[**]  	                     	
[**]  	                     	
[**]  	                     	
[**]  	                     	
[**]  
	   [**] 	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  
	   [**] 	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  
	   [**] 	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  
	   [**] 	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  
	   [**] 	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  
	   	 	   	 	   	 	
[**]  	 	   	 	   
	   [**] 	 	
[**]  	 	
[**]  	 	   	 	
[**]  	 	
[**]  
	   	 	 	 	 	 	 	 	 	 	 
	   [**] 	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  	 	
[**]  
	   [**] 	 	
[**]  	 	
[**]  	 	   	 	
[**]  	 	   

SPECIFICATION [**]  

	Parameter 	  	
Test  	  	Specification 	 
	
[**]  	                       	[**] 	                       	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	[**] 	 	[**] 	 	[**] 	 
	
[**]  	 	[**]  	 	
[**]  	 

SPECIFICATION [**]  

	Parameter 	  	
Test  	  	Specification 	 
	
[**]  	                       	[**] 	                       	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	[**] 	 	[**] 	 	[**] 	 
	
[**]  	 	[**]  	 	
[**]  	 

SPECIFICATION YEAST EXTRACT

	 	
Parameter  	 	Specification 	 
	 	 [**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 
	 	[**]  	 	
[**]  	 

SPECIFICATION [**]

	Parameter 	   	Specification 	 
	[**]  	                         	   	 
	[**]  	 	
[**]  	 
	 [**]  	 	
[**]  	 
	[**]  	 	
[**]  	 
	[**]  	 	   	 
	[**]  	 	
[**]  	 
	[**]  	 	   	 
	[**]  	 	
[**]  	 
	[**]  	 	   	 
	[**]  	 	
[**]  	 
	 [**]  	 	   	 
	[**]  	 	
[**]  	 

SPECIFICATION [**]

	Parameter 	   	Specification 	 
	[**]  	   	   	 
	[**]  	   	   	 
	[**]  	   	
[**]  	 
	[**]  	   	
[**]  	 
	[**]  	   	   	 
	[**]  	   	
[**]  	 
	[**]  	   	   	 
	[**]  	   	
[**]  	 

SPECIFICATION [**]

	Parameter 	   	Specification 	 
	[**]  	   	
[**]  	 
	[**]  	   	
[**]  	 

SPECIFICATION [**]  

	Parameter 	  	
Test  	  	Specification 	 
	
[**]  	                       	[**]  	                       	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 

SPECIFICATION [**]

	Parameter 	   	Specification 	 
	[**]  	   	
[**]  	 

SPECIFICATION [**]  

	Parameter 	  	
Test  	  	Specification 	 
	
[**]  	                       	   	                       	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 
	[**] 	 	[**] 	 	[**] 	 
	[**] 	 	[**] 	 	[**] 	 
	[**] 	 	[**] 	 	[**] 	 
	[**] 	 	[**] 	 	[**] 	 
	[**] 	 	[**] 	 	[**] 	 
	[**] 	 	[**] 	 	[**] 	 
	[**] 	 	[**] 	 	[**] 	 
	[**] 	 	[**] 	 	[**] 	 
	
[**]  	 	[**]  	 	
[**]  	 
	
[**]  	 	[**]  	 	
[**]  	 

[**]

  Exhibit E 

  

  Product Price

  During the first three (3) years from the date of the receipt by Savient of the first commercial batch of the Product, the Price of the Product shall be as follows: 

       (i)   For each
  gram, [**] United States Dollars (USD$[**]) for any aggregated quantities
  of the Product up to and including [**] ordered during any calendar year that
  commercial batches of Product are shipped, i.e. after the first commercial
batch of Product has been shipped.  

       (ii)   For each
  gram, [**] United States Dollars (USD$[**]) for any aggregated quantities
  of the Product between [**] and [**] ordered during any calendar year as above.;
and 

       (iii)   For each
  gram, [**] United States Dollars (USD$[**]) for any aggregated quantities
  of the Product equal to or greater than [**]ordered during any calendar year
as above.

  The Parties agree that Savient will enter into
  a supply agreement with NOF, the supplier of [**], and will order and pay for
  PEG needed in Product manufacture on an ongoing basis. In the event that BTG
  purchases PEG directly from NOF or any other manufacturer, the cost of the
PEG will be invoiced to Savient.

  Beginning on the Third (3rd) anniversary of the date of receipt of the first commercial batch of Product by Savient, and on each successive first (1st) January thereafter, the Price of the Product shall increase by an amount equal to the average increase in the United States Consumer Pricing Index (CPI) over the immediately preceding twelve (12)
month period; such percentage increase shall be applied to each amount specified in (i) through (iii) above. 

Exhibit F

Residual Rights Agreement

AMENDED AND RESTATED 

RESIDUAL RIGHTS AGREEMENT

This Amended and Restated Residual Rights Agreement (“Agreement”) is entered into on the 17th day of July, 2005, by and between Savient Pharmaceuticals, Inc., a
public company duly organized under the laws of the State of Delaware (“Savient”) and Bio-Technology General (Israel) Ltd., a private company duly organized under the laws of the
State of Israel (“BTG”), to replace and supersede the Residual Rights Agreement previously signed and dated 20 June, 2005. 

(Savient and BTG shall be referred to jointly as the “Parties” and individually as a “Party”). 

WHEREAS, BTG is a wholly owned subsidiary of Savient; and 

WHEREAS, the Parties are parties to a Manufacturing Services Agreement effective January 1, 1996 (the “Manufacturing Agreement”) and a Research and Development
Services Agreement dated January 1, 1996 (the “R & D Agreement”) (the Manufacturing Agreement and the R & D Agreement being collectively referred to hereunder as the
“Inter-Company Agreements”); and 

WHEREAS, pursuant to the Share Purchase Agreement (the “SPA”) and the Asset Purchase Agreement (“APA”), each dated March 23, 2005 (the SPA and APA, collectively, the “Divestiture Agreements”), Savient intends to sell to Ferring B.V. all of the issued and
outstanding share capital of BTG, and to Ferring International Centre S.A. (together with Ferring B.V., the “Buyer”) all of Savient’s right, title and interest in and to
certain assets and rights of Savient in the drug products and drug candidates developed and/or manufactured at BTG pursuant to the Inter-Company Agreements (the “Divestiture” and
the “Divested Products”, respectively), but not in any case in the drug candidate known as “Peguricase” (a/k/a
“Puricase”); and 

WHEREAS, the development of Puricase is ongoing and Savient shall require, and BTG is willing to render, continued development, manufacturing and other services of BTG in relation to Puricase, following the Closing (as defined in
the Divestiture Agreements); and 

WHEREAS, the Parties wish to record certain specific understandings in relation to certain [**] technology (the “[**] Technology”) as to which Savient has
retained title, in furtherance of the understandings set out in the SPA in relation thereto, which [**] Technology forms part of the Puricase Technology, but which can also be used for the manufacture of other products (all

products that may be manufactured using the [**] Technology, other than Puricase, Divested Products and HA (as defined below), being referred to herein as “[**] Products”); and 

WHEREAS, the Parties wish to record certain specific understandings in relation to the OCS-funded project, known as BTG-271 (“BTG-271”), in furtherance of the
understandings set out in the SPA in relation thereto; and 

WHEREAS, certain of the Divested Products, Puricase, the [**] Technology and BTG-271 were developed at BTG within the framework of research and development programs carried out with the support of the Office of the Chief Scientist
at the Ministry of Industry, Trade and Labor (“Approved Programs” and the “OCS” respectively) and Savient has
ownerships rights thereto but BTG possesses other rights as set forth in Savient’s letter to the OCS of July 15, 2003 (the “OCS Letter”), a copy of which is attached as
Annex “A”; and 

WHEREAS, the Parties have agreed to terminate the Inter-Company Agreements and wish to record their understandings in relation to the continued development and/or manufacture of Puricase and/or other services that may be rendered
by BTG in relation thereto; and 

WHEREAS, the Parties wish to record their understandings in relation to the royalties that may be payable to the OCS (“Royalties”) in relation to the Divested
Products, Puricase, other products embodying Puricase Technology, [**] Products and BTG-271, all subject to and effective as from the Closing. 

Now therefore, in consideration of the foregoing premises, which are incorporated into and made a part of this Agreement, and of the mutual covenants which are recited herein, the Parties agree as follows: 

	
1.        	
Termination of the Inter-Company Agreements
  
	 	 	 
	 	
1.1.        	
Prior to the Closing, Savient and BTG shall comply with the terms and conditions of the Inter-Company Agreements, including any payment obligations by Savient thereunder. Notwithstanding anything to the contrary
contained in the Inter-Company Agreements, all of the provisions of the Inter-Company Agreements shall automatically terminate effective as of the Closing, including provisions that were intended to survive termination. Savient shall not have any
further obligation to pay BTG in respect of Reimbursable Costs (as such term is defined in the R & D Agreement) or Processing Fees (as such term is defined in the Manufacturing Agreement) that may be outstanding as of such time in relation to
Divested Products, and BTG shall be considered as having waived such payments.
  
	 	 	 
	 	
1.2.        	
In connection with such terminations, and for the avoidance of doubt, the Parties agree that:
  
	 	 	 	 
	 	 	
1.2.1.        	
Notwithstanding the provisions of Section 1.1 and Section 3.2 of the Manufacturing Agreement, title to all work in process relating to Divested Products and inventory of Divested Products shall automatically vest
in the Buyer, as of the Closing;
  

	
          	
               	
1.2.2.        	
Notwithstanding the provisions of Section 1.1 above and Section 11.3 of the Manufacturing Agreement, as of the Closing, BTG shall process and deliver Divested Products ordered prior to the Closing to the Buyer or
the Buyer’s designee, and Savient shall have no responsibilities in relation thereto;
  
	 	 	 	 
	 	 	
1.2.3.        	
As of the Closing, Savient and BTG agree that any liability of Savient to pay BTG for development activities, regulatory or other services of any nature that may have been carried out by BTG for Savient prior to
the Closing under the R & D Agreement or otherwise have been satisfied as of the Closing; and
  
	 	 	 	 
	 	 	
1.2.4.        	
The provisions of the Manufacturing Term Sheet attached hereto as Annex “D” shall apply to work in process relating to Puricase existing
as of the Closing and the delivery of Puricase that may have been ordered prior to the Closing.
  

	
2.        	
Ownership in Technology; Patent Rights; Other Rights
  
	 	 	 
	 	
2.1.        	
Savient has and shall have the exclusive right, title and interest in and to Puricase and the Puricase Technology, subject to (i) BTG’s irrevocable and perpetual right to conduct research and development with
the Puricase Technology developed in the course of Approved Programs, excluding clinical trials that BTG is not in a position to monitor from Israel and (ii) BTG’s right to manufacture Puricase in Israel. BTG shall have commercialization rights
with respect thereto only as provided in Section 6 herein or as provided in the Divestiture Agreements. In the case of clauses (i) and (ii), BTG’s rights shall always remain subject to the terms and conditions of any existing supply,
manufacturing or development agreement between the Parties. For the avoidance of doubt, Savient and an additional manufacturer on its behalf approved by the OCS, will have the right to use the [**] Technology in order to manufacture
Puricase.
  
	 	 	 
	 	
2.2.        	
Savient has and shall have the exclusive right, title and interest in the [**] Products and the [**] Technology subject to BTG’s exclusive, irrevocable, perpetual and unconditional license for purposes of
research and development and production. BTG shall have commercialization rights with respect thereto only as provided in Section 6 herein or as provided in the Divestiture Agreements.
  
	 	 	 
	 	
2.3.        	
For the purposes of this Agreement, the term “Puricase Technology” means the technology described in the patent applications listed on
Annex “B” as 1.1 (the “Puricase Patents”), and any developments, discoveries, inventions, improvements,
designs, methods, processes, techniques, devices, formulae and trade secrets which may be developed, acquired and conceived by BTG and are derived from any Development Program in relation to Puricase which have been or may be carried out at any time
after the submission of the Puricase Patents and all patents that may be issue from patent applications claiming or describing such
  

	
          	 	
technology, information and know-how and filed in addition to the Puricase Patents after their submission.
  
	 	 	
For the purposes of this Agreement, the term “[**] Technology” means the technology described in the patent applications listed on
Annex “B” as 1.2 (the “[**] Patents”) and any developments, discoveries, inventions, improvements,
designs, methods, processes, techniques, devices, formulae and trade secrets which have been or may be developed, acquired and conceived by BTG and are derived from any Development Program which have been or may be carried out at any time after the
submission of the [**] Patents and all patents that may issue from patent applications claiming or describing such technology, information and know-how and filed in addition to the [**] Patents after their submission.
  
	 	 	 
	 	 	
For the purposes of this Agreement, “Development Programs” shall mean research and development work carried out by BTG for Savient.
  
	 	 	 
	 	
2.4.        	
The Puricase Patents, and the [**] Patents (collectively, the “Savient Patents”) are owned by Savient. BTG shall have no rights with respect to
the Savient Patents, other than as provided herein or as provided in the Divestiture Agreements. Savient has the sole control over filing and prosecuting applications for United States and foreign patents covering the Puricase Technology and the
[**] Technology and may file and prosecute the same in Savient’s name. The cost for all such filings and prosecutions are and shall be borne by Savient. BTG and its employees and consultants shall provide Savient, without compensation other
than recovery of out of pocket expenses, with the necessary authorizations, powers of attorney and other documents and assistance reasonably requested by Savient from time to time to file, secure and maintain Savient’s patent rights in
connection with the Savient Patents and BTG hereby grants to Savient powers of attorney to execute and file on BTG’s behalf any documents reasonably necessary to secure and maintain such patent rights.
  
	 	 	 
	 	 	For the purposes of this Agreement, the term “Savient
        Patents” means the patents listed
        on Annex B and
        any disclosures, continuations, continuations-in-part, divisionals, provisionals,
        PCT applications, reissuances, revisions, substitutions, conversions,
        renewals, extensions, prolongations, and reexaminations thereof, any
        technology and inventions covered thereby, and any corresponding international,
    regional, and national applications and patents. 
	 	 	 
	
         	
2.5.        	
BTG shall, from time to time and as soon as practicable following Savient’s request, provide Savient with documentation describing the current Puricase Technology and [**] Technology held by or under the
control of BTG and any other report reasonably requested by Savient. For the avoidance of doubt, Puricase Technology and [**] Technology shall be described in sufficient detail to allow Savient to manufacture Puricase, or use the [**] Technology (as
the case may be) it being understood and agreed, however, that Savient shall not commence manufacture of Puricase or of a [**] Product (i) unless so permitted by the OCS, if such permission is required; and (ii) unless in compliance with
any
  

	 	
 
  	 	agreement between the Parties relating to such
    manufacture and supply; and (iii) provided that such permission by the OCS
    does not trigger any additional obligations of BTG vis-à-vis Savient
    or the OCS, above and beyond those provided in such agreement of manufacture
    and supply or in this Agreement. In any event, BTG may retain copies of such
    documentation for archival purposes.
	 	 	 
	 	
2.6.        	
For the sake of clarity:
  
	 	 	 	 
	 	 	
2.6.1.        	
Nothing herein is intended to derogate from BTG’s ownership of the real property, tools, machinery and equipment which have been or may be acquired by it in furtherance of, or incidental to, the Development
Programs;
  
	 	 	 	 
	 	 	
2.6.2.        	
Neither “Puricase Technology” nor “[**] Technology” shall be deemed to
include general methods of production or analysis that are generally known in the pharmaceutical industry but have been or will be applied to a Divested Product, HA, Puricase or any [**] Product.
  
	 	 	 
	 	
2.7.        	
Savient hereby grants BTG and its Affiliates a non-transferable, royalty-bearing, perpetual, worldwide nonexclusive, unconditional (save for the reasonable consideration to be paid for commercialization rights
hereunder) license, under the Puricase Patent to develop products which are not PEGylated recombinant porcine uricase (urate oxidase), and to manufacture and commercialize any such product, it being understood and agreed, however, that the royalties
that will be due and payable by BTG to Savient in respect of the commercialization rights to any such product, and other terms and conditions of such license, shall be subject to the negotiation, in good faith, of a mutually acceptable license
agreement containing normal and customary terms for transactions of a similar nature (the “License Agreement”). Should the Parties fail to execute the License Agreement within 90
(ninety) days of either Party initiating such negotiations, then the matter may be referred for resolution by either Party, in accordance with the provisions and the procedures attached hereto as Annex F. Nothing in the Parties’ failing to execute the License Agreement or the initiation or conduct of any such procedures shall bar BTG from exercising the license granted to it pursuant to this Section 2.7 pending the decision of the
expert.
  
	 	 	 
	 	
2.8.        	
The provisions of this Section 2 shall survive the termination or expiration of this Agreement.
  
	 	 
	
3.        	
Research & Development; Regulatory Services; Manufacturing Services
  
	 	 	 
	 	
3.1.        	
BTG hereby agrees to the extent and on the terms set out in Annexes “C” and “D”
hereto (as such Annexes may be modified or superseded by a final definitive agreement between the Parties) to (i) complete the ongoing research and development currently being conducted in respect to Puricase; (ii)
transfer the process to BTG’s facility in Be’er Tuvia, Israel; (iii) produce a sufficient quantity of Puricase as required for Phase 3 clinical trials and the initial commercial launch
  

	 	
of Puricase and perform all related stability and other testing and activities required for worldwide regulatory filing; (iv) render assistance to Savient in relation to the worldwide regulatory filings related
thereto; and (v) remain a back-up supplier to the new manufacturer (if any) throughout the time period set forth in Section E of Annex “D” attached hereto or any successive
Manufacturing Services Agreement between the Parties.

  
	 	 
	 	
3.2.        	
In the event that BTG breaches any of its obligations to Savient under this Section 3, in addition to any other remedies that may be available to Savient in law or equity, BTG shall, promptly upon Savient’s
request, cooperate and collaborate with Savient in applying to the OCS for Savient to carry out the work in question through a third party. Nothing in the foregoing should be construed as relieving BTG from its contractual obligations pursuant to
Section 3.1, and
  
	 	 	
Annexes “C” and “D” attached hereto.

  
	 	 	 
	
4.        	
Technology Transfer
  
	 	 
	 	
Subject to the approval of the OCS, Savient shall be entitled to request BTG to render to Savient and/or its third party manufacturer technical assistance relating to the transfer of the Puricase Technology or the
[**] Technology. The terms and conditions upon which BTG shall be obligated to render such assistance in relation to the Puricase Technology are set out in Annex “E” attached hereto.

  
	 	 
	
5.        	
Compliance with Law for the Encouragement of Research and Development in Industry and the Regulations, Rules and, Procedures Promulgated Thereunder (collectively, the “Law”)
  
	 	 
	 	
5.1.        	
BTG hereby confirms and acknowledges that as from the Closing BTG and/or the Buyer (as the case may be) shall be fully responsible for the payment of Royalties pursuant to the Law in relation to income derived from
the Divested Products and income derived by BTG from the commercial exploitation of a [**] Product pursuant to the license granted to it by Savient pursuant to Section 6.2 below, and BTG hereby agrees to indemnify Savient for any liability that may
be imposed upon it by the OCS in relation thereto. BTG shall provide Savient with copies of its semi-annual reports to the OCS in relation to the payment of such Royalties, together with evidence of payment. Moreover, BTG shall notify Savient of any
audit conducted by the OCS in respect thereto and the result of such audit, and provide Savient with copies of any written audit report. BTG has been using the [**] Technology in the production of caroboxpeptidase as of February 2005, and Royalties
pursuant to the Law in relation to income derived from carboxypeptidase are thus payable to the OCS. As there is uncertainty as to whether these Royalties should be allocated to OCS file 27141 (Puricase) and/or OCS file 10281 (APA), it is hereby
agreed that BTG and Savient shall mutually refer the question of the allocation of such Royalties and the relevant background information to Keren Tmurah at the OCS (“Keren Tmurah”) within 30 days of this Agreement, and Keren Tmurah’s directives shall be binding upon the Parties.
  

	
5.2.        	
Savient hereby confirms and acknowledges that as from the Closing Savient shall be fully responsible for the payment of Royalties pursuant to the Law in relation to income derived by Savient from Puricase, Puricase
Technology, a [**] Product and the [**] Technology and hereby agrees to indemnify BTG for any liability that may be imposed upon it by the OCS in relation thereto.
  
	 	 
	
5.3.        	
Due to the fact that BTG shall remain a conduit for the payment of Royalties as set forth in Section 5.2, and in order to ensure Savient’s compliance with the requirements of the Law, Savient irrevocably and
unconditionally undertakes to periodically provide BTG with the funds required for making such payments of Royalties in a timely manner. In furtherance thereof:
  
	 	 
	 	
5.3.1.        	
Savient shall provide BTG with semi-annual reports on its development and commercialization activities in respect of Puricase, Puricase Technology, the [**] Products and the [**] Technology, and any other
information related thereto, that may be requested by the OCS from time to time, for conveyance to the OCS, as required. Such reports shall be accompanied by a financial report signed by Savient’s Chief Financial Officer showing the calculation
of the amounts due to the OCS pursuant to the Law in respect of the period covered by the said report and the funds necessary to make the appropriate payments to the OCS, it being understood and agreed, however, that the funds will be transferred by
Savient to BTG by no later than 15 (fifteen) days before timely payment has to be made by BTG to the OCS. Such financial reports shall be certified by an independent auditor, once a year, at Savient’s expense.
  
	 	 	 
	 	
5.3.2.        	
Savient shall keep complete, accurate and correct books of account and records consistent with sound business and US generally accepted accounting principles and practices, in such form and in such details as to
enable the verification and the determination of the amounts due to the OCS in respect of Puricase, Puricase Technology, the [**] Products and the [**] Technology. Savient shall retain such books of account for 7 (seven) years after the end of each
calendar year.
  
	 	 	 
	
5.4.        	
BTG hereby undertakes to irrevocably and unconditionally remit the funds received from Savient pursuant to Section 5.3.1 above to the OCS in a timely manner, without any set-offs, deductions or withholdings of any
nature.
  
	 	 
	
5.5.        	
BTG and Savient shall comply with any request by the OCS to conduct, inter alia, an audit at Savient. In such event, BTG and/or the OCS shall be entitled
to appoint a representative to inspect, during normal business hours, and to take copies of Savient’s books of accounts, records and other documentation to the extent relevant or necessary for the ascertainment or verification of the amounts
due to the OCS under the Law, at Savient’s expense.
  

	
    6.        	
    [**] Patents

	 	 
		
		
  6.1.        	
In addition to BTG’s rights in relation to the [**] Technology, as set out in Section 2.2 above, Savient hereby grants BTG and its Affiliates an irrevocable, fully paid-up, transferable, non-royalty-bearing,
perpetual, worldwide, exclusive, unconditional license, under the [**] Patents, to offer for sale, sell and import Divested Products and HA. Nothing in the foregoing shall be construed as a representation on BTG’s part, that such license, or
the rights set out in Section 2.2, are required in order to develop, manufacture or commercialize any or all of the Divested Products or HA.
  
			 
		
  6.2.        	
Savient hereby grants BTG and its Affiliates a non-transferable, royalty-bearing, perpetual, worldwide nonexclusive, unconditional (save for the reasonable consideration to be paid for commercialization rights
hereunder) license, under the [**] Patents to offer for sale, sell and import [**] Products, it being understood and agreed, however, that the royalties that will be due and payable by BTG to Savient in respect of the commercialization rights and
other terms and conditions of such license, shall be subject to the negotiation, in good faith, of a mutually acceptable license agreement containing normal and customary terms for transactions of a similar nature (the “[**] License Agreement”). Should the Parties fail to execute the [**] License Agreement within 90 (ninety) days of either Party initiating such negotiations, then the matter may be referred for
resolution by either Party, in accordance with the provisions and the procedures attached hereto as Annex F. Nothing in the Parties’ failing to execute the [**] License Agreement
or the initiation or conduct of any such procedures shall bar BTG from exercising the license granted to it pursuant to this Section 6.2 pending the decision of the expert. Nothing in the foregoing shall derogate from the terms and conditions of any
existing supply, manufacturing or development agreement between the Parties.
  
			 
		
  6.3.        	
Should Savient decide to abandon a [**] Patent at any time during the first 5 (five) years following the Closing; Savient undertakes to notify BTG in writing,at least 60 (sixty) days prior to the date on which such [**] Patent would become finally abandoned in the absence of action on the part of the party prosecuting or maintaining such patent. Savient shall afford BTG the right, during such 60 (sixty) day period, to acquire such patent application or patents. Should the Parties fail to reach a mutually acceptable agreement as to the terms and conditions upon which BTG may acquire such patent applications or patents, Savient shall be entitled to abandon the same.

			 
	
    7.        	
    BTG-271

	 	 
		
		
  7.1.        	
Prior to the Closing, Savient shall either (a) transfer the patent applications listed in Annex “G” attached hereto (the
“BTG-271 Patents”) to a third party and arrange with the OCS for a full release of BTG’s obligation to pay royalties to the OCS with respect to subsequent sales in relation
thereto or (b) transfer the BTG-271 Patents to BTG.
  

	 	
7.2.        	
Subject to OCS approval, BTG undertakes to relinquish its rights in the BTG-271 project under the OCS Letter in the event that the BTG-271 Patents are transferred to a third party prior to the Closing or as
envisaged under Section 7.3 below.
  
	 	 	 
	 	
7.3.        	
Notwithstanding the foregoing, should negotiations between Savient and Eager BioGroup Ltd., a corporation registered in Israel, or any affiliated company registered in Israel and controlled by Prof. Max Herzberg,
be ongoing at the time of the Closing, Savient shall have an additional period of 90 (ninety) days from the Closing in order to finalize such transaction (the “Eager Transaction”),
and Savient shall bear the cost of the BTG-271 Patents throughout such time period. Should
the Eager Transaction not be consummated with OCS approval within such time period,
for any reason whatsoever, then the BTG-271 Patents shall be transferred to BTG.
  
	 	 	
 

  
	 	
7.4.        	
Should the BTG-271 Patents be transferred to BTG, then BTG-271 shall be treated as a “Divested Product” for purposes hereof.
  
	 	 	 
	
8.        	
Promoter Patents
  
	 	 
	 	
8.1.        	
BTG hereby grants Savient a fully paid-up, non-royalty-bearing, perpetual, worldwide nonexclusive license, with the right to sub-license, under the patents and patent applications listed in Annex “H” attached hereto (the “Promoter Patents”), to use the Osm B promoter claimed therein to make, have made, use,
offer for sale, sell and import Puricase, it being understood and agreed, however, that the manufacture “of Puricase outside of Israel is subject to the approval of the OCS.
  
	 	 	 
	 	
8.2.        	
BTG shall favorably consider any request by Savient to expand the scope of the license granted to it under Section 8.1. In such circumstances, the Parties shall negotiate in good faith with a view towards entering
into a mutually acceptable license agreement containing normal and customary terms for transactions of a similar nature.
  
	 	 	 
	 	
8.3.        	
Should BTG decide to abandon any of the Promoter Patents at any time during the first 5 (five) years following the Closing, BTG undertakes to notify Savient in writing, at least 60 (sixty) days prior to the date on
which such Promoter Patent would become finally abandoned in the absence of action on the part of the party prosecuting or maintaining such patent. BTG shall afford Savient the right, during such 60 (sixty) day period, to acquire such patent
application or patents.
  
	 	 	 
	 	 	
Should the Parties fail to reach a mutually acceptable agreement as to the terms and conditions upon which Savient may acquire such patent applications or patents, BTG shall be entitled to abandon the
same.

  
	
9.        	
Indemnification
  
	 	 
	 	
Each Party shall indemnify, hold harmless and defend the other Party and its officers, directors and employees against damages, costs and expenses (including reasonable

  

	 	
attorney’s fees) incurred as a result of such Party’s failure to comply with its undertakings under this Agreement.

  
	 	 
	
10.        	
Term; Effect of Termination
  
	 	 
	 	
10.1.        	
This Agreement shall enter into force and effect upon the Closing and shall continue to be in force for as long as the Puricase Technology and the [**] Technology is in use by either Party.
  
	 	 	 
	 	
10.2.        	
Should the Divestiture Agreements be terminated without the Closing taking place, for any reason whatsoever, this Agreement shall be null and void.
  
	 	 	 
	 	
10.3.        	
The termination of this Agreement for whatever cause shall not prejudice or affect the accrued rights and obligations of either Party.
  
	 	 	 
	
11.        	
Disclosure of Information
  
	 	 
	 	
11.1.        	
BTG and its Affiliates shall not furnish copies of documents, patents, patent applications, copyrights, drawings, specifications, bills of materials, devices, equipment, prototypes and other information relating to
the Puricase Technology other than as contemplated by this Agreement (and other than to any of their respective Affiliates) and shall not, without the prior approval of Savient, disclose such information to any third party, except to the extent that
such disclosure is necessary for BTG’s manufacture of Puricase for Savient, and then only if (i) such disclosure is subject to the same limitations on the recipient as on BTG, and (ii) such limitations are set forth in a written agreement in
form and substance satisfactory to Savient. “Affiliate”, as used herein, means, any corporation which controls, is controlled by, or is under common control with, BTG, following
the Closing. A corporation shall be deemed to control another corporation if it owns, directly or indirectly, more than 50% (fifty percent) of the voting shares, or has the power to elect more than half the directors, of such other corporation. For
purposes of this Section 11.1, “Puricase Technology” shall not include information which is in or becomes, part of the public domains through no act or omission by BTG or any of
its employees.
  
	 	 	 
	 	
11.2.        	
No publication with respect to any activity undertaken pursuant to a Development Program shall be made, nor any manuscript submitted for publication, without the prior review and written approval of Savient such
approval not to be unreasonably withheld.
  
	 	 	 
	 	
11.3.        	
The Parties agree that remedies at law may be inadequate to protect against breach of this Section 11, and in case of such a breach BTG hereby consents to the granting of injunctive relief, whether temporary,
preliminary or final, in favor of Savient without proof of actual damages.
  
	 	 	 
	 	
11.4.        	
The provisions of this Section 11 shall survive the termination or expiration of this Agreement.
  

	
12.        	
Non - Compete
  
	 	 
	 	
From the Closing Date until the expiration of the later to expire (following issuance) of the Puricase Patents; BTG agrees not to, and shall cause its Affiliates not to, use the Puricase Technology to manufacture,
promote, market or sell any Competing Product in the Territory, or to license or sublicense the Puricase Technology to any third party. As used in this Agreement, “Competing Product” shall mean any prescription pharmaceutical product that
(i) contains uricase as an active ingredient or (ii) has a primary use in a particular country, based on a majority of prescription use in such country, for the treatment of gout (in any form). As used in this Agreement, “Territory” shall
mean, collectively, every country in the world.

  
	 	 
	
13.        	
Governing Law and Dispute Resolution
  
	 	 
	 	
13.1.        	
This Agreement and any disputes hereunder shall be governed by and construed in accordance with the laws of the State of New York, United States of America, without giving effect to any choice or conflict of law
provision or rule that would cause the application of any other laws.
  
	 	 	 
	 	
13.2.        	
Save as provided in Section 6.2 hereof, any disputes, claims or controversies between the Savient and BTG in connection with this Agreement, including any question regarding its formation, existence, validity,
enforceability, performance, interpretation, breach or termination (any such dispute, claim or controversy, a “Dispute”), shall be finally resolved by binding
arbitration.
  
	 	 	 
	 	
13.3.        	
Any arbitration hereunder shall be conducted under the Rules of Arbitration of the London Court of International Arbitration. The arbitration shall be conducted in the English language before three arbitrators
chosen according to the following procedure: within 20 (twenty) days after commencement of the arbitration, each of Savient and BTG shall appoint one arbitrator, and within 20 (twenty) days after the appointment of both such arbitrators, the two
arbitrators so chosen shall choose the third arbitrator. If the two arbitrators chosen by Savient and BTG cannot agree on the choice of the third arbitrator within a period of 20 (twenty) days after their appointment, then the third arbitrator shall
be appointed by the London Court of International Arbitration.
  
	 	 	 
	 	
13.4.        	
Each of the arbitrators shall be a lawyer or former judge. The chairman of the three arbitrators shall have experience arbitrating disputes in the pharmaceutical industry.
  
	 	 	 
	 	
13.5.        	
Any arbitration that would otherwise be conducted pursuant to this Section 13 that relates to the subject matter of any arbitration conducted pursuant to Section 10.15 of the SPA shall be combined into a single
arbitration before the same panel of three arbitrators, conducted in accordance with Section 10.15 of the SPA.
  
	 	 	 
	 	
13.6.        	
Each of the Asset Buyer and the Seller hereby irrevocably waives all rights to trial by jury in any Dispute.
  

	 	
13.7.        	
The place of the arbitration shall be London, England.
  
	 	 	 
	
14.        	
Miscellaneous
  
	 	 
	 	
14.1.        	
Unless the context explicitly dictates otherwise, all references herein to “patents” and/or “patent applications” herein shall be deemed to include any disclosures, continuations,
continuations-in-part, divisionals, provisionals, PCT applications, reissuances, revisions, substitutions, conversions, renewals, extensions, prolongations, and re-examinations thereof, any technology and inventions covered thereby, and any
corresponding international, regional and national applications.
  
	 	 	 
	 	
14.2.        	
From time to time after the date hereof and prior to the Closing, the Parties may modify and/or replace any of Annexes C, D or E hereto, which modified or replaced Annexes shall automatically constitute part of
this Agreement.
  
	 	 	 
	 	
14.3.        	
Nothing in this Agreement or in the Divestiture Agreements shall derogate from BTG’s rights under the Technology Transfer Agreement effective February 1, 1998, pursuant to which BTG acquired Savient’s
process for the manufacture of sodium hyaluronate (“HA”), as described and claimed in U.S. Patent No. 4,780,414, and the related patent applications, patents, trademarks and domain
names listed in Annex “I”. Savient and its employees shall provide BTG, without compensation, with the necessary authorizations, powers of attorney and other documents and
assistance reasonably requested by BTG from time to time to record the assignment of said intellectual property rights from Savient to BTG.
  
	 	 	 
	 	
14.4.        	
This Agreement constitutes the entire agreement between Savient and BTG with respect to the subject matter hereof, and supersedes any prior agreements or understandings between Savient and BTG with respect to such
matters.
  
	 	 	 
	 	
14.5.        	
Each Party agrees to execute, acknowledge and deliver such further documents and instruments and do any other acts, from time to time, as may be reasonably necessary, to effectuate the purposes of this
Agreement.
  
	 	 	 
	 	
14.6.        	
Neither this Agreement nor any of the rights, interests, or obligations hereunder may be assigned by either Party without the prior written consent of the other Party hereto, except that either Party may assign its
rights hereunder to any entity that acquires all or substantially all of such Party’s business or assets (provided that no such assignment shall relieve the assigning Party of its obligations hereunder, and the assigning Party shall remain
primarily liable for such obligations). Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.
  
	 	 	 
	 	
14.7.        	
All notices, requests, demands, claims and other communications hereunder shall be in writing. Any notice, request, demand, claim or other communication hereunder shall be deemed duly delivered four Business Days
after it is sent by
  

	 	
registered or certified mail, return receipt requested, postage prepaid, or one Business Day after it is sent by overnight delivery via a reputable national courier service, in each case to the intended recipient
as set forth below:

  
	 	 
	 	
If to Savient:

  
	 	 
	 	
Savient Pharmaceuticals Inc. 

  
	 	
One Tower Center, l4th Floor

  
	 	East Brunswick, New Jersey 08816, USA
	 	 Telecopy: +1-732-418-9065
    
	 	Attention: Philip K. Yachmetz, Esq.
	 	 
	 	
If to BTG:

  
	 	 
	 	
Bio-Technology General (Israel) Ltd.     

  
	 	Kiryat Weizmann
	 	Building 17
	 	Rehovot 76326, Israel
	 	Telecopy: +972-8-9409041
	 	Attention: Dr. Dov Kanner
	 	 
	 	
A “Business Day” shall be any day other than (i) a Saturday or Sunday or (ii) a day on which banking institutions located in New York, New York, United States of America or in Israel are permitted or
required by law, executive order or governmental decree to remain closed.

  
	 	 
	 	
Any Party may give any notice, request, demand, claim, or other communication hereunder using any other means (including personal delivery, expedited courier, messenger service, telecopy, telex, ordinary mail, or
electronic mail), but no such notice, request, demand, claim or other communication shall be deemed to have been duly given unless and until it actually is received by the Party for whom it is intended. Any Party may change the address to which
notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other Party notice in the manner herein set forth.

  
	 	 
	
14.8.        	
Savient and BTG may mutually amend or waive any provision of this Agreement at any time. No amendment or waiver of any provision of this Agreement shall be valid unless the same shall be in writing and signed by
both of the Parties.
  
	 	 
	
14.9.        	
Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the
validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the
Parties agree that the body making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration or area of the term or provision, to delete specific
  

	 	
words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
unenforceable term or provision, and this Agreement shall be enforceable as so modified.

  
	 	 
	
14.10.        	
Except as otherwise specifically provided to the contrary in this Agreement, each of the Parties shall bear its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement
and the transactions contemplated hereby.
  
	 	 
	
14.11.        	
This Agreement may be executed in one or more counterparts, each of which shall be deemed an original; but such counterparts shall together constitute but one and the same instrument.
  

[Intentionally Left Blank]

IN WITNESS WHEREOF the Parties hereto have set their signatures as of the date first mentioned above. 

	/s/ Christopher Clement
	SAVIENT PHARMACEUTICLAS, INC.
	By: Christopher Clement 
	Title: President and Chief Executive Officer

	/s/ Philip K. Yachmetz 
	BIO-TECHNOLOGY GENERAL (ISRAEL) LTD.
	By: Philip K. Yachmetz
	Title: Director

	List of Annexes:	 
	 	 
	Annex “A”	OCS letter
	Annex “B”	Puricase Patents
	Annex “C”	Development and Regulatory Work - Puricase
	Annex “D”	Term Sheet for Manufacture of Puricase
	Annex “E”	Term Sheet for Technology Transfer
	Annex “F”	Expert Procedures
	Annex “G”	BTG-271 Patents
	Annex “H”	List of osmB promoter patents/patent applications
	Annex “I”	List of HA Patents, Trademarks and Domain
    Names

Annex A 

OCS letter

Mr. Avi Feldman, Esq. 

General Counsel to the

Office of the Chief Scientist 

Ministry of Industry, Trade and Labor

4 Mevo Hamatmid Street 

Jerusalem 91021 

Dear Mr. Feldman, 

Re: Bio-Technology General (Israel) Ltd. (“BTG Israel”) 

We have been informed of the meeting that took place in Jerusalem on June 15, 2003 with the participation of representatives of the Chief Scientist (the “CS”) and BTG Israel. 

We understand that during the course of the meeting, the parties resolved certain issues that arose in relation to CS-approved R & D programs at BTG Israel (the “Approved Programs”) as follows: 

	
1.        	
BTG Israel will have title to all future Approved Programs, relating to new projects.
  
	 	 
	
2.        	
BTG Israel will have an exclusive irrevocable and perpetual right from us to conduct R&D with technology developed in the course of Approved Programs which are completed or ongoing, excluding clinical trials
that BTG Israel is not in a position to monitor from Israel; and
  
	 	 
	
3.        	
Except as otherwise approved by the CS, BTG Israel will have an exclusive right from us to manufacture in Israel products developed through Approved Programs..
  

We understand that the CS will not unreasonably withhold its consent to the conduct of such R&D activities outside of Israel if BTG Israel is finable to carry out such activities, or the manufacture of such products outside of
Israel, if commercially unfeasible or if BTG Israel is unable to carry out such activities. 

We also understand it was agreed that upon receipt of our agreement to the foregoing, funds withheld by the CSO upon the 2002 audit as well as funds that would otherwise have been payable in 2002 (if properly spent and reported)
wilt be immediately released to BTG Israel. 

On the basis of such understandings, and without waiving any rights that we may have from time to time under the Law for the Encouragement of Research and Development in Industry, we hereby confirm our agreement to the
understandings set out above. 

	Respectfully yours,
	 
	/s/ Sim Fass
	Savient Pharmaceuticals, Inc.
	By: 	Sim Fass 
	Title: 	Chairman & CEO

	
cc:        	
Mr. Amos Efrati 
  
	 	Mr. Shaul Freilich
	 	
Deputies to the Chief Scientist

  
	 	 
	 	
Y. Baratz
	 	
D. Kanner
	 	
R. Shaw

 

Annex B 

  

  Puricase Patents

	1.      	New Applications 

	 	1.1. 	Puricase

	File 	Country 	Status 	Appln No 	Appln Date 	Title 
	Reference 	     	     	     	     	     
	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 

	 	1.2. 	Protein Purification

	File 	Country 	Status 	Appln No 	Appln Date 	Title 
	Reference 	     	     	     	     	     
	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 

Annex C

Development and Regulatory Work

Puricase 

The following outline summarizes the key elements of ongoing development work and regulatory services relating to Puricase which will be required from BTG as from the Closing, certain elements of which are required under agreement
with the OCS. This outline will form the basis of a detailed work plan covering these activities, which will be concluded prior to the Closing. It is anticipated that the detailed work plan when completed, will include a specific list of
deliverables and a timetable for performance and delivery. 

While every effort has been utilized to make this outline as comprehensive as possible, certain activities shown here may need to be expanded to include normal and customary related activities. 

     [**] A total of two pages were omitted pursuant to a request for confidential treatment.

Annex D

Term Sheet 

Manufacturing Services

The following outline summarizes the key elements of manufacturing services that will be required from BTG as contract manufacturer with respect to the manufacturing Puricase (the “Product”), as required from BTG as from
the Closing. This outline will form the basis of a detailed work plan covering these activities, which will be concluded prior to the Closing. It is anticipated that the detailed work plan when completed, will include a specific list of deliverables
and a timetable for performance and delivery. 

While every effort has been utilized to make this outline as comprehensive as possible, certain activities shown here may need to be expanded to include normal and customary related activities. 

[**]. A total of five pages were omitted pursuant to a request for confidential treatment. 

Annex E

Term Sheet 

Technology Transfer

The following outline summarizes the key elements of the technology transfer relating to Puricase which may be required from BTG, after the Closing. This outline will form the basis of a detailed work plan covering these
activities, which will be concluded prior to the Closing. It is anticipated that the detailed work plan when completed, will include a specific list of deliverables and a timetable for performance and delivery. 

While every effort has been utilized to make this outline as comprehensive as possible, certain activities shown here may need to be expanded to include normal and customary related activities. 

These terms and conditions shall be binding upon the Parties, unless and until superseded by a definitive Technology Transfer Agreement and/or a detailed work plan: 

[**].

ANNEX F

Expert Procedures

Pursuant to Sections 2.5 and 6.2 of the Residual Rights Agreement:

[**].

Annex G 

BTG-271 Patents

	
BTG 271 Patent Applications  
	   	   	   	   	   	   	   	   	
Applicant/  
	
Docket ID  	
File Ref.  	
Country  	
Status  	
Substatus  	
Appl. No  	
Appl. Date  	Expiry 	
Patentees  
	
  [**]  	
  [**]  	
  [**]  	
  [**]  	 	
  [**]  	
  	
  [**]  	
  [**]  

	   
	
[**]  	   	   	   	   	   	   	   	   
	 	 	 	 	 	 	 	 	 
	
A total of two pages were omitted pursuant to a request for confidential treatment.  	   	   	   

	
1  
	
647/IP/BT
G 271 Patent Applications  	

8 March, 2005  
	
US1DOCS 7036064v1    	   

	
Annex H  
	   
	
osmB promoter patents/patent application  
	 

	
Docket

ID  	
File Ref    	
Country    	
Annuity Due    	
Status    	
Applic.

No  	
Appl. Date    	
Grant

No.  	
Grant Date    	
Expiry    	
Application/

Patentees  
	[**] 	[**] 	[**] 	[**] 	[**] 	[**] 	[**] 	 	 	[**] 	[**] 
	[**] 	[**] 	[**] 	 	[**] 	[**] 	[**] 	 	 	 	[**] 
	[**] 	[**] 	[**] 	 	[**] 	[**] 	[**] 	 	 	 	[**] 
	[**] 	[**] 	[**] 	 	[**] 	[**] 	[**] 	 	 	 	[**] 
	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  
	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  	
[**]  

Annex I 

List of HA Patents, Trademarks and Domain Names

	
1.        	
Patents
  
	 	 
	 	
Refer to attached list

  
	 	 
	
2.        	
Design Right Registrations
  
	 	 
	 	
2.1.        	
US: Des. . 403064 - Filed June 28, 1995, Granted December 22, 1998, Expiration date December 22, 2012.
  
	 	 	 
	 	
2.2.        	
Israel: Design 23832 - Filed January 22, 1995, Granted June 20, 1995; Expiration date January 22, 2010
  
	 	 	 
	
3.        	
Trademarks
  
	 	 
	 	
Refer to attached list

  
	 	 
	
4.        	
Domain Names
  
	 	 

	 	Name 
  	Domain 
  
	 	biolon	.info
	 	biolon	.co.il
	 	biolon	.us
	 	biolon	.com
	 	euflexxa	.com
	 	nuflexa	.com
	 	nuflexxa	.com

	
HA PATENTS  
	 

	File Ref. 	Country 	Status 	
Appl. No  	
Appl. Date  	Grant No 	Grant Date 	Expiry 	
Applicant/  
	   	   	   	   	   	   	   	   	
  Patentees  
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 
	  [**]  	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 	  [**] 

	
HA TRADEMARKS  
	 

	
File Ref.  	
Country  	
Trademark  	
Class  	
Reg. Owner  	
Appl. No.  	
Appl. Date  	
Reg. No.  	
Reg. Date  	
Status  
	  [**]  	  [**]  	  [**]  	  [**]  	  [**]  	  [**]  	  [**]  	  [**]  	  [**]  	
  [**]  

	   
	
[**]  	   	   	   	   	   	   	   	   	   
	 	 	 	 	 	 	 	 	 	 
	
A total of four pages were omitted pursuant to a request for confidential treatment.  	   	   	   	   

Exhibit G

Product Specifications

	
Summary of Release Testing of Bulk Uricase Intermediate  	   
	 	 

	 	 	Provisional
          Acceptance 	 
	Parameter 	Test 	Criteria 	Revision 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 

 

	Summary of Release Testing
    of PEG-uricase API  
	  	  	 	  

	 	 	Provisional
          Acceptance 	 
	Parameter 	Test 	Criteria 	Revision 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	[**] 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	 	[**] 	[**] 	[**] 
	  	[**] 	[**] 	[**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]